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ABSTRACT
Colon cancer is the second largest cause of cancer death in United States. Chronic
inflammation and obesity predispose patients to colon cancer. Adipose tissue is a source of
bioactive substances called adipokines. Adiponectin (APN), an adipokine has antiinflammatory property and found at lower levels in obese patients. Selenium (Se), a trace
mineral and a dietary supplement, is inversely associated with cancer risk and possess antiinflammatory and anti-carcinogenic properties. The overall purpose of this dissertation is
to determine if chronic inflammation leading to colon and intestinal cancer are regulated
by APN or Se rich diet or both. The working hypothesis is that APN deficiency will
decrease goblet cell mucous production in colon leading to greater chronic inflammation
and exacerbate the clinical symptoms and tumor load related to colon cancer. Se rich diet
alone or in combination with APN administration will increase goblet cell production and
apoptosis of cancer cells leading to reduced clinical symptoms, tumor load and
inflammation. The specific aim 1 studied the role of APN deficiency in chronic
inflammation induced colon cancer (CICC) and its effect of goblet cell production.
Absence of APN increased the severity of CICC and its administration on goblet cell lines
decrease their apoptosis with increase Math-1 production and upregulated mucin (Muc-2)
secretion through the activation of its receptors APN R1 and R2. Specific aim 2 was
designed to study the effect of Se rich diet and APN deficiency in positive modulation of
CICC. Our result indicated a sharp decline in the physical manifestations of colon cancer
with Se rich diet and higher severity of CICC with APN deficiency providing another proof
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for the protective role of APN in CICC. Specific aim 3 studied the effect of APN
administration or Se rich diet or both on intestinal cancer. We found a protective effect of
Se, APN and both in reducing the clinical score and tumor load of intestinal cancer. Several
mechanism of action of both Se and APN were studied in all the 3 aims. In conclusion,
APN and Se could be used as a complimentary medicine in the treatment of colon and
intestinal cancer.
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CHAPTER 1
INTRODUCTION
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Colorectal cancer is the second largest cause of cancer death in United States and
ranks fourth in the estimated new cases every year (R. Siegel, Naishadham, & Jemal, 2013).
Some of the physical symptoms associated with colon cancer include rectal bleeding,
change in bowel habits including constipation and diarrhea, abdominal pain, anemia,
weight loss and constant fatigue (Korsgaard, Pedersen, Sorensen, & Laurberg, 2006).
Etiology of colon cancer is very complex and heterogeneous and ranges from dietary and
lifestyle factors to genetic mutations (Fearon, 2011). Certain risk factors associated with
colon cancer includes age greater than 50, history of polyps or colorectal cancer or
inflammatory bowel disease (IBD), family history of familial adenomatous polyposis
(FAP) and hereditary non-polyposis colorectal cancer (HNPCC), race and ethnic
background, food choices, lack of exercise, obesity, smoking and alcohol use. People who
are obese are at greater risk of developing colorectal or intestinal cancer (Bardou, Barkun,
& Martel, 2013). Obesity or increased fat consumption leads to an increase in the size of
adipocytes, which puts an undue pressure on the adipose tissue leading to the necrosis of
adipocytes. This event then results in an increase in the pro-inflammatory markers like M1
macrophages, Interleukin (IL)-6, Tumor Necrosis Factor (TNF)-α and a concomitant
decrease in the anti-inflammatory markers like M2 macrophages and IL-10 (Makki,
Froguel, & Wolowczuk, 2013). This switch of phenotype form anti-inflammatory to proinflammatory leads to the chronic cycle of inflammation leading to the activation of
Nuclear factor kappa-light-chain-enhancer of active B cell (NFκB) mediated proinflammatory cytokines and other inflammatory mediators. Repeated cycles of
inflammation in addition to carcinogenic exposure or mutation or increase gut permeability
could result in pre-cancerous lesions which if could get transformed in to tumors. Studies
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have shown that obesity leads to a decrease level of serum APN and exercised or trained
individual have higher serum APN (Sakurai et al., 2013). APN is a protein secreted
predominantly by adipocytes. Levels of serum APN has been inversely related with body
weight and visceral fat accumulation. Our preliminary data indicated that APNKO mice
given DMH to induce colon cancer showed significantly higher clinical score when
compared to WT mice given the same treatment. Tumor number was also found to be
significantly higher in APNKO mice given DMH when compared to its WT counterpart.
Otani et al., 2010 has shown that intraperitoneal injection of APN (1.5mg/kg/week) 10
times from age 6 weeks to age 15 weeks significantly reduced adenomatous polyps in small
intestines. Another recent study by Moon and Mantzoros 2013, have shown that coadministration of APN and Metformin, an anti-diabetic drug reduced malignant potential
in Signal transducer and activator of transcription (STAT) 3 and Liver Kinase B1 / 5'
adenosine monophosphate-activated protein kinase (LKB1/AMPK) dependent manner
(Moon & Mantzoros, 2013). They also showed an important role of IL-1β in colon cancer.
APN has been shown to reduce oxidative stress by the downregulation of Transforming
Growth Factor β (TGF-β) through the activation of AMPK (Cheng et al., 2015). TGF-β
alongwith β catenin has been shown to increase cellular proliferation and cell migration
leading to epithelial to mesenchymal transition (EMT). Under the influence of β catenin,
epithelial cells lose the tight junction or adherence and transit to more loose and mobile
mesenchymal phenotype. During the EMT, epithelial cells lose the expression of proteins
like ZO-1 and cadherin which are required for continued normal gut barrier and
maintaining the integrity of the gut epithelium (Tian et al., 2011). Another important study
by Moon at al., 2013 has shown that APN administration (5μg/mouse/day) for 28 days
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reduced implanted tumor growth and angiogenesis and increased anti-inflammatory
cytokines and improves insulin resistance in mice fed with high and low fat diet (Moon et
al., 2013). All these studies have indicated the protective role of APN in inflammation and
colon cancer.
In addition to medication, diet plays an important role in protection form diseases
and ailments. Selenium (Se), a non-metal and a well-known anti-oxidant has been shown
to have several potential benefits including anti-ageing, it boosts immunity, improves brain
function, anti-heart disease, anti-diabetic, formation of many selenoenzymes, which plays
an important role in hormone regulation and has anti-cancer properties (K. H. Lee & Jeong,
2012). Se has been implied in the treatment of breast cancer (Chen, Prabhu, Das, & Mastro,
2013), has been considered as a potential treatment in cancer metastasis (Chen, Prabhu,
Das, et al., 2013), osteosarcoma (Wang et al., 2013) and widely studied in colon cancer
(Gupta, Jaworska-Bieniek, Lubinski, & Jakubowska, 2013; Hu et al., 2013; Z. Li, Meng,
Xu, Qin, & Zhou, 2013; Maseko, Howell, Dunshea, & Ng, 2014) and other gut related
disorders (Nagy, Fulesdi, & Hallay, 2013). Colon cancer patients tend to have Se
deficiency or lower Se level. A recent study by Li et al., 2013 on human colorectal
carcinoma cell lines (HCT 116 and SW620) has shown that Se administration leads to the
apoptosis of the colon cancer cells by Bcl2 associated X protein (Bax) dependent pathway.
Another study by Luo et al., 2013 has shown that supranutritional dosage of sodium
selenite leads to the apoptosis of colon cancer cells by reactive oxygen species (ROS)
modulation of phosphatase and tensin homolog (PTEN) mediated Phosphatidylinositol4,5-bisphosphate 3-kinase/ Protein Kinase B/ Foxhead box O3 (PI3K/AKT/FoxO3a)
signaling pathway. High and low dose of sodium selenite had showed a reduction in the
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TGF-β1 signaling in diabetic rat kidney (Roy, Dontamalla, Mondru, Sannigrahi, &
Veerareddy, 2011). A recent study by Bi et al., 2013 has shown that Se and sulindac
synergistically act to suppress the Wnt/ β-catenin signaling by the induction of their
inhibitor including p27 and p53. Although there are several publications defining the role
of Se in the treatment of colon cancer but most of the studies are focused on cancer cells
apoptosis on colon cancer cell lines rather than animal models of colon or intestinal cancer.
Also, at the same time these studies are focused on studying a single mechanism that deals
with the apoptotic pathway leading to colon cancer cell apoptosis. There is a need to expand
research and explore several other pathways leading to protection mediated by Se rich diet.
Currently there are several therapies available for the treatment of colon cancer
including chemotherapy, radiotherapy, radiofrequency ablation, cryosurgery, and target
therapy. But all these have been associated with severe to mild side effects and there is a
greater chance of recurrence. Also depending on the stage of the colon or intestinal cancer
these therapies and medication may not produce desire effects and could permanently
reduce the quality of the patient’s life. In order to prevent these side effects, reoccurrence,
improve recovery and the quality of life in colon or intestinal cancer patients, it is necessary
to use alternative and complementary medicine, which might include the use of APN and
Se rich diet. Alone or the combination of these might be effective in reducing the severity
of colon cancer and may play an important role in recovery and prevent side effects.
Although there is some published research indicating the role of Se and APN in the
treatment of colon cancer but the mechanism of action of these remain unclear. Also, there
is no published research that could indicate that the combination of these could be effective
in the treatment of colon cancer. Based on our preliminary data and published studies by
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several researchers around the globe it will be interesting to study the effect of Se rich diet
and APN both alone and in combination in reducing the severity of intestinal and chronic
inflammation induced colon cancer.
The overall purpose of this dissertation is to determine if chronic inflammation
leading to colon and intestinal cancer are regulated by APN or Se rich diet or both.
AIM 1: To determine if chronic inflammation induced colon cancer (CICC) is
regulated by APN.
Hypothesis: APN deficiency will exacerbate the pathology and the severity of
CICC leading to greater inflammation and tumor load caused by reduction in goblet cell
production and mucus secretion.
Rationale: APN is an adipocytokine secreted by adipocytes in response to various
signals. It has been considered as an anti-inflammatory and anti-cancerous molecule. It
works through the autocrine or paracrine and endocrine pathway (Ealey & Archer, 2009).
Several epidemiological studies have linked lower APN levels with greater incidences of
obesity related disorders including prostate, breast, endometrial and more aggressively
with colon cancer (Dalamaga, 2013; Gulcelik et al., 2012; Wei, Giovannucci, Fuchs,
Willett, & Mantzoros, 2005). APN has been shown to be involved in energy regulation,
cycle of inflammation and remodeling (Brochu-Gaudreau et al., 2010). In vitro and clinical
studies have indicated an inverse relationship of APN with colorectal cancer through
mechanism involving inhibition of cancer cell growth and promoting cancer cell apoptosis
(Byeon et al., 2010; A. Y. Kim et al., 2010). APN has been known to shown majority of its
effect by activating AMPK. It also works by activating STAT-3, mitogen activated protein

6

kinase (MAPK), mammalian target of rapamycin (mTOR), PI3K/Akt and NF-κB (Obeid
& Hebbard, 2012; Shackelford & Shaw, 2009). APN increased LKB expression in the
breast cancer cell lines which resulted in AMPK activation leading to inhibition of tumor
cell migration and adhesion (Moon & Mantzoros, 2013). Besides the above published
evidences, our preliminary data indicated the protective role of APN in DMH induced
colon cancer. Significantly higher clinical score including diarrhea, weight loss and fecal
hemoccult was found in APNKO given DMH when compared to WT mice. Tumor number
was also found be significantly higher in APNKO mice in comparison to WT mice.
Although there have been published study indicating negative effects of APN deficiency
Our preliminary data and the published research provides sufficient evidence to study the
effect of APN deficiency in chronic inflammation and CICC.
AIM 1.1 To study the effect of APN deficiency on clinical score and tumor load in CICC.
Hypothesis: APNKO mice will have greater clinical score and tumor load when
compared to WT mice given the same treatment.
AIM 1.2 To determine the effect of APN deficiency on goblet cell production and mucus
secretion.
Hypothesis: APN deficiency will exacerbate CICC through reduced production of
goblet cell production and mucus secretion.
AIM 1.3 To study how APN administration could affect goblet cell production and
epithelial to goblet cell transition with mucin production in goblet cell lines.
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Hypothesis: APN administration to the goblet cell line will decrease the apoptosis
of goblet cells and will increase mucin secretion leading to greater protection from colon
cancer.
AIM 2: To determine if Se rich diet can interact with APN to alleviate CICC.
Hypothesis: Se rich diet can interact with APN to significantly reduce the severity
of CICC by reducing oxidative stress and increasing goblet cell mediated protection and
cancer cell apoptosis.
Rationale: Selenium has been shown to be useful in the treatment of inflammation
and several types of cancers including prostate (Hurst et al., 2012), breast (Jiang, Ganther,
& Lu, 2000), fibrosarcoma (Yoon, Kim, & Chung, 2001), melanoma (Yan, Yee, Li,
McGuire, & Graef, 1999), lung (Yan & DeMars, 2012; Zhuo, Smith, & Steinmaus, 2004)
and colon cancer (Nolfo et al., 2013; C. F. Tsai, Ou, Liang, & Yeh, 2013). Our preliminary
data indicate that the administration of selenium rich diet was effective in reducing the
clinical score that is diarrhea, weight loss and blood in stools of both APNKO and WT
mice in DMH induced colon cancer. We also observed a reduction in the tumor number
and tumor area of APNKO and WT mice administered Se rich diet with significant
reduction in the APNKO mice. In this aim we will study the effect of Se rich diet on chronic
inflammation induced by DSS, DMH induced colon cancer and CICC induced DSS+DMH.
This study will also delineate the different mechanism of action of Se in reducing tumor
load in all the three treatment groups. Several in vitro and in vivo (J. H. Kim et al., 2011)
studies have shown that Se administration could upregulate antioxidant selenoproteins
which could be one of the major mechanism of action of Se in reducing the severity of
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CICC. Luo et al., 2013 has shown that selenite induced the apoptosis of the human
colorectal cancer cell lines HTC 116 and SW480 through the activation of caspase 9 with
the involvement of AKT/FoxO3a/Bim/PTEN axis (Luo et al., 2013). Although there have
been several studies depicting the role of Se in different types of cancers, there are limited
publications indicating the protective role of Se in the treatment of colon cancer and
delineating the mechanism of action of Se in reducing the severity of colon cancer. By the
means of this aim, we are trying to provide an explanation for the protective role of Se in
reducing the clinical score and tumor load in DMH induced colon cancer. The focus of this
aim lies in determine the preventive effect of Se rich diet on chronic inflammation and
colon cancer. This aim will study the different mechanism of action of Se including how
Se could reduce inflammation by overexpression of antioxidant selenoproteins in the colon
and reducing the expression of pro-inflammatory cytokines and proteins. It will also study
the effect of Se rich diet on colon cancer cells apoptosis and goblet cell renewal leading to
greater mucus secretion, which could provide protection against colon insult.
AIM 2.1 To study the effect of selenium rich diet and APN deficiency on clinical score
and tumor load in CICC.
Hypothesis 2.1 Se rich diet and APN will significantly reduce clinical score and tumor
load associated with CICC leading to reduced pathology and severity of disease.
AIM 2.2 To determine the effect of Se rich diet and APN deficiency on selenoproteins
expression and oxidative stress.
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Hypothesis 2.2 Se rich diet with APN will significantly increase the expression of
selenoproteins leading to reduced oxidative stress resulting in lower inflammation and
CICC.
AIM 2.3 To study the effect of Se rich diet and APN deficiency on colon cancer cell
apoptosis and goblet cell production.
Hypothesis 2.3 Se rich diet and APN will significantly increase the expression of
pro-apoptotic markers leading to the colon cancer cell apoptosis and simultaneously
increase the production of goblet cells leading to reduced severity of CICC.
AIM 3: To study the combined effects of Adiponectin and Selenium administration
on the genetic model of intestinal cancer.
Hypothesis: Adiponectin administration in addition to Se rich diet will reduce the
severity of intestinal cancer by cancer cell apoptosis, increased goblet cells production and
by the modulation of inflammatory marker.
Rationale: Adiponectin, an adipocytokine secreted by the adipose tissue has been
implicated as an anti-inflammatory and anti-cancerous protein. Our published data clearly
indicate that APNKO mice are at increased risk of developing DMH induced colon cancer
with higher clinical score and more tumor number when compared to the WT counterparts.
Otani et al., 2010 has shown that intraperitoneal injection of APN (1.5mg/kg/week) 10
times from age 6 weeks to age 15 weeks significantly reduced adenomatous polyps in small
intestines. However, this study failed to identify any mechanistic and physical attributes of
colon cancer except polyp count. Another recent study by Moon and Mantzoros 2013, have
shown that co-administration of APN and Metformin, an anti-diabetic drug reduced
10

malignant potential in STAT3 and LKB1/AMPK dependent manner. Another important
study by Moon at al., 2013 has shown that APN administration (5μg/mouse/day) for 28
days reduced implanted tumor growth and angiogenesis and increased anti-inflammatory
cytokines and improves insulin resistance in mice fed with high and low fat diet. Also,
APN treatment in HT29 colon cancer cell lines shows an increase expression of Muc2 in a
dose dependent manner. APN has also been shown to inhibit goblet cell apoptosis via
modulation of Bax/Bcl2 ratio and is dependent on APN R1 and R2 receptors (Saxena et al.,
2013). Adiponectin administration increased the expression of p21, p27 and p53 in mouse
MCA 38 and human HT29 colon cancer cell lines leading to colon cancer cell apoptosis
(Moon, et al., 2013). Although these studies provided evidences for the protective role of
APN administration in colon cancer but failed to study mechanism of action in animal
models of colon and intestinal cancer rather focused more on in vitro studies.
Our preliminary data has also shown that Se administration was effective in reducing the
severity of clinical score and tumor number in both WT and APNKO mice with CICC.
Recent study by Bi et al., 2013 has shown that the combination of Se and sulindac
significantly increase the expression of p27, p53 and c-Jun N-terminal kinases (JNK) 1
phosphorylation leading to suppression of β catenin and its downstream signaling resulting
in decreased intestinal tumorigenesis (Bi, Pohl, Dong, & Yang, 2013). Our preliminary
data indicates that APCMin/+ mice have significantly reduced serum APN when compared
with the WT mice. On the basis of this preliminary and published data, we would want to
study the effect of administration of APN alone and in addition with Se diet in APCMin/+
mice model of intestinal cancer. This study will provide another proof of the use of Se as
anti-inflammatory and anti-cancerous dietary supplement. In this aim, we will study the
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preventive role of both APN and Se rich diet in reducing the severity of intestinal cancer
by increasing goblet cell production in both SI and colon and hence producing more mucus.
The co-administration of both APN and Se rich diet may increase the apoptosis of the
cancer cells and at the same time reduce apoptosis of the colon epithelial cells.
AIM 3.1 To study the combined effect of APN administration and Se rich diet on clinical
score and tumor load in APCMin/+ mice model of intestinal cancer.
Hypothesis 3.1 APN administration alone and in addition to Se rich diet will
significantly reduce the severity of intestinal cancer by reducing clinical score,
inflammation and tumor load.
AIM 3.2 To study the combined effect of APN administration and Se rich diet on goblet
cell production and cancer cell apoptosis.
Hypothesis 3.2 APN administration alone and in addition to Se rich diet will
significantly increase goblet cell production, mucin expression and will lead to apoptosis
of cancer cells in small intestine.

AIM 3.3 To determine the combined effect of APN administration and Se rich diet on
oxidative stress.
Hypothesis 3.3 APN administration in addition to Se rich diet will reduce oxidative
stress leading by downregulating Nitrotyrosine and 4HNE expression and increasing Gpx2 protein expression.
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Working Model

Figure 1.1. Working Model
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Central idea of this dissertation is to study the protective effect of APN and Se rich
diet on intestinal cancer and CICC and delineate the mechanism for this protection. To
achieve this, we will be using the inducible (DSS+DMH) model for studying CICC and
APCMin/+ mice model for studying intestinal cancer. DMH+DMH and APCMin/+ mice
models are very widely used model for studying colon and intestinal cancer respectively
(Tong, Yang, & Koeffler, 2011). Colon cancer in most of the cases is preceded by cycles
of chronic inflammation and exposure to carcinogen sparking the formation of colon polyp.
Colon and intestinal cancer at the clinical level is marked by blood in stools, diarrhea,
weight loss, nausea, vomiting, constipation and constant fatigue. At the molecular level,
colon and intestinal cancer is marked by increase in pro-inflammatory marker and proteins
and suppression of anti-inflammatory response. Earlier stage pathology of the colon and
intestine indicates pre-cancerous lesion and inflammation, which later on develops into
colon tumors of varying size and shape. Our model of CICC is very near to mimic human
stage II and III of colon cancer progression. Additionally, APCMin/+ mutation accounts for
majority of the intestinal and colon cancer cases along with a large similarity in the
symptoms with human condition. There have been published study indicating the role of
Se rich diet and APN administration in colorectal or intestinal cancer but these studies are
limited in explaining the mechanism of action and most of the studies are in vitro. Also the
combination of the above intervention has never been used in colon or intestinal cancer
related studies.
This thesis is divided in to 3 different aims, where the 1st aim is based on our
preliminary experiment, which indicate that APNKO mice showed a significantly higher
clinical score when compared to WT mice treated with DMH to induce colon cancer. We
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also found a significant increase in the tumor number in APNKO mice when compared to
WT mice given DMH to induce colon cancer. On the basis of our preliminary data, we are
trying to study whether CICC is regulated by APN deficiency. APN has been considered
as an anti-inflammatory, antidiabetic and anti-cancer molecule secreted by the adipose
tissue. However, in obese individuals, a reduction in serum APN has been reported (Nigro
et al., 2014). APN has been shown to decrease inflammation by the activation of AMPK
(A. Y. Kim, et al., 2010). Our first aim will study the effect of APN deficiency on chronic
inflammation induced colon cancer. In this aim, we will determine the effect of APN on
clinical score, tumor load and inflammatory markers associated with chronic inflammation
and CICC. Aim 1.2 will study the effect of APN through AMPK and STAT3 activation
and Cyclooxygenase (Cox) -2 mediated chronic inflammation and cancer. In addition to
this we will study the effect of APN on hairy and enhancer of split (Hes)-1 and mouse
atonal homolog (Math)-1 mediated goblet cell production and mucus secretion. The last
part of this aim will study the how APN administration on goblet cell lines could affect
goblet cell production and mucin secretion.
Our second aim is also based on our preliminary data where we found that Se rich
diet (0.75ppm) was effective in reducing the clinical score and tumor number of mice with
colon cancer. Se has been widely studied for it benefits in reducing inflammation, oxidative
stress and to some extent leads to the reduction in cancer pathology. Se has been found to
cause apoptosis of the colon cancer cells in vitro (Luo, et al., 2013). In this aim, we will
study the role of Se and APN in reducing the severity of chronic inflammation and colon
cancer by administering Se rich diet to APNKO and WT mice model with chronic
inflammation, colon cancer and CICC. Aim 2.1 will study the reduction in tumor and
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clinical score through the mechanism leading to colon cancer cell apoptosis in the response
to Se rich diet and serum APN. Since Se is a well-known antioxidant and anti-inflammatory
non-metal, it could be easily derived that Se rich diet might be increasing the production
of antioxidant selenoproteins like Glutathione peroxidase (Gpx) I and II which could
reduce overall oxidative stress in the state of CICC and hence reducing inflammation
leading to reduce pathology of CICC (Aim 2.2). It could be possible that Se might play an
important role in increasing the goblet cell production and the secretion of mucus from
goblet cells providing protection form the DSS and DMH induced colon insult, which will
be studied under aim 1.3.
There have been very limited studies indicating the protective role of APN
administration on colon or intestinal cancer (Luo, et al., 2013). In aim 3 of this proposal
will study the protective effect of both APN administration and Se rich diet on intestinal
cancer. This will provide a reinforcement of our previous aims by studying a genetic model
of intestinal and colon cancer (APCMin/+) along-with exploring the effect of APN
administration alone and in conjugation with Se rich diet on colon cancer. Aim 3.1 will
study the clinical score, colon and intestinal tumor number and area, histopathology and
inflammation and infiltration of immune cells; mainly concerning the physical attributes
of intestinal and colon cancer in both colon and iliac part of small intestine. Sodium selenite
has been shown to cause apoptosis of colon cancer cell in vitro by the activation of Bax
dependent mitochondrial pathway (Z. Li, et al., 2013). APN treatment has also been shown
to increase the apoptosis of the implanted colon cancer cells (Moon, et al., 2013). Aim 3.2
will determine the effect of both co-administration and individual effect of Se rich diet and
APN administration on caspase 9 mediated apoptosis of the cancer cells in addition to
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goblet cell production. This aim will also study the pathways leading to the change in the
phenotype from epithelial to goblet cells (Hes1 and MATH1 expression) and mucin
production (Muc2). Aim 3.3 will further study the in-depth mechanism providing an
explanation for the protective effect of the Se rich diet and APN on reducing oxidative
stress (Nitrosylation and Lipid Peroxidation) by increasing Gpx2 expression. By the means
of this proposal will test the role Se rich diet and APN in murine model of intestinal and
colon cancer.
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CHAPTER 2
LITERATURE REVIEW
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2.1 What is Colon Cancer?
Colon cancer is an uncontrolled growth of epithelial cell of the colon leading to
inflammation and polyps formation. Repeated cycles of inflammation and colon insult
leads to the formation of pre-cancerous lesions. As these lesion grows, gut bacteria and
toxins present in the colon invades the inner layer of the colon leading to mutations in the
epithelial cells of the colon which is translated into polyps. The small polyps if not detected
at an early stage develops into tumors. In 2014, estimated new cases of colorectal cancer
in United States were around 130,000 and estimated number of deaths were around 50,000
including both sexes (R. Siegel, Ma, Zou, & Jemal, 2014). Colon cancer is the second
largest cause of cancer death in United States and is the third most commonly diagnosed
cancer in the men and second in women worldwide (Baena & Salinas, 2015). Higher
incidence of colon cancer is found in North America and European countries where the
incidence has reached 44.8 cases per 100,000 men and 32.2 cases per 100,000 women
population. However, the rates have been significantly low in Western African countries
with only 4.5 and 3.8 cases per 100,000 men and women population respectively (Baena
& Salinas, 2015). This variability in incidence indicates towards the difference in the
environmental and dietary factors in the two population. Especially for CRC, diet is one of
the most important risk factor besides sex, age and family history of the disease (Anand et
al., 2008; Brenner, Kloor, & Pox, 2014).
Patients suffering from colon cancer tends shows symptoms including weight loss,
diarrhea, blood in the stools, nausea, discomfort in bowel movement, abdominal pain and
cramping, bloating, change in appetite and fatigue. One of the most common and more
aggressive symptoms of colon cancer including weight loss, diarrhea and fecal hemoccult
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are being used in animal models to determine the severity of the disease at various stages
of colon cancer and other related diseases like IBD, Colitis and CD.
Etiology of colon cancer is widespread and diverse. Certain risk factors associated
with colon cancer includes age greater than 50, history of polyps or colorectal cancer or
inflammatory bowel disease (IBD), family history of familial adenomatous polyposis
(FAP) and hereditary non-polyposis colorectal cancer (HNPCC), race and ethnic
background, food choices, lack of exercise, obesity, smoking and alcohol use (Bardou, et
al., 2013). There is a decrease in the incidence of the colon cancer since two decades but
this decrease is attributed to increased awareness and early screening.

2.2 Chronic inflammation and Colon Cancer:
Inflammation is a very complex biological response to a harmful stimuli including
allergen, pathogen, damage tissue and injury (Ferrero-Miliani, Nielsen, Andersen, &
Girardin, 2007). Inflammation is a protective response of the immunovascular system
which eliminate tissue injury, pathogen and allergen and initiate tissue repair process. The
process of inflammation is regulated by the body where too little or excessive inflammation
leads to injury and damage to the respective tissue or organ leading to disease and disorders.
Acute phase of inflammation with respect to the condition or injury is helpful but chronic
inflammation leads to permanent damage, cancer or disease. Rudolf Virchow in 186
hypothesized that the sited of chronic inflammation are same the sites for the origin of
cancer (Virchow, 1989). It was based on the presence of “lymphoreticular infiltrate” in
human tumors. Twenty five percent of all cancers have been linked with chronic
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inflammation, environmental exposure or pathogen infection (Balkwill & Mantovani,
2010). It has been found that DNA damage is present during inflammation and its
accumulation during chronic inflammation leads to mutation which culminates into colon
cancer (Kidane et al., 2014). Chronic inflammation is marked by infiltration of the
inflammatory cells including neutrophils, macrophage, platelets and lymphocytes. These
cell provides signals for the production of pro-inflammatory or T helper -1 (TH1) cytokines
and markers including IL-6, TNF-α, INF-γ, IL-1β, lipid mediators and other related
chemokines. On the other hand, they reduce the expression of anti-inflammatory or TH2
cytokines including IL-4, IL-10, IL-11 and IL-13. During chronic inflammation this storm
of cytokines produce more damage than repair leading to abundant accumulation of
chemokines resulting in neovascularization, angiogenesis and finally tumor growth
(Coussens & Werb, 2002). Tumor growth is complemented by the production of various
cytokines and chemokines that attract leukocytes which in turn produced more cytokines
and inflammatory mediators like matrix metalloproteinases (MMP), ROS, Interleukins and
Interferons. All these factors further exacerbate the condition leading to the activation of
inflammatory pathways including STAT3 and NFκB leading to the vicious cycle of chronic
inflammation, tumor growth and metastasis.

2.3 Obesity and Colon cancer:
Obesity and higher visceral fat is associated with greater incidence of colon cancer,
around 11% of the colorectal cases have been associated with overweight and obesity
(Bardou, et al., 2013). According to world health organization (WHO), obesity is defined
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as the body mass index (BMI) ≥ 30 and overweight as BMI ≥25. According to center for
disease control and prevention (CDC), 16.9% of the adults were obese in 2011-2012 in
United States. Increase incidence of CRC with higher BMI appears to be more consistent
in men as compared to women. This sex difference could be attributed to the hormonal
difference and the onset of metabolic syndrome. Visceral obesity has been suggested to
promote metabolic changes culminating in to angiogenesis (Sarkanen et al., 2012). Adipose
tissue though seems to provide all the detrimental effects but it also act an active endocrine
organ secreting adipocytokines including APN, leptin, resistin, visfatin and cytokines
including IL-10, IL-8, IL-6 and IL-1 receptor agonist and TNF-α. Although, adipose tissue
act a source of these beneficial molecule but in obesity, secretion of these adipocytokines
is altered leading to metabolic disorders which exacerbate chronic inflammation and CRC
(Barb, Williams, Neuwirth, & Mantzoros, 2007).

2.4 Adiponectin, an anti-inflammatory and anti-cancer adipocytokine:
APN is a well-known insulin sensitizing adipocytokine whose serum levels has
been inversely linked with obesity, chronic inflammation and colon cancer (Barb, et al.,
2007). It is an abundant protein with the blood concentration of a healthy individual ranging
from 5-20 µg/mL and accounts for 0.01% of the total blood protein (Fayad et al., 2007; J.
Y. Kim & Scherer, 2004; Kishida, Funahashi, & Shimomura, 2014). It has a complex
structure and is structurally homologous to TNF-α and C1q (complement factor). Its
monomer is made of the globular and collagenous domain and could polymerize in to
dimer, trimer and other higher molecular weight isomer (Waki et al., 2003). Greater levels
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of polymerization leads to low, medium and higher molecular weight APN. Most of the
APN levels in the serum are inversely related to the body’s visceral fat content. The
mechanism of this relationship remains unclear. Lower levels of APN is associated with
several disease including hypertension, type-2 diabetes, dyslipidemia, coronary artery
disease, stroke, sleep apnea, non-alcoholic fatty liver disease, inflammatory bowel disease,
colon cancer, breast cancer, leukemia, prostate and gastric cancer (Kishida, et al., 2014).
Higher APN levels or hyperadiponectinemia is associated with cardiac dysfunction,
pulmonary and kidney diseases. APN exerts its function by binding to its receptors
ADIPOR1 and ADIPOR2 (seven transmembrane domain receptors) which is located in the
various cell types and tissue in the body. They act through multiple pathways including
p38 mitogen activated proteins (MAP) kinase and adenosine monophosphate (Kadowaki
& Yamauchi, 2005). APN can bind to several growth factors including platelet-derived
growth factor (PDGF), fibroblast growth factor (bFGF) and heparin binding epidermal
growth factor (HB-EGF) and differential binding of APN to these growth factors is
precluded by the binding of these growth factors to their respective receptors leading to
cessation of their DNA synthesis and cell proliferation (Wang et al., 2005). APN has been
known to show several anti-inflammatory properties including inhibition of tumor necrosis
factor alpha (TNF-α), STAT3 and NFᴋB resulting in the downregulation of proinflammatory cytokines like IL-6 and Il-1β and induction of several anti-inflammatory
cytokines like IL-10 (Fantuzzi, 2005). High fat diet has been shown to increase the colon
tumor number and area and APN treatment has been to significantly reduce tumor weight
with larger center necrotic tumor area. It has also been shown to decrease cell proliferation
in the human LoVo and mouse MCA38 colon cancer cell lines. Anti-proliferative effect of
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APN has been shown to be mediated by the activation of AMPK. Administration of APN
has been shown to increase the phosphorylation of AMPK in HT29 colon cancer cell lines.
Higher doses of APN has been shown to inhibit the STAT3 phosphorylation in HT209
colon cancer cell lines (Moon, et al., 2013). APN has also been shown to downregulate
Cox-2 and upregulate T-cadherin mRNA expression in human colon cancer HCT116 cell
lines (Tae et al., 2014b). All the above data provides string evidence for the use of APN as
an anti-inflammatory anti-cancerous compound for the treatment of chronic inflammation,
colon cancer and CICC.

2.5 Role of AMPK, STAT3, NFᴋB and Cox-2 in inflammation and colon cancer
AMPK is the energy sensor of the body which is known to regulate lipid and
glucose homeostasis, protein synthesis, insulin sensitivity and autophagy. It is a
heterotrimeric complex composed of regulatory β and γ subunits and catalytic α subunit
(Grahame Hardie, 2014). Its expression is found in almost all the tissue of the body and is
activated by the increase in adenosine monophosphate (AMP) to adenosine triphosphate
(ATP) ratio in addition to the modulating hormone levels (J. S. Tsai et al., 2014). Antitumor function of AMPK comes from the idea that AMPK might aid LKB1, which is
known tumor suppresser (Lizcano et al., 2004). AMPK has the ability to inhibit all
biosynthetic pathways that is required for growth and could cause cell cycle arrest.
Chronically AMPK activation leads to the promotion of more energy efficient pathways
that is oxidative metabolism and opposing aerobic glycolysis which is the primary tumor
supporting mechanism (Vander Heiden, Cantley, & Thompson, 2009). Activators of
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AMPK including metformin and phenformin delay the onset of tumor in tumor prone mice
(X. Huang et al., 2008). Transgenic mice overexpressing the Myc oncogene showed
accelerated development of lymphoma whole body AMPK-α1 knockout mice (Faubert et
al., 2013). Besides the tumor suppressive function, AMPK is evidently know to show antiinflammatory effects. Macrophages related studies have shown that AMPK activation
attenuates the production of inflammatory cytokines (Sag, Carling, Stout, & Suttles, 2008).
STAT3 is mediator of the JAK/STAT signaling pathway and is an important
member of the STAT family of transcription factors located in the cytoplasm in an inactive
state. After the phosphorylation activation of STAT3 by extracellular signals including
Janus Kinase (JAK), cytokines and hormones, it dimerizes and translocate to the nucleus
leading to the expression of several critical genes required for proliferation, survival,
migration, invasion and progression of cell cycle (Buettner, Mora, & Jove, 2002). STAT3
autocrine feedback loop functionally link inflammation and cancer where oncogenic events
leads to the increased expression of intrinsic STAT3. NFᴋB and STAT3 are activated
further in response to inflammatory cytokines like TNF-α, IL-6, IL-17 and IL-22 forming
a vicious loop (Pandurangan & Esa, 2014). The phosphorylated STAT3 was found to be
significantly elevated in patients with colorectal cancer; along with the activation of antiapoptotic genes including Bcl2 and Bclxl that are related with metastasis, tumor growth and
bad prognosis. Therefore STAT3 pathway is suggested to be the target pathway for the
treatment of colon cancer (Atreya & Neurath, 2008).
NFᴋB is a transcription factor that under basal conditions is present in the
cytoplasm as a heterotrimer consisting of 3 subunits including p50, p65 and IκBα. It has
an important role in the immune system to target and eliminate terraformed cells. However,
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this is true only under acute inflammation where its activation leads to the attack of
cytotoxic cells on cancer cells preventing tumor formation. In chronic condition, continued
activation of NFᴋB leads to the certain pro-tumorigenic activity (Disis, 2010). Activation
of NFᴋB leads to the phosphorylation, ubiquitination and degradation of IκBα protein and
translocation of p50 and p65 subunit to the nucleus, initiating the transcription activation
of several downstream target genes. These gene targets including genes responsible for
inflammation, cytokine production like TNF-α, IL-1, IL-6 and IL-8, cell proliferation and
survival, angiogenesis, neovascularization (upregulation of VEGF), invasion, epithelial to
mesenchymal transition (EMT) and metastasis (upregulation of MMPs and loosening the
extracellular matrix for the invasion of cancer cells). (Aggarwal, Vijayalekshmi, & Sung,
2009). Besides other inflammatory pathway, STAT3 and TNF-α is highly interconnected
with the activation of NFᴋB. Mutation of NFᴋB signaling genes is directly associated with
lymphoid malignancies. Studies on animal models have shown a correlation between
increased expression of activated NFᴋB or its mutation with increase severity of
hepatocellular carcinoma, breast cancer, melanoma, lung and even colon cancer. NFᴋB has
also been shown to polarize the classic M1 macrophages towards M2 phenotype which
instead of attacking tumor foster it for further growth and metastasis (Hoesel & Schmid,
2013). Due to the above mentioned reasons, NFᴋB pathway is one of the popular pathways
to be targeted by chemotherapeutic agents. Inhibition of NFᴋB might be appropriate for
reducing the severity of chronic inflammation and colon cancer.
Cyclooxygenase (COX) is an enzyme that catalyze the rate-limiting step of
converting arachidonic acid to prostaglandin. There are 2 isoforms of COX: COX-1 and
COX-2. COX-1 is expressed in several tissues in the body and is required to maintain

26

normal physiological functions like maintaining gastric mucosa, renal blood flow and
platelet aggregation. Overexpression of COX-2 has been associated with several cancers
(Miladi-Abdennadher et al., 2012) and is contributing factor in the development of colon
cancer. 85% of the sporadic human colorectal cancer especially neoplastic epithelial cells
have reportedly increased expression of COX-2. It may induce angiogenesis, metastasis,
alter extracellular matrix adhesion and resistance to apoptosis. Overexpression of COX-2
has been determined in the carcinogenesis induced by mutation of APC gene leading to
increased intestinal tumor. Celecoxib, a COX-2 inhibitor has been shown to reduce the
incidence of AOM induced colon cancer by 93% and rofecoxib another COX-2 specific
inhibitor significantly decreased the rectal polyp number and size in patients with familial
adenomatous polyposis (Higuchi et al., 2003; Miladi-Abdennadher, et al., 2012). Besides
these evidences it is still controversial to use COX-2 as a prognostic marker for the
recurrence and survival of the patients with colorectal cancer (Petersen et al., 2002). Its be
concluded form the above that the overexpression of COX-2 is directly related with
increased severity of colorectal cancer and the reduced expression could a better outcome
for the treatment of colon cancer.

2.6 Goblet cell and Mucus Secretion
Colon epithelial tissues is the one of the tissues with highest turnover and is
proliferative in nature. Colon and intestinal tissue composed of four different cell types: 3
belongs to the secretory lineages: enteroendocrine cells (endocrine in nature), goblet cells
(mucus secretion) and Paneth cells (antimicrobial) and one enterocytes (absorptive in
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nature). These cell are derived from the multipotent stem cells located at the base of the
Crypts of Liberkühn (Shroyer, Wallis, Venken, Bellen, & Zoghbi, 2005). The mechanism
which leads to the formation of the crypts and fates of these cells to the respective lineage
is not completely understood. Several genes and factors are involved in the differentiation
of these cells to their defined fate including Wnt β-catenin pathway, Notch signaling, Math1, Hes-1 and KLF-4. Expression of Hes-1 in the progenitor cells leads to the absorptive
enterocytes fate while those expressing Math-1 get committed to the secretory lineage
which could then become goblet cells, enteroendocrine cells or Paneth cells. The section
of the final fate of the secretory lineage still remains unclear (Schonhoff, Giel-Moloney, &
Leiter, 2004). The colon is the home of millions of bacteria that under normal healthy
condition are friendly and aid in the digestion of food. Bacteria in the colon doesn’t directly
lie on the epithelial cell layer but are separated by the protective mucus covering or it can
be summed up in a two layer design where inner mucus layer is anchored to the colon
epithelium and excludes the bacterium while the upper layer provides a thriving place for
commensal bacteria (Johansson et al., 2008). The mucus scaffold primarily consist of
MUC2 which is a prominent member of the mucin family. Mucins are high molecular
weight O-linked glycoproteins which are distributed in different parts of the body and plat
critical pathophysiological role. Twenty know mucin genes have been identified in
humans, most of which are expressed in the gastrointestinal tract. MUC2 being the major
mucus forming mucin is constitutively expressed by the goblet cells and its core is covered
with glycans (almost 80% glycans in mature MUC2). These glycans are not destroyed by
the host enzymes but they can degraded by the bacterial enzymes. However, the complexity
of these glycans make degradation a time consuming process. Although, some parasitic
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bacteria like Entamoeba histolytica produce proteases that could cleave the MUC2 in such
a way that the whole complex structure falls apart but commensal bacteria including
Lactobacilli and Bacteroidetes family don’t produce any mucin that will degrade MUC2
(Johansson & Hansson, 2013). Goblet or mucus secreting cells of the colon were found to
be significantly reduced in colon adenocarcinoma alongwith the significant reduction in
the HATH1 mRNA expression in clinical samples. HATH1 expression was also
downregulated in the various human colon cancer cell lines (Leow, Polakis, & Gao, 2005).
Math-1-/- mice failed to develop the gastrointestinal secretory lineages including goblet cell,
paneth cell and enteroendocrine cells (Q. Yang, Bermingham, Finegold, & Zoghbi, 2001).
All the above provides an important role of goblet cell, Hes-1 and MATH-1 in reducing
the pathogenesis of colitis and colorectal cancer. Secretion of mucus and especially MUC2
is very critical for the normal maintenance and working of the colon and prevention form
toxins and gut bacterial invasion.

2.7 Selenium, an anti-oxidant and anti-cancer molecule
Selenium is an essential micronutrient and is widely accepted as an anti-oxidant
non-metal (Maseko, et al., 2014). This micronutrient forms selenocysteine, which is the
twenty-first amino acid and integrates into proteins to form 25 selenoproteins (Metanis &
Hilvert, 2014). It has been shown to lay a wide physiological role including immune
function, male fertility and thyroid function. Se can be obtained in the diet through several
sources including Brazil nut, fish, liver, chicken, certain vegetables and meats (Maseko, et
al., 2014). The recommended dietary allowance for Se is 55μg per day for human adults

29

and the upper safe limit is 400 μg/day. Beneficial effects of Se can be obtained at a dosage
of 200 μg per day. Se has been shown to reduce the severity of cancers including prostate
(Gerstenberger et al., 2014), breast (Arsenyan et al., 2014) and lung (Okuno, Honda,
Arakawa, Ogino, & Ueno, 2014b) and has acted as a useful supplementation for several
ailments including cystic fibrosis (Ciofu & Lykkesfeldt, 2014), male and female infertility
(Balazs & Racz, 2013), glucose metabolism in type 2 diabetes (Mao & Teng, 2013),
grave’s disease (Kryczyk & Zagrodzki, 2013) and other related inflammatory and
autoimmune diseases. A dosage of 200 μg/day of Se has been shown to decrease the total
incidence of cancer by 25% (Reid et al., 2008). Higher intake or the overdose of Se is
associated with severe toxicity. A dosage higher than 400 µg per day is associated with
selenosis. Some of the symptoms associated include gastrointestinal disorders, fatigue,
irritability, hair loss and neurological disorders. During extreme cases, it can result in liver
cirrhosis, pulmonary edema and even death. An inverse association has been established
between higher Se status and colorectal cancer (Hughes et al., 2014). The protective effect
of the Se in various diseases and conditions is mostly due to the anti-oxidative property
leading to an increase in the production of selenoproteins like glutathione peroxidases
(Gpx), which neutralize or prevent the formation of reactive oxygen species (ROS)
(Kosaric et al., 2014). Se metabolism is complex and most of the biological effects of
elemental Se that is ingested are mediated by selenoproteins (Labunskyy, Hatfield, &
Gladyshev, 2014). Gpx-1 and Gpx-2 are the most abundant selenoproteins present and
mediate most of the protective effect of Se. Gpx-1 is ubiquitously presents in the cytosol
and the mitochondria in all the tissues of the body, while Gpx-2 is mostly concentrated in
the intestinal epithelium (Brigelius-Flohe & Maiorino, 2013). Gpx-1 or Gpx-2 knockout
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mouse or double knockout mouse has shown to exhibit severe pathology of colorectal
cancer (Krehl et al., 2012; D. H. Lee, Esworthy, Chu, Pfeifer, & Chu, 2006) and Se rich
diet has been shown to increase Gpx activity in mice model of colorectal cancer. Increased
activity of Gpx-1 and Gpx-2 has also been linked to the chemo preventive effect of Se
supplementation (Hu, McIntosh, Le Leu, & Young, 2010).
A recent study by Li et al. 2013 on human colorectal carcinoma cells (HCT 116
and SW620) has shown that different dosages (1 μM, 5 μM and 10 μM) of Se lead to
apoptosis of the colon cancer cells by Bax dependent pathway (Z. Li, et al., 2013) with 10
μM being the most effective. Another study by Luo et al. 2013 has shown that
supranutritional dosage of sodium selenite (10 μM) lead to apoptosis of colon cancer cells
by ROS modulation of phosphatase and tensin homolog (PTEN) mediated
PI3K/AKT/FoxO3a signaling pathway in colon xenograft animal model (Luo, et al., 2013).
Sodium selenite has also shown to reduce inflammation by downregulating the expression
of nuclear factor kappa light-chain-enhancer of activated B cells (NFκB) and related
cytokines (Pillai, Sugathan, & Indira, 2012). All the above mentioned evidence provide a
strong case for the use of Se rich diet in the treatment of chronic inflammation and
colorectal cancer.

2.8 Oxidative Stress and Cancer cell apoptosis
According to the 2014 statistics, cancer is the cause of one in four deaths in United
States (R. Siegel, et al., 2014) and colorectal cancer is the major cause of cancer worldwide
and accounts for 9% of total cancer incidence. Oxidative stress refers to the uncontrollable
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overproduction of free radicle and their derivatives that interact with macromolecules like
lipid, proteins and DNA and modulate their structure and function (Perse, 2013). Among
the wide etiology of cancer, DNA damage by ROS is one of the main culprit for the onset
and the development of cancer. Increase in oxidative byproducts of the normal metabolism
leads to increase inflammation which in presence of an external stimulus including toxin
or carcinogen leads to cancer. Studies have shown the protective role of antioxidants and
phyochemicals including vitamin E, selenium, glutathione, resveratrol, catechins,
sulforaphane, curcumin and genistein on inflammation and cancer (Shukla, Meeran, &
Katiyar, 2014). ROS may oxidize polyunsaturated fatty acids (PUFA) and initiates the
process of lipid peroxidation that leads to the formation of other free radicles and
substances like hydroperoxides, lipoperoxides, conjugated dienes, aldehydes which are
toxic in nature and malondialdehyde (MDA). This process of lipid peroxidation increase
membrane permeability, results in the loss of gradient maintenance and inflammation
(Finaud, Lac, & Filaire, 2006). MDA and 4-hydroxy-2-nonenal; products of lipid
peroxidation can act at different levels and could modulate cell proliferation and gene
expression leading to greater production of ROS which could further modify or oxidize
protein and render them non-functional (Marnett, 2002). Oxidized protein are either
catabolized to amino acids or rapidly degraded by proteasomes or in worst case scenario
may accumulate in the cell leading to pathologies and inflammation (Grune, Merker,
Sandig, & Davies, 2003). Nitrosylation is another consequence of the oxidative stress
which leads to the production of Nitric Oxide (NO) that reacts with the cysteine residue of
different proteins and could inhibit or promote the activity of those proteins. This process
of nitrosylation shutdowns the activity of caspases which are responsible for apoptosis of
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cancer cells. It may also inactivate certain DNA repair enzyme leading to the accumulation
of mutations and DNA damage further promoting inflammation and cancer (Floyd,
Chandru, He, & Towner, 2011). Therefore one of the mechanism for the treatment of colon
cancer is the use of anti-oxidant such as Se which has been shown to increase activity of
antioxidant protein like Gpx that can reduce oxidative stress and hence decrease the
severity of inflammation and colon cancer.
Apoptosis or programmed cell death is an orchestrated process which includes a
sequence of biochemical and morphological changes that eliminate the old and infected
area and create space for new cell growth and repair (Huerta, Goulet, Huerta-Yepez, &
Livingston, 2007). Se administration has been shown to increase the apoptosis of the
human colorectal carcinoma cell lines (HCT 116 and SW620) by Bax dependent pathway
(Z. Li, et al., 2013). Methylseleninic acid has been shown to cause the apoptosis of breast
cancer cell by the activation of caspase 8 and 9 (Z. Li, Carrier, & Rowan, 2008). Another
study by Luo et al., 2013 has shown that supranutritional dosage of sodium selenite leads
to the apoptosis of colon cancer cells by reactive oxygen species (ROS) modulation of
phosphatase and tensin homolog (PTEN) mediated PI3K/AKT/FoxO3a signaling pathway
(Luo, et al., 2013). APN has been to know to act by the activation of AMPK which in turn
play a critical role of in the suppression of cellular proliferation and cancer cell apoptosis
by the activation of p53 and p21. APN has been shown to cause the apoptosis of the
Barrett’s adenocarcinoma cell line OE-19 by the upregulation of Bax and downregulation
of Bcl2. APN can induce apoptosis of the gastric, liver and endometrial carcinoma in Bax
dependent manner along with the activation of caspase 3 (Dalamaga, Diakopoulos, &
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Mantzoros, 2012). Both APN and Se has been known to cause apoptosis of the cancer cells
and could be used alone or in conjugation for the treatment of colon and intestinal cancer.

2.9 Wnt Pathway, β catenin, TGF-β and ZO1
More than 80% of the colorectal cases are caused by the truncation of the Apc
protein. Wnt signaling is one of the primary mechanism that is involved in cell
proliferation, polarity and cellular differentiation during embryogenesis, development and
homeostasis (Logan & Nusse, 2004). A slight mutation in the Wnt pathway result in birth
defects, cancer and related diseases. There are 2 types of Wnt pathways: canonical and
non- canonical. Canonical Wnt pathway is the most studied pathway and causes the
accumulation of β catenin in the cytoplasm and final translocation in to the nucleus where
it act as a transcription factor and leads to the activation of certain genes.
Colon and intestinal epithelium is one of the most dynamic and self-replenishing
organ in the mammalian system which get renewed in 3-5 days along the crypt villus axis
(Leblond & Stevens, 1948). Colon and small intestine is designed in a way to increase the
surface area of the organ for maximum absorption. Several in vivo and in vitro studies have
indicated the important role of Wnt signaling in maintaining the proliferative and
pluripotent nature of the intestinal stem cells. In the absence of the Wnt signal, Apc/Axin
complex or the destruction complex degrades the cytoplasmic β catenin by targeting it for
ubiquitination which has a potential to go in the nucleus and activate the Wnt target genes
(Burgess, Faux, Layton, & Ramsay, 2011). However in the presence of Wnt ligand and
following its binding to the Frizzled (Fzd) receptor and low density lipoprotein, disheveled
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(Dvl) protein is phosphorylated and it inactivates glycogen synthase kinase-3-β (GSK3-β)
which leads to the disruption of destruction complex and β catenin accumulates in the
cytoplasm leading to its translocation to the nucleus. In the nucleus, β catenin forms a
complex with the TCF/LEF transcription factor and leads to the transcription of Wnt target
genes which further leads to cell proliferation, inflammation, cell migration and
carcinogenesis (Sebio, Kahn, & Lenz, 2014). β catenin is also the part of the complex that
forms the adherence junctions and plays an important role in embryogenesis and EMT. β
catenin is also considered as a proto-oncogene and its mutation is common in several
cancers including liver cancer, ovarian cancer, breast cancer, lung and colon cancer (Forbes
et al., 2011).
β catenin is responsible for several morphogenetic changes in the epithelial cells of
the colon. Under the influence of β catenin, epithelial cells lose the tight junction or
adherence and transit to more loose and mobile mesenchymal phenotype. During the EMT,
epithelial cells lose the expression of proteins like ZO-1 and cadherin which are required
for continued normal gut barrier and maintaining the integrity of the gut epithelium (Tian,
et al., 2011). TGF-β is a 25 kDa cytokines that plays a critical role in carcinogenesis,
homeostasis, cell proliferation, migration, apoptosis, fibrosis, differentiation of cell and
wound healing. TGF-β signaling pathway is one of the most common altered signaling. It
can play a dual role as a tumor suppressor and as a cancer promotor. During the progression
of the human colon TGF-β1 switches form being inhibitor to tumor cell growth promotor.
Higher TGF-β protein levels is associated with an increased incidence of tumor
reoccurrence (Friedman et al., 1995). TGF-β alongwith β catenin has been shown to
enhance EMT and angiogenesis leading to greater severity of colon cancer (Lampropoulos
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et al., 2012). APN and Se administration independently has been to reduce the expression
of TGF-β and β catenin. Therefore studying the role of APN and Se on Wnt mediated β
catenin activation and TGF-β will provide conclusive evidence for the protective role of
APN and Se in cancer, inflammation and CICC.

2.10 Mouse Model of colon cancer
Development of colon cancer is a sequential process involving the genetic changes
or toxic exposure in the colon epithelium leading to the formation of pre-cancerous lesions.
These lesions then develop in to adenomatous polyp which finally progress in to invasive
tumors which invade the different layers of the colon epithelium depending on the stage of
the colon cancer. The survival rate of the colon cancer various depending on the stage of
colon cancer with 92% 5 year survival at stage I and only 11% survival at stage IV.

2.11 Chemically induced colon cancer mouse models:
Induction of colon cancer by carcinogen and inflammatory chemicals is rapid in
mice and very reproducible which marks the conversion from adenoma to adenocarcinoma
that overlaps with the sequence of events that occurs in human colorectal cancer.
Commonly used carcinogen include the following: 1,2 Dimethylhydrazine (DMH),
azoxymethane (AOM), 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP), 2amino-33-methylimidazo [4,5-f], 3,2′-dimethyl-4-aminobiphenyl (DMAB) and N-methylN′-nitro-N-nitrosoguanidine (MNNG). Repeated exposure to DMH intraperitoneally
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produces colon tumors that leads to severe pathology which is very similar to the human
disease. This makes DMH as one of the most commonly used carcinogen along with AOM
which serve the same function as DMH. Several studies have successfully indicated the
use of DMH in developing pre-cancerous lesions and tumor associated with colon and
rectal cancer. Our preliminary data indicated that intraperitoneal DMH injection (20mg/kg
mouse body weight) once a week for 12 weeks was effective in producing tumor in both
APNKO and WT mice (Tong, et al., 2011).
DMH can also be complemented by DSS which is a sodium salt that is effective in
producing both chronic and acute inflammation depending on the amount, duration and
frequency of exposure. DSS alone is commonly used in acute and chronic model of murine
colitis (Okayasu et al., 1990). DSS is usually administered in drinking water and the
concentration usually varies with the study duration and exposure time. 1.5 to 3% DSS in
the drinking water has been reported in studies relating to colitis and colon cancer. In the
DSS+DMH model, dysplasia could be observed initially after DMH administration
followed by the first DSS cycle in the colon mucosa. Mutation of the β catenin in the later
stage of the colon cancer could be observed in 80-100% of the DSS+DMH induced CICC.
Similar result could be obtained by using AOM instead of DMH (Seril, Liao, Yang, &
Yang, 2003; Tong, et al., 2011).

2.12 Genetic model of Intestinal Cancer: APCMin/+
Adenomatous polyposis coli (APC) is a human gene that is commonly associated
with tumor suppression by downregulating the canonical pathway of Wnt signaling as
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discussed above. It acts by binding to β catenin as a part of the destruction complex
resulting in its degradation. Loss of APC impairs the degradation of β catenin leading to
its accumulation in the cytoplasm, followed by its translocation to the nucleus where it
activates the LEF/TCF transcription factors. These transcription factor further activates the
Wnt target genes which is one of the common pathway in tumorigenesis of the colorectal
cancer and shows a similar pathology observed in the human subjects (Korinek et al.,
1997). APC mutation is the truncating mutation of the APC gene at codon 850.
Homozygous APCMin-/- mutation are lethal at the early embryonic stages but the
heterozygous APCMin/+ mutation on the C57BL/6 background survives and develops
around 30 tumors at an age of 16 weeks with more than 50 tumors at an age of 20 weeks
in the intestine. Most of the tumors are concentrated in the small intestine with few tumor
invading the colon. In both small intestine and the colon, tumors are located more towards
the distil end that is in the iliac part of the small intestine and the descending part of the
colon (Tong, et al., 2011). Abnormal intestinal epithelial and goblet cell morphology is
also observed in the APCMin/+ mice model of intestinal cancer. There are several mutants
of the APC gene including mutations at 716 (truncating mutation), 1638N (neomycin
insertion at codon 15 resulting in truncation of codon 1638), 1638T (hygromycin insertion
at codon 15 resulting in truncation of codon 1638) and frameshift of 580 and 474 codon
(Colnot et al., 2004; Moser, Pitot, & Dove, 1990; Pretlow, Edelmann, Kucherlapati,
Pretlow, & Augenlicht, 2003; Sasai, Masaki, & Wakitani, 2000). These difference in the
mutation sites results in different number of polyps in the small intestine but the colon
polyps remains the same. In addition to tumor development these mice show loss of both
mature and immature thymocytes with a complete regression of thymus at an age of 18
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weeks (Coletta et al., 2004). Bone marrow shows depletion of immature and progenitor B
cells. IL-6 levels have been reported to increase 10 fold as compared to the C57BL/6 mice
which causes the development of cachexia that is accompanied by the loss of fat and muscle
mass leading to extreme weight loss (Baltgalvis et al., 2008). Due to these complication,
the maximum lifespan of these APCMin/+ mice is 24 weeks with and average lifespan of 1620 weeks depending on the degree of cachexia (Tong, et al., 2011).
Due to the above mentioned reasons and on the basis of our preliminary data we
will be using DSS+DMH model of CICC and APCMin/+ mice model of intestinal cancer in
our colon cancer prevention studies.
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CHAPTER 3

ADIPONECTIN DEFICIENCY: ROLE IN CHRONIC INFLAMMATION INDUCED COLON
CANCER1
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3.1 Abstract
Adiponectin (APN), an adipokine, exerts an anti-inflammatory and anti-cancerous
activity with its role in glucose and lipid metabolism and its absence related to several
obesity related malignancies including colorectal cancer. The aim of this study is to
determine the effect of APN deficiency on the chronic inflammation-induced colon cancer.
This was achieved by inducing inflammation and colon cancer in both APN knockout (KO)
and C57B1/6 wild type (WT) mice. They were divided into four treatment groups (n= 10):
1) control (no treatment); 2) treatment with three cycles of dextran sodium sulfate (DSS);
3) weekly doses of 1,2-dimethylhydrazine (DMH) (20 mg/kg of mouse body weight) for
twelve weeks; 4) a single dose of DMH followed by 3 cycles of DSS (DMH+ DSS). Mice
were observed for diarrhea, stool hemoccult, and weight loss and were sacrificed on day
153. Tumor area and number were counted. Colonic tissues were collected for Western
blot and immunohistochemistry analyses. APNKO mice were more protected than WT
mice from DSS induced colitis during first DSS cycle, but lost this protection during the
second and the third DSS cycles. APNKO mice had significantly severe symptoms and
showed greater number and larger area of tumors with higher immune cell infiltration and
inflammation than WT mice. This result was further confirmed by proteomic study
including pSTAT3, pAMPK and Cox-2 by western blot and Immunohistochemistry.
Conclusively, APN deficiency contributes to inflammation-induced colon cancer. Hence,
APN may play an important role in colorectal cancer prevention by modulating genes
involved in chronic inflammation and tumorigenesis.
Keywords: Adiponectin, Inflammation, Colon, Cancer
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3.2 Introduction

Patients with inflammatory bowel disease, such as Crohn's and ulcerative colitis
(UC), are at increased risk for developing colorectal cancer (Guthrie et al., 2002; Itzkowitz
& Yio, 2004). UC patients, in particular, have ten to forty fold increased risk of developing
cancer, compared with the general population (Munkholm, 2003; Whelan, 1991). The
pathogenesis of colitis-associated colorectal cancer is thought to be related to an increased
rate of epithelial cell proliferation associated with the repetitive cycles of inflammation,
damage and regeneration (Eaden, Abrams, & Mayberry, 2001; Seril, et al., 2003). In
addition, obesity, an established risk factor for colorectal cancer, is characterized by the
accumulation of excessive adipose tissue, which is the source of a variety of biologically
active substances, collectively referred to as adipokines (Berg, Combs, & Scherer, 2002;
Giovannucci et al., 1995). Adiponectin (APN), an adipokine secreted by the adipose tissue,
has been found at low levels in obese subjects (Wei, et al., 2005; Weiss et al., 2003).
Obesity and APN have been linked to colon cancer by various studies (Bianchini, Kaaks,
& Vainio, 2002; Birmingham, Busik, Hansen-Smith, & Fenton, 2009; Calle & Kaaks,
2004; Gunter & Leitzmann, 2006; Larsson & Wolk, 2007). Furthermore; obesity is
associated with a heightened inflammatory response in Crohn's disease (CD) patients who
have typical alterations of mesenteric fat deposits (Blain et al., 2002). Adiponectin exerts
its activity through its receptors. Two receptors, AdipoR1 and AdipoR2, had been
identified for APN and were found to mediate glucose and fatty acid metabolism by
Adenosine mono-phosphate kinase (AMPK) activation, although no mechanism has been
devised for its activation (A. Y. Kim, et al., 2010; Yamauchi et al., 2003; Yamauchi et al.,
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2002; Yamauchi et al., 2007). AMPK is a serine threonine kinase, which is activated by
phosphorylation, in the presence of cellular stress (Carling, 2004; Shaw et al., 2004).
AMPK has anti-inflammatory effects and has been considered as a potential therapeutic
target for cancer (Grossmann, Nkhata, Mizuno, Ray, & Cleary, 2008; Hwang, Ha, & Park,
2005; Masferrer et al., 2000; Ouchi et al., 2004). APN increases the rate of phosphorylation
of AMPK and suppresses cell growth by inhibiting the mammalian target of rapamycin
(mTOR) (Ouchi, et al., 2004). AMPK activity also inhibits the activity of Cyclooxygenase
(Cox)-2, an enzyme that is upregulated in the presence of various stimuli like inflammation,
tumorigenesis, metastasis, and growth factors (Grossmann, et al., 2008; Masferrer, et al.,
2000). More importantly, APN has been linked to reduce expression of Cox-2 in APNKO
mice treated with azoxymethane (Hwang, et al., 2005).

Signal transducer and activator of transcription (STAT)-3 is overexpressed in many
cancers and is a potent indicator of inflammation (Bowman, Garcia, Turkson, & Jove,
2000). It plays a critical role in tumor progression and metastasis through transcriptional
activation of anti-apoptotic genes like Bcl-xL, Mcl-1 and survivin, cell-cycle regulators
(e.g. cyclin D1 and c-Myc) and inducers of angiogenesis (e.g. vascular endothelial growth
factor) (Darnell, 2005; Miyazaki, Bub, Uzuki, & Iwamoto, 2005).

In this paper, we have used dextran sodium sulphate (DSS), a potent inducer of
inflammation and promoter of colorectal carcinogenesis. It was administered in mice for
three cycles to induce chronic inflammation, while dimethylhydrazine (DMH) was injected
intraperitoneally to induce cancer. APN knockout (KO) and the C57Bl/6 wild type (WT)
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mice were given different treatments to elucidate the role of APN deficiency in chronic
inflammation-induced colon cancer (CICC).

We hypothesized that APNKO mice are more susceptible to CICC as compared to
their WT counterpart, which could be deduced by greater weight loss, bloody stools,
diarrhea, larger number and size of the tumors. It is also evident by the up-regulation of
pro-cancerous and downregulation of anti-cancerous and inflammatory genes.

3.3 Methods

Animals and experimental groups: Six to eight week old male APNKO (n=24) and male
C57BL/6 (WT, n=24) were housed in conventional animal room and treated in the animal
facility at the University of South Carolina. All APNKO mice were homozygous for APN
deficiency (−/−). The mice were on a 12:12 h light–dark cycle in a low stress environment
(22 °C, 50% humidity and low noise) and had access to food (Purina Chow) and water ad
libitum. All animal care followed institutional guidelines under a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Carolina. APNKO
and WT mice were randomly assigned to 4 different groups of equal number (n=6 mice per
group): 1) DMH+DSS; 2) DMH; 3) DSS and 4) Control or no treatment. The body weight
of both APNKO and WT mice showed no significant difference at the beginning of the
study.
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Induction of chronic inflammation and cancer: Chronic inflammation was induced in
the WT and APNKO mice assigned to the DSS treatment group. These mice received 2%
dextran sodium sulfate (DSS) (MP Biochemicals, MW: 36,000–50,000) dissolved in their
drinking water for five days, followed by five days of regular drinking water, this
represented single cycle and DSS was administrated for three cycles on days 4, 27 and 50.
To establish chronic inflammation induced colon cancer, another group of mice received 3
cycles of DSS and a single injection of DMH intraperitoneally (i.p) (SIGMA ALDRICH)
(20 mg/kg body weight) administered at the beginning of the DSS treatment. Cancer was
induced in the WT and APNKO mice assigned to DMH treatment group by administering
weekly dose of DMH i.p. for twelve weeks and the mice were sacrificed on day 153.

Monitoring animal health: Mice were observed daily for clinical signs of disease
attributed by weight loss, fecal hemoccult and diarrhea during all treatments and till day
153. Ranking for the weight loss was based on the following scale: 0 = 0–5% weight loss;
1 = 6–10% weight loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 = >20%
weight loss. The appearance of diarrhea was scored as: 0 = well-formed pellets, 2 = pasty
and semi-formed stools that do not adhere to the anus, 4 = liquid stools that adhere to the
anus. Appearance of blood in the stools was assessed using a hemoccult kit (BECKMAN
COULTER) and scored as: 0 = no blood, 2 = positive hemoccult, 4 = gross bleeding. The
clinical score was then determined by totaling the weight loss, hemoccult, and diarrhea
scores with the highest score being twelve.
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Tissue collection and tumor quantification: The mice were euthanized by cervical
dislocation. The colon was removed and flushed with PBS containing 5000 IU/mL and
5000 IU/mL penicillin and streptomycin (CELLGRO) respectively. Two 2 mm 2 sections
of the descending colon were dissected and stored at −80 °C for Western blot analysis and
at 37 °C, 5% CO2with overnight incubation for tissue culture. The remaining colon was
fixed in 10% formalin (AZER SCIENTIFIC) for a day. It was then stained with 0.2%
methylene blue (FISHER SCIENTIFIC) to count tumors and measure tumor area followed
by its swiss roll and sectioning it for immunohistochemistry and Hematoxylin and Eosin
(H&E) staining. Tumor quantification was done in blinded condition by two individuals.

Colonic cytokines and serum APN measurement: The secreted concentrations (pg/mg
of protein) of IL-6, IL-10, IL-1β and TNF-α in the tissue culture were determined by
Enzyme Linked Immunosorbent Assay (ELISA) using BD OptEIA kit (BD
BIOSCIENCES). Serum APN was determined in all the treatment groups at the beginning
and at the end of the study. This was achieved by diluting the serum samples to 1:2000 and
performing ELISA using DuoSet mouse/Acrp30 kit (R&D SYSTEMS).

Protein determination and western blot: Tissues frozen at −80 °C were thawed and
homogenized in RIPA buffer (SIGMA) containing 1:1000 dilution of protease inhibitor
solution (SIGMA). Concentration of the total protein in the solution of homogenized tissue
was calculated by Bradford protein assay. Protein homogenate from each group was loaded
and electrophoresed on 10% SDS-PAGE gels and transferred to a nitrocellulose membrane
at constant voltage of 200 mA for 150 min at 4 °C. The membrane was then blocked with
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5% non-fat dry milk (BIO-RAD) in DPBS (cellgro)+0.1% Tween 20 (BIO-RAD) for one
hour at room temperature followed by overnight incubation at 4 °C with STAT3 and
pSTAT3 (1:000) (CELL SIGNALING TECHNOLOGY), AMPK and pAMPK (1:1000)
(SANTA CRUZ BIOTECHNOLOGY) and GAPDH (1:3000) (R&D SYSTEM) diluted in
DPBS+0.1% Tween 20. Membrane was subsequently washed 5 times for 10 min with
DPBS+0.1% Tween 20 with consequent incubation with anti-rabbit or anti goat secondary
antibody conjugated with horseradish peroxidase enzyme (1:3000) (SANTA CRUZ
BIOTECHNOLOGY) for 1 h. The membrane was washed and incubated for 5 min in
Amersham ECL Plus Western blot detection system (GE HEALTHCARE) with
subsequent detection on high performance chemiluminescence film (Amersham Hyperfilm
ECL, GE HEALTHCARE). GAPDH was used as a loading control to normalize the protein
expression by densitometry using Image J software (NCBI). Western blot for each protein
was done thrice by using all samples from the same treatment group to determine statistical
significance.

Immunohistochemical staining: Serial tumor and non tumor sections of mouse colon
tissues were incubated with antibodies against cyclooxygenase-2 (Cox-2; rabbit
polyclonal; diluted 1:5000; CAYMAN CHEMICAL). To ensure even staining and
reproducible results, sections were incubated by slow rocking overnight in primary
antibodies (4 °C) using the Antibody Amplifier (ProHisto, LLC). Following incubation
with primary antibody, sections were processed using EnVision+System-HRP kit (DAKO
CYTOMATION). The chromogen was 3,3′-diaminobenzidine and sections were
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counterstained with 0.5% methyl green. The positive control tissue was colon cancer
sections which were highly positive for iNOS, Cox-2, TNF-α, p53, and p53-phospho-Ser15.
Stained tissues were examined for intensity of staining using a method similar to that
previously described by Nishihara et al., 2008. Briefly, intensity of staining in colon
sections was evaluated independently by two blinded investigators. For each tissue section,
the summation of the intensity of staining and the percentage of the positively stained cells
was analyzed and quantified on a scale of 4, where 0 represents no staining, 2 — 50–75%
of moderately stained cells, and 4 indicates more than 75% of darkly stained cells. All the
images were taken in 20X magnification with Nikon e600 microscope. The scale bar
represents 120 µm.

Hematoxylin and Eosin staining and histological scoring: To determine the pathological
state of the colon, a standard protocol for H&E staining was used. Quantification of
severity of disease including inflammation and immune cell infiltration was done on the
scale of 4 for both the parameters, where 0 = no infiltration or no inflammation; 2 =
moderate infiltration or inflammation; and 4 = severe inflammation with distorted crypts
or infiltration and formation of lymphatic follicles. All the images were taken in 20×
magnification with Nikon e600 microscope. The scale bar represents 120 µm.

Aberrant crypt foci (ACF): The H&E stained slides for DSS treated groups for APNKO
and WT were scanned by two investigators in the blinded conditions for aberrant crypt
foci. The ratio of the number of ACF to normal crypts was calculated in the 2 mm2 area
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and was plotted on a graph. All the images were taken in 40× magnification with Nikon
e600 microscope. The scale bar represents 60 µm.

Statistical analysis: Two-way analysis of variance (ANOVA), Two-way repeated measure
ANOVA and One-way ANOVA was used to analyze the data with Tukey post hocanalyses. A p value<0.05 was considered statistically significant. All the statistical analyses
were done by using SigmaStat 3.5 (SPSS, Chicago, IL).

3.4 Results

Clinical manifestation of CICC in APNKO and WT mice

To study the role of APN deficiency in CICC, WT and APNKO mice were given
three different treatments and were observed for weight loss, diarrhea and hemoccult for
153 days and during this time clinical score was calculated. After the first DSS cycle in
DSS and DSS+DMH group, WT mice lost their protection from DSS in comparison to
APNKO mice and showed a significantly higher clinical score on day 18 in DSS group
(Fig. 1B and C). However, no significance was observed in DSS+DMH group. After the
second DSS cycle, APNKO mice manifested significantly higher clinical score on days 32,
34 and 36 when treated with DSS alone, but in DSS+DMH treatment group, it was
observed on day 29 (Fig. 1B and C). Following the third DSS cycle, there was a complete
loss of protection from DSS in the DSS and DSS+DMH group resulting in a significantly
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higher clinical score in APNKO mice as compared to WT mice (Fig. 1B and C). Mice in
DSS+DMH group didn't recover from the treatment and the clinical score continued to
remain significantly higher in APNKO mice till the date of sacrifice (Fig. 1C). DSS treated
mice recovered after every DSS cycle but after the third cycle, APNKO mice showed a
comparatively higher clinical score than WT (data not shown). In DMH treatment group,
significantly higher clinical score was observed in APNKO mice when compared to WT
mice on days 77, 105 and 128, after which the score continued to remain higher till the date
of sacrifice (Fig. 1A).

Tumor development in APNKO and WT mice

Immediately following the sacrifice, mice colon was fixed and stained in methylene
blue for tumor quantification (Fig. 2A). APNKO mice had a significantly greater tumor
number than WT mice in all the treatment groups (Fig. 2A and B). The degree of
significance was higher in DMH group, but the number of tumors was higher in
DSS+DMH group as compared to others. In DSS+DMH group, APNKO mice showed a
significantly larger tumor area as compared to the WT group (Fig. 2C). Most of the tumors
were observed in the descending and the rectal part of the colon.

Colon morphology

To study the change in the colon morphology in CICC, H&E staining for all the
treatment groups was done for both WT and APNKO mice and quantified on a scale of one
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to four. It was observed that the APNKO mice treated with DSS+DMH showed a complete
loss of structural integrity of the colon epithelium. Infiltration of the immune cells was also
observed in addition to crypt destruction. Tumor growth was more prominent and the
number of tumors was observed to be greater in APNKO mice than WT in DSS+DMH
group (Fig. 3A). APNKO mice treated with DSS+DMH had significantly severe immune
cell infiltration, inflammation and distorted crypts as compared to WT mice (Fig. 3B).
Significance in the severity of inflammation and infiltration was also observed in APNKO
mice treated with DMH (H&E not shown). DSS treated group showed no significant
difference between the APNKO and WT mice (Fig. 3B). DSS treated group however
showed a significantly higher ACF in the APNKO mice as compared to WT mice (Fig. 3C
and D). Other treatment groups were observed for ACF, but neither showed ACF as they
have developed tumors or the observed difference was not significant between the APNKO
and WT mice.

Systemic APN in WT mice and secreted cytokine profiling for all the treatment groups

To determine the effect of different treatments on the systemic APN levels, sera
were obtained from the WT mice at the beginning of the study or pre-treatment and at the
time of sacrifice. It was observed that the serum APN concentration in DSS+DMH treated
group was significantly less when compared to the WT mice treated with DSS or DMH
alone and with the control group (Fig. 4E). DMH treated mice showed a significantly lower
concentration of serum APN than the DSS alone and control group. Significant decrease
in the serum APN level was observed in the DSS+DMH and DMH alone treated WT mice
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on days 153 and 0 (Fig. 4E). However no significant difference was found in the mice
treated with DSS and the control group (Fig. 4E).
The tissue culture media was then used to perform secreted cytokine profiling and the
concentration of the secreted IL-6, IL-10, TNF-α and IL-1β was calculated in all the
treatment groups by using ELISA. APNKO mice showed a significantly higher colonic IL6 and TNF-α levels in DSS and DSS+DMH groups when compared to the WT mice (Fig.
4A and D). IL-1β, another pro-inflammatory cytokine was found to be secreted in
significantly higher concentrations in APNKO mice in DMH and DSS+DMH group (Fig.
4C). IL-10, grouped as an anti-inflammatory cytokine was quantified and it was found that
in all the treatment groups, was a significant decrease in APNKO mice with greater
significance in the DSS+DMH group as compared to WT mice. IL-10 level in APNKO
mice of DSS+DMH group was comparable to the baseline untreated control group (Fig.
4B).

Colonic STAT3, AMPK, and Cox-2 expression

We investigated the effect of APN deficiency on various pathways involved in
inflammation and colon cancer in our different treatment groups. We observed
significantly higher expression levels of pSTAT3Ser727 and Cox-2 in APNKO mice treated
with DSS+DMH and DMH in comparison to WT mice. However, no significant difference
was observed in the expression level of APNKO and WT mice administered with DSS
alone (Fig. 5A, B and D). No to minimum expression of pSTAT3Ser727 was detected in
control group (Fig. 5A and B). However, low expression of Cox-2 was observed in
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APNKO mice in control group while there was no expression in WT mice (Fig. 5A and
D). p-AMPK-α ½Thr

172

was downregulated and significantly decreased expression in

APNKO mice treated with DSS+DMH and DSS alone in comparison to the WT mice.
Comparatively, higher expression of p-AMPK-α ½Thr 172 was observed in control group
(Fig. 5A and C). GAPDH was used as a loading control and was used to normalize all the
protein density measurements (Fig. 5A). Ratio of the phosphorylated protein to full protein
was represented on the graph.

Cox-2 localization

After proteomic study by Western blot, localization of Cox-2 was determined, by
immunohistochemistry for Cox-2 antigen in the tumor and the non tumor area of the
descending colon section of both APNKO and WT mice. This study revealed significantly
higher expression of Cox-2 in the tumor area than the non tumor area of the mice treated
with DSS+DMH, irrespective of mice genotype (Fig. 6A, B and C). APNKO mice also
showed significantly higher expression of Cox-2 when compared with WT mice treated
with DSS+DMH (Fig. 6A, B and C). Significant difference was also found in APNKO
mice of the tumor and the non tumor group and most importantly between the APNKO and
the WT mice treated with DSS+DMH in the tumor group (Fig. 6A, B and C). However,
the Cox-2 expression level was insignificant between the WT and APNKO mice treated
with DSS+DMH in the non tumor sections and other treatment group including DSS alone
and DMH alone group with no expression in untreated groups (Fig. 6A, B and C).
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3.5 Discussion

Protective role of APN in obesity, cancer and other disease models has been
established but, in this paper, we have tried to delineate its function in the CICC, which is
a common condition in patients suffering from IBD and have been the second leading cause
of cancer death in the United States (R. Siegel, et al., 2014). This study was primarily
designed to deduce the effect of APN deficiency on the physical and molecular attributes
of CICC. Our results showed a significantly severe clinical manifestation in the APNKO
mice treated with DSS+DMH after the third DSS cycle. It continued to remain severe till
the date of sacrifice. However there was no significant difference observed after the first
and second DSS cycles. This observation is in accordance with common diseased state
observed during colon cancer and could be explained by the loss of protection in the colonic
epithelium of APNKO mice treated with DSS and DMH in chronic conditions. Absence of
APN made the mice more vulnerable to DSS induced colitis and DMH induced colon
cancer. Our group has shown that in acute phase in WT mice, this effect was not prominent
as APN binds to growth factors like HB-EGF, bFGF that prevents the renewal of the
colonic epithelium and hence there was no significant difference between the clinical score
of APNKO and WT mice treated with DSS+DMH (Fayad, et al., 2007). This paper adds
another chapter in APN research on the much-debated topic of APN as an antiinflammatory or pro-inflammatory adipokine. Our results show a peculiar behavior of APN
deficiency that has an anti-inflammatory effect in acute phase and a pro-inflammatory
entity in chronic condition and colon cancer. Nishihara et al. (Nishihara et al., 2008)
showed significant weight loss in the APNKO mice treated with AOM than WT mice;
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however we followed a more comprehensive approach and combined weight loss with
diarrhea and hemoccult.

DSS+DMH treated group was found to show the highest number of tumors and
tumor areas. A significant difference was found between the WT and APNKO mice for
both area and number of tumors. This observation could be explained by the results of
Brakenhielm et al. (Brakenhielm et al., 2004), where they proved APN to induce antiangiogenesis and to perform anti-tumor activity involving caspase- mediated endothelial
cell apoptosis. DSS and DMH alone groups also showed a significant difference in the
tumor number between the WT and APNKO. Most of the tumors observed were in the
descending and the rectal portion of the colon with greater tumor area in the descending
colon. Spleen was also found to be enlarged and more number of tumors was observed in
the APNKO mice as compared to WT (data not shown). However, no metastasis was found
in the lungs and liver. These data are in agreement with our previous observations and
provide an insight about the role of APN in tumor development with absence of APN being
a risk factor for chronic colonic inflammation and colitis. It also follows the same pattern
as counted by Nishihara et al. (Nishihara, et al., 2008).

Ferroni et al. (Ferroni et al., 2007) had regarded lower serum APN as an adjunctive
prognosis for the risk of colorectal cancer. Likewise, we found significantly decreased level
of serum APN in the DSS+DMH treated WT mice as compared to control and along the
length of the experiment (days 0 and 153). This indicates an inverse relation between the
APN and CICC and could be attributed to greater chronic inflammation and cancer growth
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(Ishikawa et al., 2005). A study conducted by Karmiris et al. showed significantly elevated
APN levels in UC patients (Karmiris et al., 2006). On the contrary, we observed no
significant difference in the APN level of the WT mice treated with DSS and control and
also during the length of the experiment. This disparity could be due to that most of the UC
patients received 5-aminosalicylic acid, which has been shown to increase PPAR-γ
expression, which in turn increases APN production (Westerink & Visseren, 2011). In
addition, the DSS model that we used is not an ideal model for UC. This protective role of
APN was further strengthen by our histological evidences which indicates significantly
greater formation of ACF in APNKO mice treated with DSS as compared to WT mice,
which has been debated by several pathologist as a diagnostic tool for colon cancer. We
confirmed the results obtained by Fujisawa et al. (Fujisawa et al., 2008) indicating
significantly higher ACF and aberrant crypt in APNKO under high fat diet condition.
However, we obtained the same results under normal diet with DSS treatment. Further
exploration was done by quantification of inflammation and immune cell infiltration in
DSS+DMH group, which was found to be significantly higher in the APNKO mice.
Tumors could be histologically observed in the APNKO mice treated with DSS+DMH.
Higher infiltration of the immune cells and greater inflammation, epithelial cell disruption
and formation of the primary and secondary lymphatic follicles were common sightings,
which is a clear indication of greater colon epithelium insults in APNKO mice when
compared to WT.

Adipose tissues have been linked to the secretion of several proinflammatory
cytokines and APN has been proved to play an important role in regulating their secretion
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by downregulating the autocrine release of adipose tissue derived pro-inflammatory
cytokines like IL-6, IL-8 from macrophages (Bruun et al., 2003; Dietze-Schroeder, Sell,
Uhlig, Koenen, & Eckel, 2005). Our results indicate similar finding with significantly
higher secretions of pro-inflammatory cytokines like IL-6, IL-1β and TNF-α and reduced
secretion of anti-inflammatory cytokines like IL-10 in the descending colon section of the
APNKO mice treated with DSS+DMH as compared to WT mice. IL-6 and TNF-α was also
found to show significantly higher level in the APNKO mice treated with DSS while IL1β was found to show significantly higher level in APNKO mice treated with DMH while
IL-10, an anti-inflammatory cytokine, level was significantly downregulated in the same
group. Higher secretion of TNF-α was observed in the DSS-treated than DSS+DMHtreated APNKO mice, but the difference was not significant. This could be explained by
the multifunctional roles of this cytokine in apoptosis, cell survival and inflammation (van
Horssen, Ten Hagen, & Eggermont, 2006). Although some investigators argue that the
higher TNF-α levels are associated with tumorigenesis but at the same time, TNF-α is a
well-known pyrogen that induce apoptotic cell death and acts synergistically with
cytostatic drugs in cancer treatments (Kapas et al., 1992; van Horssen, et al., 2006). Lower
levels of TNF-α in DSS+DMH treated APNKO mice directly correlate with greater tumor
number and size. Higher TNF-α production in DSS treated APNKO mice could be
primarily due to the greater secretion of TNF-α by macrophages and lymphocytes due to
chronic inflammation (Carswell et al., 1975; Trayhurn & Wood, 2004), delayed recovery
from the third DSS cycle and the involvement of the gut microflora that may exacerbate
the inflammatory condition (Gordon, Hooper, McNevin, Wong, & Bry, 1997). However,
these mechanisms are remained to be investigated. These data provide a link between the
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absence of APN and higher production of pro-inflammatory cytokines and decrease
production of anti-inflammatory cytokines under the conditions including cancer,
inflammation and CICC. This might be regarded as the first direct influence of the APN
deficiency on CICC.

To further investigate the role of the APN deficiency in CICC, we searched deeper
in to the protein expression especially targeting the key pathways involved in cancer and
inflammation. Our main focus lies on the JAK/STAT signaling pathways, followed by
phosphorylation of AMPK, which is directly correlated with the major protein synthesis,
mTOR pathway. Phosphorylation of the STAT3 was found to be up-regulated in oppose
of AMPK phosphorylation in the APNKO mice treated with DSS+DMH. This indicates
higher inflammation and reduction in the energy state milieu and might be the reason for
slower recovery. This up-regulation of JAK/STAT3 signaling pathway could be mediated
by IL-6 and regulated by SOCS3 signaling (Y. Li et al., 2010; Shu et al., 2009). However,
partial hepatectomy or liver regeneration studies showed reduced expression of
phosphorylated STAT3 with the concomitant increase in SOCS3 mRNA in APN null mice
(Shu, et al., 2009). This variability could be accounted to the variable SOCS3 mediated
activation pattern of STAT3, during different time points along the length of the study.
Another explanation could be the variable roles of APN that may play in different tissues
and disease models. Higher STAT3 expression was observed in the control group as
compared to DSS treated groups, which could be attributed to the constitutive expression
of STAT3. However, only the activated or the phosophorylation of the protein could be
affected by the diseased state. This was followed by another investigation of the Cox-2
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expression, which plays multiple roles in oncogenesis, metastasis and inflammation related
to cancer. Cox-2 was found to be over-expressed in the APNKO mice treated with
DSS+DMH and DMH alone. However in heart ischemia model, APN was found to
increase the expression of Cox-2 (Shibata et al., 2005). This provides another evidence of
the multifaceted nature of adiponectin. By the means of Cox-2 expression studies, we
confirmed the results of Nishihara et al. (Nishihara, et al., 2008), but in our CICC model
we went a step further to investigate localized expression of Cox-2 in tumor and non-tumor
area by immunohistochemistry. Cox-2 was found to be significantly over-expressed in
tumor area of the colon as compared to non-tumor area, which could be due to the
combined effect of the overexpression of cancer epithelial cells in addition to the localized
secretion by inflammatory mononuclear cells, fibroblast and vascular endothelial cells.
However the majority of the intensity and the extent of Cox-2 are due to the overexpression
by cancer cells (Mikkelsen, Rumessen, & Qvortrup, 1991; Sano et al., 1995). In APNKO
mice treated with DSS+DMH, Cox-2 expression was found to be the highest and
significantly greater than WT mice in the tumor area. This approach was also instrumental
in studying the histopathology of the colon, which was found to show a complete disruption
of the tissue architecture in the tumor area along with the formation of the primary
lymphoid follicle.

Although, our study established a link between the absence of APN and its effects
on the molecular and physical attributes of CICC, with its absence linked with higher
expression of pro-inflammatory and pro-cancerous markers, it did not illustrate the direct
role of APN in CICC. To define the function of APN in our model system, our future work
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will be to reconstitute APN in all the treatment groups and observe its role during the same
timeline. It could also be suggested to further explore the role of APN in apoptotic
pathways and establish the interplay of APN in other molecular and cellular pathways by
the application of whole genome microarray. Further characterization of APN isoforms
could also result in clinical applications.
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3.6 Figure Legends

Figure 3.1. Clinical score of DSS and DMH treatments. (A–C) Clinical score for DMH,
DSS and DSS+DMH was plotted against the different time point during the study. The
arrows represent the days of DSS administration in DSS and DSS+DMH study groups. The
score was calculated out of twelve points; four points for each weight loss, diarrhea and
hemoccult. Two-way repeated measure analysis of variance (ANOVA) was applied to
calculate the significant difference between the clinical score for APNKO and WT mice
thought the length of the experiment. **p<0.05, #p<0.001, *p<0.03 (n=6).
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Figure 3.2. Tumor development in APNKO and WT mice treated with DSS and
DMH. (A) Colon of WT and APNKO mice treated with DSS+DMH and stained with 0.2%
methylene blue. (B) Average number of tumors counted per mice per group for all the
treatments in order of their severity. (C) Average tumor area in mm2 counted for each
mouse per group plotted in the order of their severity. One-way ANOVA was used to
calculate significant difference between APNKO and WT mice given the same treatment
for all the experimental groups.*p<0.05 and #p<0.03 (n=6).

Figure 3.3. Hematoxylin and Eosin staining and aberrant crypt foci. (A) H&E stained
sections of the descending colon of KO and WT mice in DSS group with 20× magnification
(scale bar=120μm). (B) Quantification of inflammation and immune cell infiltration in all
the treatment groups on a scale of four. (C) H&E stained slides of the descending colon
section of the APNKO and WT mice treated with DSS alone and observed and marked for
Aberrant crypt foci with 40× magnification (scale bar = 60μm). (D) Quantification of the
ACF by calculating the ratio of the aberrant crypts to the normal crypts. Degree of
significance was calculated by One-way ANOVA between the KO and WT of the same
treatment group. *p<0.05 and #p<0.01 (n=5).

Figure 3.4. Cytokine secretion from the colon of APNKO and WT mice. (A-D) Amount
of IL-6, IL-10, Il-1β and TNF-α secreted respectively from the colon of the APNKO and
WT mice subjected to treatment of DSS, DMH and DSS + DMH and to the control group.
(E) Serum adiponectin levels (µg/mL) in WT mice treated with DSS + DMH, DMH alone,
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DSS alone and control group at days 0 and 153. Significant difference was observed in the
serum adiponectin level of the WT mice treated with DSS + DMH and DMH alone, DSS
alone and control group, and WT mice treated with DMH and DSS alone and control group.
Significant difference was also observed within the DSS + DMH and DMH alone group at
days 0 and 153. One way ANOVA was applied to calculate the significant difference
between the secretion of cytokine from APNKO and WT mice belonging to the same
group. *p < 0.01,**p < 0.04, ***p < 0.02, #p < 0.05 (n=6).

Figure 3.5. Protein expression of STAT3, pSTAT3, AMPK, pAMPK, COX-2 in
APNKO and WT mice under different treatment conditions. A) Western blot
representing the expression of STAT3, pSTAT3, AMPK, pAMPK, COX-2 and GAPDH.
B–D) Graphs showing the ratio of the relative density of the bands for pSTAT3/STAT3
(B), p-AMPK/AMPK (C) and COX-2 (D) being normalized by GAPDH, for control and
three other treatments in the order of their severity in WT and APNKO mice. ANOVA was
used to determine the significant difference between APNKO and its wild counter parts for
all the treatments. *p<0.03, **p<0.05, #p<0.02 (n=5).

Figure

3.6.

Cox-2

immunohistochemical

staining

and

quantification.

(A)

Immunohistochemical staining for Cox-2 (brown) in the non-tumor area of the descending
colon (2 mm2) section of control, DSS, DMH and DSS + DMH treated groups in both WT
and KO mice. (B) Immunohistochemical staining for Cox-2 (brown) in the tumor area of
the descending colon (2 mm2) section of DSS + DMH treated groups in both WT and KO
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mice. (C) Quantification of the Cox-2 expression in the non-tumor descending colon
2 mm2 section of the WT and KO mice treated with DSS, DMH, DSS + DMH and control
group and DSS + DMH group in the tumor area. Two-way ANOVA was used for statistical
significance. # versus ‡ (p < 0.002), † and * versus § and ** (p < 0.002), §
versus **(p < 0.002), *versus ** (p < 0.002) (n=5).
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Figure 3.1. Clinical score of DSS and DMH treatments. (A–C) Clinical score for DMH,
DSS and DSS+DMH was plotted against the different time point during the study. The
arrows represent the days of DSS administration in DSS and DSS+DMH study groups. The
score was calculated out of twelve points; four points for each weight loss, diarrhea and
hemoccult. Two-way repeated measure analysis of variance (ANOVA) was applied to
calculate the significant difference between the clinical score for APNKO and WT mice
thought the length of the experiment given the same treatment. **p<0.05, #p<0.001,
*p<0.03 (n=6).
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Figure 3.2. Tumor development in APNKO and WT mice treated with DSS and DMH.
(A) Colon of WT and APNKO mice treated with DSS+DMH and stained with 0.2%
methylene blue. (B) Average number of tumors counted per mice per group for all the
treatments in order of their severity. (C) Average tumor area in mm2 counted for each
mouse per group plotted in the order of their severity. One-way ANOVA was used to
calculate significant difference between APNKO and WT mice given the same treatment
for all the experimental groups given the same treatment. *p<0.05 and # p<0.03 (n=6).
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Figure 3.3. Hematoxylin and Eosin staining and aberrant crypt foci. (A) H&E stained
sections of the descending colon of KO and WT mice in DSS group with 20× magnification
(scale bar=120 µm). (B) Quantification of inflammation and immune cell infiltration in all
the treatment groups on a scale of four. (C) H&E stained slides of the descending colon
section of the APNKO and WT mice treated with DSS alone and observed and marked for
Aberrant crypt foci with 40× magnification (scale bar=60 µm). (D) Quantification of the
ACF by calculating the ratio of the aberrant crypts to the normal crypts. Degree of
significance was calculated by One-way ANOVA between the KO and WT of the same
treatment group given the same treatment. *p<0.05 and # p<0.01 (n=5).
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Figure 3.4. Cytokine secretion from the colon of APNKO and WT mice. (A-D) Amount
of IL-6, IL-10, Il-1β and TNF-α secreted respectively from the colon of the APNKO and
WT mice subjected to treatment of DSS, DMH and DSS+DMH and to the control group.
(E) Serum adiponectin levels (µg/mL) in WT mice treated with DSS+DMH, DMH alone,
DSS alone and control group at days 0 and 153. Significant difference was observed in the
serum adiponectin level of the WT mice treated with DSS+DMH and DMH alone, DSS
alone and control group, and WT mice treated with DMH and DSS alone and control group.
Significant difference was also observed within the DSS+DMH and DMH alone group at
days 0 and 153. One way ANOVA was applied to calculate the significant difference
between the secretion of cytokine from APNKO and WT mice belonging to the same group
given the same treatment. *p<0.01,**p<0.04, ***p<0.02, #p<0.05 (n=6).
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Figure 3.5. Protein expression of STAT3, pSTAT3, AMPK, pAMPK, COX-2 in APNKO
and WT mice under different treatment conditions. A) Western blot representing the
expression of STAT3, pSTAT3, AMPK, pAMPK, COX-2 and GAPDH. B–D) Graphs
showing the ratio of the relative density of the bands for pSTAT3/STAT3 (B), pAMPK/AMPK (C) and COX-2 (D) being normalized by GAPDH, for control and three
other treatments in the order of their severity in WT and APNKO mice. ANOVA was used
to determine the significant difference between APNKO and its wild counter parts given
the same treatment. * p<0.03, **p<0.05, #p<0.02 (n=5).
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Figure 3.6. Cox-2 immunohistochemical staining and quantification. (A)
Immunohistochemical staining for Cox-2 (brown) in the non-tumor area of the descending
colon (2 mm2) section of control, DSS, DMH and DSS+DMH treated groups in both WT
and KO mice. (B) Immunohistochemical staining for Cox-2 (brown) in the tumor area of
the descending colon (2 mm2) section of DSS+DMH treated groups in both WT and KO
mice. (C) Quantification of the Cox-2 expression in the non-tumor descending colon 2
mm2 section of the WT and KO mice treated with DSS, DMH, DSS+DMH and control
group and DSS+DMH group in the tumor area. Two-way ANOVA was used for statistical
significance. # versus ‡ (p<0.002), † and * versus § and ** (p<0.002), § versus
**(p<0.002), * versus ** (p<0.002) (n=5).

69

Figure 3.7. A hypothetical model showing the effect of APN deficiency in chronic
inflammation induced colon cancer. In CICC, APN deficiency aggravates the
inflammatory condition by increased expression of pro-inflammatory molecule like
STAT3 and cytokines like IL-6, TNF-α and IL-1β and reduced production of antiinflammatory molecules like pAMPK and cytokines like IL-10. It also results in higher
ACF presence, which subsequently leads to adenocarcinoma. APN deficiency in CICC
increased Cox-2 expression in the epithelial cells with the highest been found in the tumor
area. This might be a potential mechanism of Cox-2, which inhibits apoptosis mediated by
Bcl-2 that regulates the release of cytochrome c from mitochondria with further inhibition
of caspases.
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CHAPTER 4

MUCUS AND ADIPONECTIN DEFICIENCY: ROLE IN CHRONIC INFLAMMATION
INDUCED COLON CANCER2

2

Arpit Saxena, Manjeshwar Shrinath Baliga, Venkatesh Ponemone, Kamaljeet Kaur,
Bianca Larsen, Emma Fletcher, Jennifer Greene and Raja Fayad. Accepted by Int J
Colorectal Dis. 2013 Sep; 28(9): 1267–1279. Reprinted here with the permission of
publisher.
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4.1 Abstract
Purpose: This study aims to define the role of APN in preventing goblet cell
apoptosis and in differentiation of epithelial cells to goblet cell lineage resulting in greater
mucus production and hence greater protection from CICC. Methods: 6 to 8 weeks old
male APNKO and C57BL/6 (WT) mice were randomly distributed to 3 treatment groups:
DSS, DMH, DSS+DMH and control. Chronic inflammation was induced in DSS and
DSS+DMH group by administrating 2 % DSS in drinking water for 5 days followed by 5
days of normal drinking water and this constitutes one DSS cycle. Three cycles of DSS
were administered to induce chronic inflammation. Cancer was induced in both APNKO
and WT mice in DMH and DSS+ DMH groups by intraperitoneal injections of DMH (20
mg/kg body weight) once for DSS+DMH group and once per week for 12 weeks for DMH
group. On day 129, the colon tissue was dissected for mucus thickness measurements and
for genomic studies. HT29-C1.16E and Ls174T cells were used for several genomic and
siRNA studies. Results: APNKO mice have more tumors and tumor area in DSS+DMH
group than WT mice. APN deficiency downregulated goblet to epithelial cell ratio and
enhanced the colonic mucosal erosion with reduced mucus thickness. APN increases Muc2
production with no effect on Muc1 production. APN abated goblet cell apoptosis, while
APN deficiency reduced epithelial to goblet cell differentiation. Conclusion: APN may be
involved in reducing the severity of CICC by preventing goblet cell apoptosis and
increasing epithelial to goblet cell differentiation.

Keywords: Adiponectin, Goblet cells, Colon cancer, mucus, inflammation
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4.2 Introduction

Colorectal Cancer (CRC) is globally the third most commonly diagnosed cancer
(Jemal et al., 2011). Several epidemiological studies have linked long standing
inflammatory bowel disease (IBD) with 2 to 3 fold greater lifetime risk of developing
colorectal cancer (Hartnett & Egan, 2012; Saxena et al., 2012). The development of chronic
inflammation induced colon cancer (CICC) is thought to be multifaceted and the repetitive
cycles of inflammation, damage, increase rate of epithelial cell proliferation and
regeneration initiate and promote the process of CICC (Saxena, et al., 2012).

The intestinal homeostasis is a complex interplay of microbiota, intestinal epithelial
cells (IECs) and the host immune system (Artis, 2008; Hooper & Macpherson, 2010;
Kaser, Zeissig, & Blumberg, 2010a, 2010b). Mucus overlies epithelial cells of colon and
acts as a physical barrier that prevents the invasion of colonic bacteria and thus
inflammation (Kaser, et al., 2010b). The mucus-secreting goblet cells protect the epithelial
layer and the depletion of these cells is a common characteristic of multiple models of
murine intestinal inflammation (Hooper & Macpherson, 2010; Specian & Oliver, 1991),
UC patients (Sheng, Xu, Tang, & Zhan, 2012), and colon cancer (Leow, et al., 2005). The
goblet cells are derived from the multipotent stem cells and the Notch signaling pathway
has been shown to play a major role in their differentiation (Q. Yang, et al., 2001). The
basic helix-loop-helix (bHLH) transcription factor Math1 and a transcriptional repressor
Hairy and Enhancer of split type 1 protein (Hes-1) are important downstream molecules in
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the Notch signaling pathway and their interplay may determine the onset of goblet cell
differentiation (Wong, 2004).

The viscoelastic, polymer-like properties of mucus are derived from the major gelforming glycoprotein components called mucins (Deplancke & Gaskins, 2001; Lang,
Hansson, & Samuelsson, 2007). Fifteen different mucin genes have so far been described
of which Muc1, 2, 3, 12, 13, and 17 are found in the colon (Saeki et al., 2011). Muc2, the
major colonic mucin (Tytgat et al., 1994; Van Klinken, Dekker, Buller, de Bolos, &
Einerhand, 1997), creates a functional barrier between the host and the luminal contents
and any alteration in this could act as a trigger for IBD (Johansson et al., 2010; Petersson
et al., 2011), particularly in UC patients (Petersson, et al., 2011). Mucin has also been
linked to colorectal cancer (Niv, Byrd, Ho, Dahiya, & Kim, 1992) and increased expression
of Muc1 is associated with poor prognosis (Ahmed, 2003), while Muc2 is involved in the
suppression of colorectal cancer (Sheng, et al., 2012; Van der Sluis et al., 2006; Velcich et
al., 2002) and has a protective role in IBD (Artis, 2008; Hooper & Macpherson, 2010;
Kaser, et al., 2010b).

Mounting evidence indicates a positive association between adiposity and colon
cancer (Paz-Filho, Lim, Wong, & Licinio, 2011; Renehan, Tyson, Egger, Heller, &
Zwahlen, 2008). Obesity is a chronic sub-inflammatory condition and adipocytokines,
biologically active substances produced by the adipocytes, are crucial players in the process
of CICC (Barb, et al., 2007; Saxena, et al., 2012). Obesity is also associated with a

74

heightened inflammatory response in people with CD (Blain, et al., 2002) and could result
in a vicious cycle of localized inflammation that can expedite CICC.

Recent data suggest that the adipocytokine adiponectin (APN) has an important role
in modulating the pathophysiology of the CICC. An inverse correlation has been
established between APN plasma concentrations and Body Mass Index (BMI) (Arita et al.,
1999), and with the risk of CICC (Wei, et al., 2005). The role of APN in carcinogenesis is
not yet fully understood, but its anti-inflammatory, immune-modulatory and insulinsensitizing effects are considered to be beneficial (van Kruijsdijk, van der Wall, &
Visseren, 2009). Several clinical studies have shown lower APN levels being associated
with colorectal carcinoma (Otake et al., 2005). APNKO mice have greater and larger colon
lesions as compared to C57BL/6 WT mice in chronic inflammation induced colon cancer
(CICC) model (Saxena, et al., 2012). APN modulates p53 and Bcl-2 gene expression
(Mistry, Digby, Desai, & Randeva, 2008) and provides anti-carcinogenic effects, many of
which are mediated through the AMP-activated Protein Kinase (AMPK) system via two
receptors; the AdipoR1 and R2 (van Kruijsdijk, et al., 2009).

Recent studies from our laboratory have shown that APN deficiency contributes to
CICC (Saxena, et al., 2012). In extension to our ongoing studies, this paper aims at
understanding the role of APN in preventing the DSS, DMH and DSS+DMH induced
mucus depletion. This study also aims at deciphering the role of APN in modulating Muc2
and its associated proteins. To achieve our goal, we used the human colonic goblet cell line
HT29-Cl.16E (Augeron & Laboisse, 1984) as this clonal derivative of HT29 displays a
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homogeneous and stable differentiated phenotype of mucus secreting cells. It is a validated
model for determining the regulation of mucin secretion (Gaudier, Forestier, et al.,
2004).We also used Ls174T cells, a well-established in vitro model to study mucus
production (Wright, Ford-Hutchinson, Chadee, & Metters, 2000). In addition, the Muc
gene expression profile of HT29-Cl.16E and Ls174T cells includes Muc1, Muc2 and
Muc3, the major mucins expressed in the human colon (Augeron & Laboisse, 1984;
Gaudier, Jarry, et al., 2004).

4.3 Materials and methods

Animals and experimental groups: Six- to eight-week-old male homozygous
APNKO−/− and male C57BL/6 (WT) were housed in conventional animal room and
treated in the animal facility at the University of South Carolina. The mice were on a 12:12
h light–dark cycle in a low stress environment (22 °C, 50 % humidity, and low noise) and
had access to food (Purina Chow) and water ad libitum. All animal care followed
institutional guidelines under a protocol approved by the Institutional Animal Care and Use
Committee at the University of South Carolina. APNKO and WT mice were randomly
assigned to four different groups of equal number (n=12 mice per group): (1) DMH+DSS;
(2) DMH; (3) DSS, and (4) control or no treatment. The body weight of both APNKO and
WT mice showed no significant difference at the beginning of the study.

Induction of chronic inflammation and cancer: Chronic inflammation was induced in
mice assigned to the DSS treatment group. These mice received 2 % dextran sodium sulfate
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(DSS) (MP BIOCHEMICALS, MW: 36,000–50,000) dissolved in their drinking water for
5 days, followed by 5 days of regular drinking water; this represented single cycle and DSS
was administrated for three cycles on day 8, 23, and 38. To establish chronic inflammationinduced colon cancer, another group of mice received three cycles of DSS and a single
injection of DMH intraperitoneally (i.p) (SIGMA ALDRICH) (20 mg/kg body weight)
administered at the beginning of the DSS treatment. Cancer was induced in mice assigned
to DMH treatment group by administering weekly dose of DMH i.p. for 12 and the mice
were sacrificed on day 129.

Tissue collection and tumor quantification: Mice colon were harvested and sectioned (2
mm2) to confirm the mouse histopathology of the entire group (6 mice/group). The
remainder of the colons was stored at −80 °C for gene and protein expression studies. The
dissected tissues were stained with 0.5 % methylene blue (SIGMA ALDRICH) to count
tumors and measured tumor area using a stereomicroscope followed by sectioning for
Alcian blue staining. Tumor quantification was done in blinded condition by two
individuals.

Mucus thickness: Mucus thickness was measured with micropipettes connected to a
micromanipulator (LEITZ) with a digimatic indicator (IDC SERIES 543, Mitutoyo). The
degraded luminal mucus layer was removed. Glass tubing (borosilicate tubing with 1.2 mm
OD and 0.6 mm ID; Frederick Haer) was pulled with a pipette puller (pp-83; NARISHIGE
SCIENTIFIC) to a tip diameter of 1–3 μm and to prevent mucus adhering to glass, the
pipettes were siliconized by dipping the tip of the micropipette into a silicone solution
followed by drying at 100 °C for 30 min. The luminal surface of the mucus gel was
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visualized by placing graphite particles (activated charcoal, extra pure, Merck) on the gel,
and the colonic epithelial cell surface was visible through the microscope. The micropipette
was inserted into the mucus gel at an angle of ∼30° (θ) to the surface. The distances
traveled by the micropipette from the luminal surface of the mucus gel to the epithelial cell
surface were measured with a digimatic indicator connected to the micromanipulator, and
a mean value (A) was calculated. The mucus thickness (T) was calculated using the formula
T=A (sin θ). Mean of four to five different measurements was taken as one thickness value.

Alcian blue staining: Standard deparaffinization procedure was followed using xylene and
gradation of ethanol. Alcian blue solution (1 %) of pH2.5 in 3 % acetic acid and nuclear
fast red in aluminum sulfate was prepared. Tissues were stained with Alcian blue and
counterstained with nuclear fast red solution. Goblet to epithelial cell ratio was counted per
crypt with ten crypts per section and five sections per group.

Cell culture: HT29-Cl. 1 6E and Ls174T cells (ATCC) were seeded on porous
nitrocellulose filters (MILLIPORE filters HAHY, porosity 0.45 μm; 2×106 cells per filter)
to provide improved access to basolateral membrane of cells [37]. The cells were cultured
in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) supplemented with 10 % (v/v)
heat inactivated fetal calf serum (FCS) (GIBCO). HT29-Cl.16E and Ls174T cells form at
confluence homogeneous monolayer of differentiated goblet cells, secreting a mucus gel
in the culture medium. HT29-C1.16E and Ls174T cells (106/well) were incubated at 37 °C
and 5 % CO2 in the presence of different dosages of recombinant APN (0, 0.25, 0.5, 1.0,
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1.5, 2.0 μg/mL) in one experiment and in other experiment APN (2 μg/mL), TNF-α (10
ng/mL), and APN+TNF-α (PROSPEC) for 24 h.

Muc1 and Muc2 measurement: Muc1 and Muc2 production was measured in HT29Cl.16E and Ls174T cells treated with different dosages of APN for 24 h and cell
supernatant was collected. A parallel experiment that was undertaken with the goal to
determine the spontaneous production of Muc1 and Muc2 at different time points in the
colonic epithelial cells of APNKO (n=40) and WT (n=40) mice each treated with three
cycles of DSS on day 8, 23, and 38. Mice were sacrificed at different time points after the
start of third DSS cycle on day 38, 44, 54, and 62 (n=10 each time point). Colonic epithelial
cells were scraped and cultured in DMEM supplemented with 10 % heat-inactivated FCS
for 24 h. Muc1 and Muc2 production was measured both in colonic epithelial cells and in
HT29-Cl.16E and Ls174T cell supernatant by ELISA (USCN LIFE SCIENCE) using
standard protocol.

Genes knockdown using siRNA: Small interfering RNA (siRNA) (40nM) targeting
MUC2, Bax, APN R1 and R2 (QIAGEN), and Math-1 was transfected in HT29-Cl.16E
and Ls174T cells (106) using lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer's instructions. Controls were transfected with unrelated siRNA (CsiRNA)
(SANTA CRUZ, QIAGEN, and INVITROGEN). Reductions of cell-surface proteins were
analyzed with flow cytometry. The efficacy of knockdowns was assessed by conventional
semi-quantitative RT-PCR. Assays were performed 2 days after transfection.
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Apoptosis detection by TUNEL: Terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-biotin nick-end labeling (TUNEL) technique was used as per manufacturer
instructions (R&D systems) to detect DNA strand breaks in situ. After treating cells with
APN (2 μg/mL), TNF-α (10 ng/mL), and APN+TNF-α pelleted cells were rinsed with PBS
and TUNEL staining procedure was performed. Cells were then counterstained with
methyl green. Negative controls were performed by substituting PBS for TdT enzyme,
which exhibited no immunostaining. Enumeration of apoptotic nuclei was made on ten
slides per treatment, using a Zeiss light microscope with a 40× objective and a 10×
eyepiece. All nuclei counted showing a brown labeling. The incidence of apoptotic nuclei
was given as the percentage relative to total nuclei (apoptotic ratio). The data are
representative of three repeated experiments, all displaying similar results.

Reverse

transcription-polymerase

chain

reaction:

Semi-quantitative

reverse

transcription-polymerase chain reaction (RT-PCR) was used to determine the efficacy of
siRNA transfection and relative gene expression in HT29-Cl.16E and Ls174T cells and
colonic epithelial cells. Total cellular RNAwas isolated using TRIzol reagent (Invitrogen)
according to the manufacturer's instructions. A total of 2.5 mg extracted RNA was used as
the template for complementary DNA (cDNA) synthesis using the Thermoscript reverse
transcription-polymerase chain reaction system (Invitrogen). Semi-quantitative PCR was
performed for Muc2, Bax, APN R1 and R2, Hes-1, and Math-1 using the following primer
pairs: MUC2 forward primer (FP) (5-GACATTTGTCAT GTACTCGGC-3) and reverse
primer (RP) (5-GCAAGGACTGAACAAAGACTC-3), Bcl-2 (FP-59-GACTTCGCCGA
GATGTCCAG-39 and RP-5-TCACTTGTGGCTCAGATAGG-3), Bax (FP-59-GGTTTC
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ATCCAGGATCGAGACGG-3

and

RP-5-ACAAAGATGGTCACGGTCTGCC-3),

GAPDH (HT29-Cl.16E cells) (FP-5 -GCAGGGGGGAGCCAAAAGGG-3 and RP- 5 TGCCAGCCCCAGCGTCAAAG-3 ), Hes1 (FP-CAGCCAGTGTCAACACG ACAC and
RPTCGTTCATGCACTCGCTGAG), Math1 (FPA GTGACGGAGAGTTTTCCCC and R
P- CTGCAGCCGTCCGAAGTCAA), and GAPDH (colonic epithelial cells) (FPGTCATCA TCTCCGCCCCTTCTGC and RP-GATGCCTGCTTCACCACC TTCTTG).
The synthesized cDNA was amplified by RT-PCR assay; the PCR cycle consisted of 94
°C for 1 min, 56 °C for 2 min,and 72 °C for 1 min, with final extension at 72 °C for 10
min. Relative mRNA abundance of Math-1, Hes-1, and ratio of Bax/Bcl-2 was calculated
using semiquantitative RT-PCR and Image J software (NCBI) for densitometry. GAPDH
was used as a loading control and the gels were run thrice using different samples from the
same group to calculate significant difference.

Statistical analysis: Two-way and one-way analysis of variance (ANOVA) was used to
analyze the data with Tukey post hoc-analyses. A p value<0.05 was considered statistically
significant. All the statistical analyses were done by using SigmaStat 3.5 (SPSS).

4.4 Results

Promotion of colorectal carcinogenesis in adiponectin-deficient mice

We investigated the role of APN in the progression of (CICC). No morphological
differences in the colon were observed between the WT and the APNKO control mice (Fig.
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1a) and an administration of three cycles of DSS alone did not induce tumors in both WT
and APNKO mice. However, APNKO and WT mice receiving DMH and DSS+DMH
developed tumors (Fig. 1a), with greater tumor number and size in APNKO mice treated
with DMH+DSS when compared to WT mice (Fig. 1a). These were similar to the results
obtained in our previous study (Saxena, et al., 2012). The tumors were observed mostly in
the descending colon and the rectum. Moreover, shortening of the colon length (one of the
macroscopic signs of colitis representing the severity of colitis) was more evident in DSS
+ DMH treated APNKO mice when compared to WT mice (Fig. 1a).

APN deficiency enhances colonic mucosal erosions and reduces goblet to epithelial cell
ratio

One of the consistent features of both IBD and CICC is the denudation of the mucus
layer coating the gastrointestinal tract. To evaluate the role of APN in preventing DSS,
DMH and DSS+DMH induced mucosal erosions; we measured the colon mucosal
thickness as well as the goblet to epithelial cell ratio in all the treated groups as described
by Petersson et al., 2011 (Petersson, et al., 2011). No change in the mucus thickness was
observed in untreated APNKO and WT mice (Fig. 1b). All DSS, DMH and DSS+DMH
treated mice had a significant reduction in the mucus thickness as compared to untreated
mice (Fig. 1c). APNKO mice treated with DSS, DMH and DSS+DMH had significantly
decreased (p < 0.04) mucus thickness when compared to WT mice in the same treatment
group (Fig. 1c). APNKO mice treated with DSS+DMH had the lowest mucosal thickness
compared to other groups. Additionally, when compared with the concurrent controls in
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the WT group, the number of goblet cells was reduced significantly in APNKO mice
treated with DMH and DSS+DMH, thereby offering an explanation for the loss of mucus
in these animals (Fig. 1d and 1e). The DSS treated WT and APNKO mice did not show
any difference in the goblet cell number (data not shown).

Effect of APN on in vitro and in vivo Muc2 production and TNF-α induced apoptosis.

To elucidate the role of APN in the synthesis of Muc1 and Muc2 production, HT29Cl.16E and Ls174T cells were cultured for 24 h with media containing various
concentrations of APN. The results show a dose dependent increase in the Muc2 production
with an increase in the APN concentration when compared to untreated cells (Fig 2a),
suggesting that APN has a direct role in Muc2 production by goblet cells. Similar results
were found in Ls174T cells exposed to the same treatment (data not shown). Data also
show that APN did not have any effect on Muc1 production (Fig. 2a).

To characterize the effect of APN deficiency on Muc1 and Muc2 production by the
primary epithelial cells, APNKO and WT mice treated with 3 cycles of DSS were sacrificed
at various time points. The colonic epithelial cells were collected, cultured for 24h, and
measured for Muc1 and Muc2 production by ELISA (Fig 2b). Muc2 level was significantly
reduced on day 44, and was recovered by day 54 and 62 in WT mice without any changes
in Muc1 production. However, in APNKO mice, Muc2 level was reduced dramatically and
its production was consistent by day 62, indicating that APNKO mice are prone to
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decreased Muc2 production or fewer goblet cells during and after chronic DSS
administration (Fig 2b).

APNKO mice treated with DSS, DMH and DSS+DMH had lesser goblet cells as
compared to WT mice, indicating that APN has an inhibitory role in goblet cell apoptosis.
To validate this observation, the experiment was performed to assess the impact of APN
(2μg/mL) on TNF-α (10 ng/mL) induced apoptosis in cultured HT29-CI.16E and Ls174T
cells. The results showed that supplementing the HT29-CI.16E and Ls174T cells for two
hours with media containing APN, decreased apoptosis by almost half when compared to
untreated controls (no APN or TNF- α). TNF- α increased apoptosis by almost three folds
(Fig 2c), however when these cells are co-treated with APN (APN + TNF-α), the goblet
cell apoptosis is reduced, indicating that the APN inhibits TNF- α-induced apoptosis of the
goblet cells (Fig 2c). To test whether APN inhibition of apoptosis is Muc2 dependent, we
knocked down Muc2 expression (~60% reduction) using Muc2-siRNA (Tai et al., 2008).
Muc2 knockdown resulted in a four-fold increase in the apoptosis in APN treated group
and two fold increase in APN+TNF-α group as compared to siRNA controls (p < 0.01)
(Fig 2c). APN plays an important role in inhibiting TNF-α induced apoptosis of goblet cells
and is Muc2 mediated. Similar results were found in Ls174T cells exposed to the same
treatment (data not shown).
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APN inhibits TNF- α induced apoptosis of the goblet cell by modulating Bax/Bcl-2 through
the activation of APN receptors

To analyze the Bax and Bcl-2 role in regulating TNF- α induced goblet cell
apoptosis by APN, we quantified the Bax/Bcl-2 mRNA levels in cells treated with APN,
TNF- α and APN + TNF-α. The results showed down-regulation of Bax expression with
up-regulation of Bcl-2 in cells treated with APN alone (Fig. 3a-b). TNF-α treatment
resulted in the up-regulation of Bax, while cells co-treated with APN (APN+TNF-α)
reduced TNF-α induced up-regulation of Bax with increase in Bcl-2 expression (Fig. 3b).
APN alone caused a reduction in Bax/Bcl-2 mRNA levels as compared to untreated
controls (p<0.01), also APN reduced TNF-α induced Bax/Bcl-2 mRNA expression when
compared to cells treated with APN+TNF-α (p<0.04) (Fig. 3b). The apoptosis ratio was
measured in cells with various treatments and the results show that APN reduced TNF- α
induced apoptosis ratio in control cells (p<0.03), but no significant difference was seen in
Bax depleted cells (siRNA) cells (p>0.05) . However Bax depleted cells (Bax siRNA) has
a higher apoptosis ratio in all treated groups compared to control (CsiRNA) cells (Fig. 3cd), suggesting that APN inhibits goblet cell apoptosis via Bax/Bcl-2 modulation.

To evaluate the role APN R1 and R2 in mediating APN effect on goblet cell
apoptosis by TNF- α, the HT29-Cl.16E and Ls174T cells were treated with APN, TNF-α
and APN +TNF-α in APN R1 and R2 depleted cells. The data show that APN is able to
inhibit TNF- α apoptosis ratio in control (CsiRNA) cells (p<0.01) (Fig. 3e-f), while APN
is unable to inhibit TNF- α apoptosis ratio in cells deficient of APN receptors APN R1 and
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R2 (Fig. 3g). Thus, it appears that APN may selectively inhibit TNF- α goblet cell apoptosis
through adiponectin receptors.

APN deficiency modulates genes responsible for goblet cell differentiation.

Hes-1 and Math-1 genes play an important role in epithelial to goblet cell
differentiation. We evaluated these genes expression in the colonic mucosa of WT and
APNKO mice treated with DSS, DMH and DSS+DMH. Hes-1 gene expression is
upregulated in APN deficient mice significantly (Fig. 4a), with concomitant reduction in
the expression of Math-1 gene (Fig. 4b) in DMH and DSS+DMH treated group (p<0.04),
as compared to WT mice, while DSS treated (data not shown) and untreated groups did not
show any difference in the expression of Hes-1 and Math-1 genes. These results indicate
that epithelial cells of the APN deficient mice express genes that reduce epithelial cell
differentiation to goblet cells.

Increase in Muc2 by APN is Math-1 dependent and mediated by APN receptors.

In our previous experiments it has been shown that APN induces Math-1 expression
in vivo. We detected Math-1 expression in HT29-Cl. 16E and Ls174T cells treated with
various concentrations of APN. The results indicate a dose dependent increase in the Math1 expression with an increase in APN concentration (Fig. 5a-b). In order to analyze if Math1 gene is responsible for APN induced Muc-2 production, various concentrations of APN
are treated with Math-1 deficient (by knocking down with Math-1 siRNA) cells. The results
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show a dose dependent increase in Muc-2 production with an increase in APN
concentration. There was a significant reduction in Muc-2 production in cells deficient of
Math-1 gene (Math-1 siRNA), when treated with various concentrations of APN, as
compared with control (CsiRNA) group (p<0.01) (Fig. 5c-d), suggesting that APN induced
Muc-2 production, is mediated by Math-1 gene expression.

APN R1 and R2 were knocked down in HT29-Cl.16E (Fig. 5e) and Ls174T cells
(data not shown), and were treated with APN and measured for Math-1 expression. The
results show a significant reduction in the Math-1 expression in APN R1 and R2 deficient
cells compared to control (CsiRNA) cells (p<0.02) (Fig. 5f-g), suggesting that APN R1
and R2 activation is required for Math-1 gene expression.

4.5 Discussion

Obesity and IBD are known factors that induce chronic inflammation and
contribute to the colorectal carcinogenesis (Hartnett & Egan, 2012). Deregulation of
adipose tissue derived adipokines may be directly involved in obesity-related
carcinogenesis (van Kruijsdijk, et al., 2009). Adiponectin is arguably one of the highly
investigated adipokine as its anti-inflammatory and insulin-sensitizing effects are reported
to be beneficial in various health conditions including cancer (van Kruijsdijk, et al., 2009).
The concentration of APN in plasma is reduced in obesity (Arita, et al., 1999), and an
inverse relation between serum levels of adiponectin and risk of colorectal cancer has been
established (Otake, et al., 2005; Wei, et al., 2005; Williams et al., 2008).
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Chronic colonic inflammation is a prerequisite for colitis-associated colorectal
carcinogenesis and our earlier studies have shown that APN deficiency contributes to
inflammation-induced colon cancer (Saxena, et al., 2012). The present study plans to
investigate the role of APN and goblet cells in preventing CICC by emphasizing on the
mechanism/s responsible for the protective effects.

Tumor development was found to be similar in all the treatment groups when
compared to our previous study (Saxena, et al., 2012), with significantly greater number of
tumor and tumor size in APNKO mice treated with DSS+DMH in comparison to WT mice
indicating that the absence of APN made the mice more vulnerable to DSS induced colitis
and DMH induced colon cancer. This could be explained by the apoptotic effect of APN
on tumor cells and decreased neovascularization in T241 mice fibrosarcoma (Brakenhielm,
et al., 2004). It has also been found to decrease azoxymethane-induced intestinal
carcinogenesis in Apcmin/+ and WT mice (Mutoh et al., 2011). It is quite possible that APN
mediates the protective effects possibly by inhibiting chemokine production in intestinal
epithelial cells and the following inflammatory responses, including infiltration of
macrophages and release of proinflammatory cytokines (Nishihara et al., 2006; Saxena, et
al., 2012).

The mucus layer has a crucial role in intestinal homeostasis and act as a hallmark
of human IBD, particularly UC and in mice lacking the major mucin protein Muc2 that
develop spontaneous colitis (Maloy & Powrie, 2011). The mucus layer produced by the
goblet cells is part of the innate immunity and forms a physical barrier against mechanical
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and chemical insults (Hollingsworth & Swanson, 2004; Hooper & Macpherson, 2010;
Specian & Oliver, 1991). We therefore detected the role of APN deficiency in mucin
depletion by quantifying mucus thickness in both APNKO and WT mice treated with DSS,
DMH and DSS+DMH. The results indicates significant reduction in mucus thickness in
both APNKO and WT mice, which are in agreement with earlier reports for IBD
(Johansson, et al., 2010; Pelissier, Muller, Hill, & Morfin, 2006; Petersson, et al., 2011)
and CICC (Femia, Dolara, Luceri, Salvadori, & Caderni, 2009). The depletion of mucus
was significantly pronounced in the APNKO mice, indicating that APN could directly or
indirectly modulate mucus production. We also a found a significant reduction in the goblet
to epithelial cell ratio in the APNKO mice treated with DMH alone and DSS+DMH when
compared to WT counterparts. Therefore, a positive correlation is achieved between APN
deficiency and decrease mucus production with a concomitant decrease in goblet cells.

The mucus composed of secretory (Muc2, Mic5AC, Muc5B, and Muc6) and
transmembrane proteins (Muc1, Muc3A, Muc3B, Muc4, Muc12, Muc17) that form a semipermeable barrier between the intestinal lumen and the underlying epithelium (Corfield,
Carroll, Myerscough, & Probert, 2001; Sheng, et al., 2012). Several lines of evidence point
towards a biological role of mucin in preventing colorectal cancer (Byrd & Bresalier, 2004)
with Muc2 being an active player (Velcich, et al., 2002). Muc2 may act as a trigger for
intestinal tumorigenesis as Muc2 deficient mice develop small and large intestinal and
rectal tumors (Andrianifahanana, Moniaux, & Batra, 2006; Velcich, et al., 2002).
Experiments with cultured HT29-Cl.16E and Ls174T cells have clearly shown that APN
increased the synthesis of Muc2, but not of Muc1. Similar results were obtained in the
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animal model with reduced Muc2 production in APNKO mice when compared to WT
mice. Altered Muc2 and Muc1 expression is a hallmark of IBD and colon cancer and we
provided substantial evidence that APN may participate in modulating the expression of
these two proteins and might contribute to the reduction in the symptoms associated with
CICC.
To further explore the protective role of APN, we hypothesized that APN inhibition
of goblet cell apoptosis is Muc2 dependent. To validate this hypothesis, Muc2 expression
was knocked down (~60% reduction) using siRNA (Tai, et al., 2008) and the goblet cells
(siRNA against Muc2 and controls) were investigated for the anti-apoptotic effects of APN.
We observed that Muc2 knockdown resulted in a significant increase in apoptotic ratio in
all the treatment groups with a fourfold increase in APN treated group and twice in
APN+TNF-α group when compared to CsiRNA treated cells, thereby strengthening our
hypothesis.

To further explore the mechanism of APN mediated goblet cell protection, we
calculated the relative ratio of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) mRNA
abundance in all the treatment groups (untreated, APN, TNF-α and APN+TNF-α) and
found that administration of APN decreased Bax, but increased Bcl-2 expression and
attenuated the pro-apoptotic effect of TNF-α. Additionally, using siRNA Bax, we were
able to observe that APN neither reduced apoptosis nor inhibited the pro-apoptotic effect
of TNF-α in partially depleted Bax (siRNA) in HT29-Cl.16E and Ls174T cells (Fig. 5C),
which indicates that APN reduces goblet cell apoptosis by regulating Bax/Bcl-2 ratio. To
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the best of our knowledge, this is the first study that demonstrates APN inhibiting goblet
cell apoptosis via Bax/Bcl-2 modulation.

Adiponectin has been shown to exert some of its protective effects through
adiponectin receptors (AdipoR1 and AdipoR2) (Kadowaki & Yamauchi, 2005; A. Y. Kim,
et al., 2010). The upregulation of both adiponectin receptors in tumor cells may be a cellular
response to lower circulating adiponectin levels in patients with colorectal cancer and/or a
compensatory response of their malignant cells (Williams, et al., 2008). To examine
whether the anti-apoptotic effect of APN in goblet cells is mediated through adiponectin
receptors, we repressed the expression of AdipoR1 or AdipoR2 via siRNA technique. The
results indicated that the presence of APN treatment decreased apoptosis ratio in CsiRNA
HT29-Cl.16E and Ls174T cells treated with TNF-α, but no change in the apoptotic ratio
was observed in the cells deficient in APN R1 and R2. This study provides conclusive
evidence that APN may prevent goblet cell apoptosis through the activation of its two
receptors R1 and R2 and its downstream effecters, which could further modulate Bax/Bcl2 ratio and up-regulate Muc2 expression.

Notch signaling pathway is essential in regulating the differentiation of colonic
goblet cells and stem cells/progenitor cells (Katoh, 2007; Qiao & Wong, 2009). Canonical
activation of the Notch signaling leads to Hes1 upregulation and Atoh1/Hath1/Math1
down-regulation (Leow, et al., 2005). Suppression of Notch signaling by depletion of Hes1 was associated with a significant increase in the secretory lineage of intestinal epithelial
cells and vice-versa (Jensen et al., 2000; Stanger, Datar, Murtaugh, & Melton, 2005).
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The Hes family of genes functions as transcriptional repressors of further downstream
targets like Math-1, which defines the secretory epithelial lineages (Shroyer et al., 2007).
Recent studies also indicate that Math1 possess tumor suppressor function in colorectal
neoplasia and its function is lost in some patients with colorectal cancer (Bossuyt et al.,
2009).

To further explore the role of APN in goblet cell differentiation, we quantified the
expression of Hes-1 and Math-1. We found a significant increase in the expression of Hes1 and decrease Math-1 expression in mice treated with DMH alone and DSS+DMH when
compared to WT counterpart. We further pursue this path by studying the expression of
Math-1 with the exogenous APN dose response in HT-29-Cl.16 E and Ls174T cells and
found an increase in the Math-1 mRNA expression with increasing APN dosage. This was
followed by another set of experiments where we demonstrated that the expression of Muc2
by the goblet cell is Math-1 dependent, which could be further regulated by APN. It was
also found that the expression of Math-1 is dependent on the presence of APN receptors
R1 and R2, which was achieved by silencing receptors expression and quantifying Math-1
mRNA abundance in CsiRNA and siRNA APN R1 and R2 treated groups. These results
clearly demonstrate that APN is governing the overall expression of both Muc2 and Math1 in a dose dependent manner in the presence of both APN R1 and R2 receptors and
directing the pathway of intestinal cell differentiation towards the formation of goblet cells,
which secrete mucus to form a protective layer to prevent colonic epithelial cells from
luminal factors that may induce inflammation and cancer.
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4.6 Conclusion

By the means of this study, we have established the protective role of APN and its
receptors in CICC that is depicted in our hypothetical model (Fig. 6). APN can downregulate the expression of Hex-1 with the concomitant up-regulation of Math-1 expression
leading to the differentiation of epithelial cell to goblet lineage. Also, APN can modulate
the ratio of Bax and Bcl-2, which could be a contributing factor in reducing goblet cell
apoptosis, which is Muc2 dependent. APN has also been shown to increase the production
of Muc2, which is dependent on Math-1. All these data point towards the common
observation of the protective role of APN in reducing the severity of CICC.
Although this study provided evidences of the protective role of APN in CICC, but
reconstituting APN in the same model system is crucial in defining the role of APN in
mucus production. This will be the framework for our future studies.
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4.7 Figure Legends

Figure 4.1. Tumor incidence and decrease in mucus thickness and goblet to epithelial
cell ratio with adiponectin deficiency in different treatment groups:

(A)

Representative of methylene blue-stained colonic tissues of WT and APNKO mice treated
with DMH, DSS+DMH and control group. Measurement of mucus thickness in untreated
(B), DSS, DMH and DSS+DMH (C) treated APNKO and WT mice (n=10). (D) Graph
representing goblet to epithelial cell ratio in control, DMH and DSS+DMH groups. (E)
Descending colon, 2 mm2 sections of the mice stained with Alcian Blue dye representing
goblet cells (blue). The data are representative of two independent experiments, all
displaying similar results. (n=8) *p<0.04 (APNKO versus WT in the same group)

Figure 4.2. Effect of APN on Muc2 production and goblet cell apoptosis. (A) Graph
representing the dose dependent relationship of Muc1 and 2 productions (ng/mL) by HT29CI.16E cells (106) and APN (µg/mL) treatments. (B) Spontaneous Muc1 and Muc2
production from mucosal tissue obtained from WT and APNKO mice respectively and
treated with DSS (third cycle). They were measured in different time points. (C) The gel
picture represents the Muc2-siRNA knockdown in HT29-CI.16E cells (106). The cells with
CsiRNA and Muc2-siRNA were treated with TNF- α (10ng/mL) or globular APN
(2µg/mL) or both for 2h (the peak effect of TNF-α in cell apoptosis) and the apoptosis ratio
was determined using TUNEL assay. The data are representative of two independent
experiments, all displaying similar results. The data are representative of two independent
experiments, all displaying similar results. (n=5) *p< 0.01 (treated versus untreated cells,
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TNF-α versus APN+TNF-α at 2 h time point), #p<0.04 (Muc2 levels on day 38 versus 44
in WT mice). **p<0.05 (Muc2 levels on day 38 versus 44, 54, and 62 in KO mice).

Figure 4.3. APN inhibits goblet cell apoptosis via Bax/Bcl-2 modulation and is APN
R1 and R2 dependent. (A and B) Bax and Bcl-2 expressions were measured in HT29Cl.16E treated with TNF- α (10ng/mL) or globular APN (2µg/mL) or both. (C and D)
Apoptosis ratio in CsiRNA and siRNA-Bax HT29-Cl.16E cells that were treated with TNFα (10ng/mL) or globular APN (2µg/mL) or both. (E) Gel representing the APN R1 and R2
knocked-down using siRNA. (F and G) Apoptosis ratio in CsiRNA and APN R1 and R2
siRNA injected HT29-Cl.16E cells treated with TNF- α (10ng/mL) or globular APN
(2µg/mL) or both. The data are representative of two independent experiments, all
displaying similar results. (n=5) *p<0.01 (control versus APN treated), **p<0.03 (APN
versus APN+TNF-α treated), #p< 0.04 (APN versus APN+TNF-α treated).

Figure 4.4. APNKO mediated alteration of gene expression reduction of epithelial to
goblet cell differentiation. (A) Graph and the gel picture showing the relative Hes-1
expression to GAPDH in the non-tumor colonic tissue of WT and APNKO mice treated
with DMH and DSS+DMH and control group. (B) Graph and the gel picture showing the
relative Math-1 expression to GAPDH in the non-tumor colonic tissue of WT and APNKO
mice treated with DMH and DSS+DMH and control group (n=5 mice/ group).*p<0.04
(APNKO versus WT in the same group).
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Figure 4.5. APN induces math-1 expression and an increase of Muc2 is Math-1
dependent which requires APN receptors. (A and B) Relative Math-1 mRNA abundance
in HT29-CI.16E cells (106/ml) incubated with different doses of APN (0, 0.5, 1 and 2
µg/mL). (C) Gel representing knockdown Math-1 expression using Math-1-siRNA. (D)
Graph showing APN dose dependent (µg/mL) Muc2 production (ng/mL) in HT29-CI.16E
cells (106/ml) treated with CsiRNA and math-1 siRNA. (E) Gel showing knockdown
expression of APN R1 and R2 receptors. (F and G) Math-1 expression in HT29-CI.16E
cells CsiRNA and siRNA APN R1 and R2 and treated with APN (2µg/mL). The data are
representative of two independent experiments, all displaying similar results. (n=5)
*p<0.01 (0 vs 1 and 2 µg/mL APN dosage and CsiRNA and siRNA APN R1 and R2 given
the same treatment), **p<0.01(CsiRNA vs Math-1 siRNA with same dosage).

Figure 4.6. A hypothetical model showing the effect of APN on epithelial to goblet cell
differentiation, goblet cell apoptosis and Muc-2 production. In CICC, APN may play a
protective role by reducing the expression of Hes-1 and Bax with a concomitant increase
in the production of Math-1 and Bcl-2 leading to greater epithelial to goblet differentiation
and reduction in goblet cell apoptosis. APN also increases the expression of Muc-2 leading
which affects goblet cell differentiation. All the above pathways lead to an increase in
goblet cell number and hence greater mucus secretion. This enhances the protection from
luminal factors that invade the colon epithelium and hence reducing the incidence of CICC.
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Figure 4.1. Tumor incidence and decrease in mucus thickness and goblet to epithelial cell
ratio with adiponectin deficiency in different treatment groups: (a) Representative of
methylene blue-stained colonic tissues of WT and APNKO mice treated with DMH,
DSS+DMH, and control group. Measurement of mucus thickness in (b) untreated, (c) DSS, DMH-, and DSS+ DMH-treated APNKO and WT mice (n=10). (d) Graph representing
goblet to epithelial cell ratio in control, DMH, and DSS+DMH groups. (e) Descending
colon, 2 mm2 sections of the mice stained with Alcian blue dye representing goblet cells
(blue). The data are representative of two independent experiments, all displaying similar
results. (n=8) *p<0.04 (APNKO versus WT in the same group)
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Figure 4.2. Effect of APN on Muc2 production and goblet cell apoptosis. a Graph
representing the dose-dependent relationship of Muc1 and 2 productions (nanogram per
milliliter) by HT29-CI.16E cells (106) and APN (microgram per milliliter)
treatments. b Spontaneous Muc1 and Muc2 production from mucosal tissue obtained from
WT and APNKO mice, respectively, and treated with DSS (third cycle). They were
measured in different time points. c The gel picture represents the Muc2-siRNA
knockdown in HT29-CI.16E cells (106). The cells with CsiRNA and Muc2-siRNA were
treated with TNF-α (10 ng/mL) or globular APN (2 µg/mL) or both for 2 h (the peak effect
of TNF-α in cell apoptosis), and the apoptosis ratio was determined using TUNEL assay.
The data are representative of two independent experiments, all displaying similar results.
(n=5) *p< 0.01 (treated versus untreated cells, TNF-α versus APN+TNF-α at 2 h time
point), #p<0.04 (Muc2 levels on day 38 versus 44 in WT mice). **p<0.05 (Muc2 levels on
day 38 versus 44, 54, and 62 in KO mice).
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Figure 4.3. APN inhibits goblet cell apoptosis via Bax/Bcl-2 modulation and is APN
R1 and R2 dependent. (A) and (B) Bax and Bcl-2 expressions were measured in HT29Cl.16E treated with TNF-α (10ng/mL) or globular APN (2 µg/mL) or both and the ratio of
their RNA abundance was calculated. c and d Graph showing Apoptosis ratio in CsiRNA
and siRNA-Bax HT29-Cl.16E cells that were treated with TNF-α (10 ng/mL) or globular
APN (2 µg/mL) or both. e Gel representing the APN R1 and R2 knocked-down using
siRNA. f and g Graph representing Apoptosis ratio in CsiRNA and APN R1 and R2 siRNA
injected HT29-Cl.16E cells treated with TNF-α (10 ng/mL) or globular APN (2 µg/mL) or
both. The data are representative of two independent experiments, all displaying similar
results. (n=5) *p<0.01 (control versus APN treated), **p<0.03 (APN versus APN+TNF-α
treated), #p< 0.04 (APN versus APN+TNF-α treated).
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Figure 4.4. APNKO mediated alteration of gene expression reduction of epithelial to
goblet cell differentiation. (A) Graph and the gel picture showing the relative Hes-1
expression to GAPDH in the non-tumor colonic tissue of WT and APNKO mice treated
with DMH and DSS+DMH and control group. (B) Graph and the gel picture showing the
relative Math-1 expression to GAPDH in the non-tumor colonic tissue of WT and APNKO
mice treated with DMH and DSS+DMH and control group (n=5 mice/ group).*p<0.04
(APNKO versus WT in the same group).
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Figure 4.5. APN induces math-1 expression and an increase of Muc2 is Math-1
dependent which requires APN receptors. (A and B) Relative Math-1 mRNA abundance
in HT29-CI.16E cells (106/ml) incubated with different doses of APN (0, 0.5, 1 and 2
µg/mL). (C) Gel representing knockdown Math-1 expression using Math-1-siRNA. (D)
Graph showing APN dose dependent (µg/mL) Muc2 production (ng/mL) in HT29-CI.16E
cells (106/ml) treated with CsiRNA and math-1 siRNA. (E) Gel showing knockdown
expression of APN R1 and R2 receptors. (F and G) Math-1 expression in HT29-CI.16E
cells CsiRNA and siRNA APN R1 and R2 and treated with APN (2µg/mL). The data are
representative of two independent experiments, all displaying similar results. (n=5)
*p<0.01 (0 vs 1 and 2 µg/mL APN dosage and CsiRNA and siRNA APN R1 and R2 given
the same treatment), **p<0.01(CsiRNA vs Math-1 siRNA with same dosage).
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Figure 4.6. A hypothetical model showing the effect of APN on epithelial to goblet cell
differentiation, goblet cell apoptosis and Muc-2 production. In CICC, APN may play a
protective role by reducing the expression of Hes-1 and Bax with a concomitant increase
in the production of Math-1 and Bcl-2 leading to greater epithelial to goblet differentiation
and reduction in goblet cell apoptosis. APN also increases the expression of Muc-2 leading
which affects goblet cell differentiation. All the above pathways lead to an increase in
goblet cell number and hence greater mucus secretion. This enhances the protection from
luminal factors that invade the colon epithelium and hence reducing the incidence of CICC.
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CHAPTER 5

SELENIUM RICH DIET CAN BE PROTECTIVE IN THE TREATMENT OF CHRONIC
INFLAMMATION INDUCED COLON CANCER3

3

Arpit Saxena, Kamaljeet Kaur, Samantha Truman, Matthew Rorro, Bianca Larsen, Emma
Fletcher, Alexander Chumanevich and Raja Fayad. To be submitted
103

5.1 Abstract

Background: Colon cancer is the second largest cause of cancer deaths and ranks
third in the number of new cases every year in both sexes in the United States. Repeated
cycles of chronic inflammation that are found in inflammatory bowel disease (IBD),
crohn’s disease and ulcerative colitis, have been be linked to colon cancer. Obesity is a risk
factor associated with colon cancer and increased adiposity leads to reduced production of
certain adipokines including Adiponectin (APN). It is secreted by the adipose tissue and
found to have anti-inflammatory and anti-cancerous effects. Selenium (Se) is a well-known
antioxidant non-metal which has been shown to reduce inflammation and induce cancer
cell apoptosis by the modulation of Bax and Bcl2 in colon cancer cell lines. Purpose: The
purpose of this publication is to study the effect of Se rich diet and APN deficiency on
chronic inflammation induced colon cancer. Methods: C57BL/6 and APNKO mice were
randomly assigned to 6 different treatment groups including: C57BL/6 (WT) + Control
Diet, WT+Se Diet, APNKO+Control Diet, APNKO+Se Diet, WT+DSS+ Control Diet,
WT+DSS+Se Diet, APNKO+DSS+Control Diet, APNKO+DSS+Se Diet, WT+DMH+
Control Diet, WT+DMH+Se Diet, APNKO+DMH+ Control Diet, APNKO+DMH+Se
Diet, WT+DSS+DMH+ Control Diet, WT+DSS+DMH+Se Diet, APNKO+DSS+DMH+
Control Diet and APNKO+DSS+DMH+Se. Inflammation and cancer was induced by DSS
and DMH respectively and Se rich diet (0.75 ppm) or control diet (0.02 ppm) were
administered to respective group on day 25. Mice were monitored for clinical score and
were sacrificed on day 194 and colon tissue was collected for differential analysis. Results:
Se rich diet was found to reduce clinical score, tumor load and inflammation in both
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APNKO and WT mice with CICC. Se rich diet was found to increase the serum APN in
WT mice with CICC when compared with control diet. Colon cancer cell apoptosis was
found to be significantly higher with Se rich diet as compared to control group. Se rich was
found to increase Gpx activity and the expression of selenoproteins including Gpx-1 and
Gpx-2 in normal colon tissue while higher oxidative stress in the colon tumor tissue. Se
rich diet was also found to increase goblet cell production and increase the expression of
Math-1 and Muc-2. Conclusion: Se and APN might be effective in reducing the severity of
CICC by suppressing inflammation and tumor burden and increasing cancer cell apoptosis
and goblet cell production.

Keywords: Selenium, oxidative stress, Adiponectin, colon cancer, apoptosis

5.2 Introduction

Colon cancer is the second largest cause of cancer deaths and ranks third in the
number of new cases every year in both sexes in the United States (R. Siegel, et al., 2014).
Repeated cycles of chronic inflammation that are found in inflammatory bowel disease
(IBD), crohn’s disease and ulcerative colitis, have been be linked to colon cancer(Rubin,
Shaker, & Levin, 2012). Clinical signs and symptoms of colon cancer include
hematochezia, fecal hemocult, diarrhea, weight loss, nausea, constipation and constant
fatigue(Korsgaard, et al., 2006). Etiology of colon cancer is very complex and
heterogeneous

and

ranges

from

dietary

and

lifestyle

factors

to

genetic

abnormalities(Fearon, 2011). Obesity has been considered an established risk factor for

105

colon cancer patients (Hull & Lagergren, 2014). Reduced secretion of adiponectin (APN),
an adipocytokines secreted by adipose tissue, has been linked with increased obesity and
severity of colorectal cancer (Saxena, et al., 2012). Our published report indicated that
APN deficient mice developed more tumors and showed an increase in the pathology of
chronic inflammation induced colon cancer (CICC)(Saxena, et al., 2012). Serum selenium
(Se) levels were found to be 25-30% lower in cancer patients(Gorozhanskaia, Sviridova,
Dobrovol'skaia, Zybrikhina, & Kashnia Sh, 2013). Nutritional deficiencies or malnutrition
is one of the major concern with the colon cancer patients received chemotherapy (Du et
al., 2012; Hebuterne et al., 2014). Downregulation of several selenoproteins have been also
identified in IBD(Andoh et al., 2005).There are several treatment strategies available for
colon cancer including chemotherapy and radiotherapy, but these have severe side effects
with increased morbidity and reduced quality of life. Complimentary medicine including
the use of micronutrients and phytochemicals has been gaining popularity as they aid in
reducing these side effects and lower the severity of the disease(Baliga et al., 2012; W. L.
Lee, Huang, & Shyur, 2013).

Selenium is an essential micronutrient and is widely accepted as an anti-oxidant
element (Maseko, et al., 2014). This micronutrient forms selenocysteine, which is the
twenty-first amino acid and integrates into proteins to form 25 selenoproteins (Metanis &
Hilvert, 2014). Se can be obtained in the diet through several sources including Brazil nut,
fish, liver, chicken, certain vegetables and meats (Maseko, et al., 2014). The recommended
dietary allowance for Se is 55μg per day for human adults and the upper safe limit is 400
μg/day. Beneficial effects of Se can be obtained at a dosage of 200 μg per day. Se has been
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shown to reduce the severity of cancers including prostate(Gerstenberger, et al., 2014),
breast (Arsenyan, et al., 2014) and lung (Okuno, et al., 2014b) and has acted as a useful
supplementation for several ailments including cystic fibrosis (Ciofu & Lykkesfeldt, 2014),
male and female infertility(Balazs & Racz, 2013), glucose metabolism in type 2 diabetes
(Mao & Teng, 2013), grave’s disease (Kryczyk & Zagrodzki, 2013) and other related
inflammatory and autoimmune diseases. A dosage of 200 μg/day of Se has been shown to
decrease the total incidence of cancer by 25% (Reid, et al., 2008). An inverse association
has been established between higher Se status and colorectal cancer (Hughes, et al., 2014).
The protective effect of the Se in various diseases and conditions is mostly due to the antioxidative property leading to an increase in the production of selenoproteins like
glutathione peroxidases (Gpx), which neutralize or prevent the formation of reactive
oxygen species (ROS)(Kosaric, et al., 2014). Se metabolism is complex and most of the
biological effects of elemental Se that is ingested are mediated by selenoproteins
(Labunskyy, et al., 2014). Gpx-1 and Gpx-2 are the most abundant selenoproteins present
and mediate most of the protective effect of Se. Gpx-1 is ubiquitously presents in the
cytosol and the mitochondria in all the tissues of the body, while Gpx-2 is mostly
concentrated in the intestinal epithelium (Brigelius-Flohe & Maiorino, 2013). Gpx-1 or
Gpx-2 knockout mouse or double knockout mouse has shown to exhibit severe pathology
of colorectal cancer (Krehl, et al., 2012; D. H. Lee, et al., 2006) and Se rich diet has been
shown to increase Gpx activity in these animals. Increased activity of Gpx-1 and Gpx-2
has also been linked to the chemo preventive effect of Se supplementation (Hu, et al.,
2010).
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A recent study by Li et al. 2013 on human colorectal carcinoma cells (HCT 116
and SW620) has shown that different dosages (1 μM, 5 μM and 10 μM) of Se lead to
apoptosis of the colon cancer cells by Bax dependent pathway(Z. Li, et al., 2013) with 10
μM being the most effective. Another study by Luo et al. 2013 has shown that
supranutritional dosage of sodium selenite (10 μM) lead to apoptosis of colon cancer cells
by ROS modulation of phosphatase and tensin homolog (PTEN) mediated
PI3K/AKT/FoxO3a signaling pathway in colon xenograft animal model(Luo, et al., 2013).
Sodium selenite has also shown to reduce inflammation by downregulating the expression
of nuclear factor kappa light-chain-enhancer of activated B cells (NFκB) and related
cytokines (Pillai, et al., 2012). In this study, we used dextran sodium sulphate (DSS) that
is widely used chemical to induce acute and chronic inflammation. In addition, we will be
using dimethylhydrazine (DMH), which is a potent carcinogen and has been used to induce
colon cancer in numerous published animal studies (Femia, et al., 2009; Saxena, et al.,
2012).

Although there are few studies indicating the protective role of Se in chronic
inflammation and colon cancer, most of these studies used in vitro approach and lacked the
mechanism of action of Se in reducing the severity of chronic inflammation and colon
cancer. Also, as indicated by our published data, APN has been implicated in reducing the
severity of chronic inflammation and colon cancer. Se could either be used in the
prevention or as a treatment for colon cancer. In this study we have used Se as a prevention
by administering Se on the same day as DSS or DMH.
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In this report, we studied the role of Se rich diet administration in reducing CICC
severity in C57BL/6 (WT) mice and APN knock out (KO) mice and how Se exerts such
mechanism.

5.3 Material and Methods:

Animal Model: Four week-old C57BL/6 and APNKO mice were obtained from Jackson
Laboratories and bred in the animal facility at the University of South Carolina under the
Institutional Animal Care and Use Committee guidelines. APNKO mice were homozygous
with the absence of APN expression confirmed by serum protein expression. Mice were
fed regular chow and ad libitum. Mice were then randomized into 16 different treatment
groups with n=10/group. The mice were then acclimatized to the animal facility for 24 days
in a low stress environment (22°C, 50% humidity and low noise) with 12:12 hours of lightdark cycle. The first DSS or DMH administration was performed on day 25 of the start of
the study. The groups include: C57BL/6 (WT) + Control Diet, WT+Se Diet,
APNKO+Control Diet, APNKO+Se Diet, WT+DSS+ Control Diet, WT+DSS+Se Diet,
APNKO+DSS+Control Diet, APNKO+DSS+Se Diet, WT+DMH+ Control Diet,
WT+DMH+Se

Diet,

APNKO+DMH+

Control

Diet,

APNKO+DMH+Se

Diet,

WT+DSS+DMH+ Control Diet, WT+DSS+DMH+Se Diet, APNKO+DSS+DMH+
Control Diet and APNKO+DSS+DMH+Se Diet. Mice were monitored throughout the
study period by measuring the clinical score that includes weight loss, diarrhea and fecal
hemoccult. Mice were sacrificed by cervical dislocation under anesthesia on day 194.
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There was no significant difference in the body weight of APNKO and WT mice at the
beginning of the study.

Chronic Inflammation and Colon Cancer: Depending on the treatment group, mice were
either administered DSS or DMH or both. DSS was administered alone to induce chronic
inflammation. DMH was injected to induce cancer while the combination of both was
given to induce CICC. DSS was administered in 3 cycles where one cycle constitutes 2%
DSS (MP Biochemicals, MW: 36,000-50,000) in drinking water for 5 days followed by 5
days of normal drinking water. DSS was administered on day 25, 50 and 75 to induce
chronic inflammation. DMH (Sigma Aldrich) was injected intraperitoneally at a
concentration of 20mg/kg either once for DSS+DMH treatment group on day 25 or once a
week for 12 weeks for DMH alone group. These concentration and model have been well
established to study chronic inflammation and colon cancer (Saxena, et al., 2012).

Selenium Diet Administration: Selenium rich diet containing 0.75 ppm of Se per kg was
administered to 8 groups on day 25 simultaneously with the administration of DSS, DMH,
or both or to the Control group. The diet was administered till the day of sacrifice that is
day 194. Control diet contains all the components of the Se rich diet except that the Se
content is 0.02 ppm per kg of diet.
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Clinical Score: Clinical score was measured for each mouse in each group from day 25 to
day 194. Mice were sacrificed after the last clinical score measurement. Score for the
weight loss is based on the following published scale where 0 = 0–5% weight loss; 1 = 6–
10% weight loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight
loss. Scoring of diarrhea is as follows: 0 = well-formed pellets, 2 = pasty and semi-formed
stools that do not adhere to the anus, 4 = liquid stools that adhere to the anus. Detection of
blood in the stools was determined using hemoccult kit (BECKMAN COULTER). The
higher intensity of blue color indicates greater bleeding. The followings are the score rates
for the fecal hemoccult: 0 = no blood, 2 = positive hemoccult, 4 = gross bleeding. The total
clinical score was the summation of the individual score of weight loss, diarrhea and fecal
hemoccult. The maximum score a mouse could get is 12. The clinical score was calculated
and plotted against days of DSS administration. Higher clinical score indicates more
severity of colon cancer development in animals.

Colon Tissue and Serum Collection: Blood was collected before sacrifice through retroorbital puncture and was spun down at 10,000 rpm for 18 minutes and serum was obtained
and stored at -20°C to measure APN. Mice colon was excised and flushed clean with PBS.
2mm2 colon tissue section with tumor and non-tumor area was fixed in 10% formalin. 24
hours later, tissues was submerged with with 70% Ethanol followed by paraffin embedding
and sectioning to obtain 5 µm thin section on glass slide. Sections with tumor and nontumor areas were snap frozen on dry ice and stored at -80°C for protein analysis. Another
2mm2 colon tissue section was incubated in RPMI medium containing 5000 IU/mL and
5000 IU/mL penicillin and streptomycin (CELLGRO) respectively at 37°C and 5% CO2
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for 24 hours. This was followed by centrifugation at 2500 rpm for 15 minutes. Supernatant
was obtained and stored at -20°C to measure secreted cytokine levels.

Tumor Number and Tumor Area and Histopathology: Mice colon was excised and
flushed with PBS. Tumor number and area were counted under the microscope in all mice
of different groups and significant different was calculated between different groups.

Hematoxylin and Eosin staining was used to determine the morphology of mice
colon. Histopathology was quantified based on the scoring system indicating the severity
of disease and constituting inflammation, immune cell infiltration and degree of tumor.
This was on the scale of 12 where highest score of 4 was given for each parameter, where
0 = no infiltration or no inflammation or no cancer; 2 = moderate infiltration or
inflammation or pre-cancerous lesions; and 4 = severe inflammation with distorted crypts
or infiltration and formation of lymphatic follicles or visible tumors. All the images were
taken in 20X magnification with Nikon e600 microscope. The score was measured by two
investigators in blinded fashion.

TUNEL Assay: Degree of apoptosis was measured in the tumor and non-tumor tissue
sections of the colon by TUNEL assay. TUNEL assay (EMD Millipore) was used to
determine the number of TUNEL positive cells and total number of epithelial cells of the
colon in 2mm2 tissue cross-sectional tissue area. 5 sections were randomly selected from
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each tissue section and 10 tissue sections were randomly selected from each group. The
ratio of TUNEL positive cell to total epithelial cell were used to determine the ratio of
apoptosis and plotted as a graph for different treatment groups. All the images were taken
in 20X magnification with Nikon e600 microscope.

Alcian blue staining: Standard deparaffinization procedure was followed using xylene and
gradation of ethanol. Alcian blue solution (1 %) of pH 2.5 in 3 % acetic acid and nuclear
fast red in aluminum sulfate was prepared. Tissues were stained with Alcian blue and
counterstained with nuclear fast red solution. Goblet to epithelial cell ratio was counted per
crypt with ten crypts per section and five sections per group.

Protein determination using Western Blot: Colon tissue frozen at -80°C was
homogenized in RIPA buffer added to protease and phosphatase inhibitors (SIGMA). It
was then centrifuged at 10,000 rpm for 15 minutes and supernatant was obtained for protein
analysis. Protein concentration in the supernatant was determined by using Bradford
protein assay. This was followed by loading equal amounts of protein (50 µg) in each well
for a 10% Sodium Dodecyl Sulphate (SDS) gel electrophoresis. The protein from the gel
was then transferred to a nitrocellulose membrane (Pall Scientific) and blocked with 5%
non-fat dry milk (Biorad) in phosphate buffer saline (PBS) (cellgro) with 0.1% Tween 20.
The membrane was incubated overnight with the primary antibody. The -primary
antibodies include Gpx-1, Gpx-2 and GAPDH obtained from Genetex. phospho-NFκB
p65, NFκB p65, cleaved caspase 9, MDA and Nitrotyrosine were obtained from cell
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signaling technology. Membrane was washed by PBS containing 0.1% Tween 20 (Biorad).
The membrane was then incubated with secondary antibody (Santa Cruz) followed by
another washing step. The last step includes incubating the membrane in ECL substrate
(Western Bright, Advansta). The film was developed using by using a developer (SRX101A, Konica Minolta Medical & Graphic, INC.) in the dark room. Finally the film was
scanned and the density of the protein bands obtained was analyzed using Image J software.
Enzyme Linked Immunosorbent Assay (ELISA): Spontaneous secreted cytokines were
measured from the tissue incubated in the RPMI medium for 24 hours at 37°C. The media
were collected and centrifuged at 2500 rpm for 16 minutes. Pellet was discarded and the
supernatant was isolated. Cytokines IL-6, TNF-α, IL-1β and IL-10 levels were measured
by using BD OptEIA ELISA kit obtained from BD biosciences and normalized by total
protein content estimated by using standard Bradford assay procedure.

Immunofluorescence: Colon tumor tissue sections were deparaffinzed by xylene and
dehydrated by different concentration of ethanol. The sections then underwent heat
mediated antigen retrieval step with 10nM citrate buffer (Prohisto), 0.05% Tween 20, pH
6.0 in an autoclave at 121°C, 15 psi for 20 minutes. The tissues were then blocked with
10% goat anti-rabbit serum with PBS. Tissues were then incubated in a primary antibody
that is cleaved caspase 9 (Cell Signaling Technology) for overnight incubation. This was
followed by 5 washing steps and 2 hour- incubation with anti-rabbit secondary antibody
(Aexa Flour 488) (Cell Signaling Technology). Finally the tissue section was mounted with
a DAPI based mounting media (Genetex) and covered with a coverslip. 10 random 20X
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magnification, 2x2 images of the 8 slides per group belonging to different mice were taken
and quantified by using Image J software.

Mass Spectrometry: Colon tissues were frozen-dried using lyophilizer and weight prior
to be used for mass spectrometry. The tissue was then digested using aqua regia (1 mL of
optima grade nitric acid plus 3 mL of optima grade hydrochloric acid) at 140°C and the
final volume was brought to 10 ml. The samples were analyzed for Selenium using the
Finnigan ELEMENT2 double focusing magnetic sector field inductively coupled plasmamass spectrometer (ICP-MS). Iridium was used as the internal standard. The instrument
was calibrated for element
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Se. The calibration range was from 1.0 to 60 ppb. The R

squared value for the initial calibration curve was greater than 0.99. The samples were
analyzed immediately after the initial calibration, and the target element results were within
the calibration range. The samples were then diluted (5X) and the instrument blank
contained 0.31 ppb of Se. The ending continuing calibration verification recovery for Se
standard was 112%. The results were then converted to the amount in nanomolar per gram
of the colon tissue and plotted on a graph.

Statistical analysis: Two-way and one-way analysis of variance (ANOVA) was used to
analyze the data with Tukey post hoc-analyses. A p value<0.05 was considered statistically
significant. All the statistical analyses were done by using SigmaStat 3.5 (SPSS).
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5.4. RESULTS

Clinical Score:

All the treatment groups were monitored for the changes in the clinical score, which is a
combination of weight loss, diarrhea and hemoccult, thrice a week till day 194. Control
and Se rich diet were administered on day 25 to all treatment and control groups. WT mice
administered control diet in the DSS alone group showed severe clinical manifestation
characterized by a significantly higher clinical score when compared to WT mice
administered Se rich diet (figure 1a). APNKO mice showed lower clinical score as
compared to WT mice after the first DSS cycle in the same treatment group. APNKO mice
administered Se rich diet showed a lower clinical score with significance on day 40 after
the first DSS cycle when compared to control diet. APNKO and WT mice fed control diet
showed significantly higher clinical score as compared to the APNKO and WT mice given
Se rich diet. After the third DSS cycle administartion (day 96-194), the difference in the
clinical score became even more significant between the Se rich diet and control diet in
both WT and APNKO mice and continued to remain high till the date of sacrifice (figure
1a). APNKO mice also showed a higher clinical score than WT given both control and Se
rich diet. In the DMH alone group, APNKO and WT mice given control diet showed
significantly higher clinical score as compared to the same phenotypic mice given Se rich
diet, towards the end of this study (day 185-194). APNKO mice were found to have a
higher clinical score as compared to their WT counterparts (figure 1b). In the DSS+DMH
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group, no significant difference in the clinical score was found in the WT and APNKO
administered control and Se rich diet after the first and the second DSS cycle. However,
after the third DSS cycle (day 85-194), both APNKO and WT mice given control diet
showed significantly higher clinical score as compared to APNKO and WT mice given Se
rich diet. APNKO mice fed either control or Se rich diet showed higher clinical score when
compared to WT mice fed the same diet. DSS+DMH treatment group showed the highest
clinical score as compared to DSS alone and DMH alone group. Both APNKO and WT
mice received control diet continued to show higher clinical score as compared to mice
given Se rich diet and APNKO mice showed higher score than WT mice till the date of
sacrifice (figure 1c).

Tumor Quantification:

After sacrificed on day 194, mice colon was resected and washed with PBS. Colon was
then cut longitudinally and flattened to count tumor number and area (figure 2a). No
significant difference in the colon tumor number was found in DSS group with control or
Se rich diet. APNKO mice given Se rich diet and treated with DMH alone was found to
have significantly lower tumor number as compared to the APNKO mice received control
diet in the same group. No significant difference was observed between the WT mice fed
control diet and Se rich diet in the DMH group. Significant reduction in tumor number was
observed in WT and APNKO mice administered Se rich diet in the DSS+DMH group as
compared to the WT and APNKO mice given control diet in the same group. No significant
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difference was found in the tumor number of APNKO and WT mice given control or Se
rich diet in DSS+DMH group, however APNKO mice received control diet showed greater
tumor number as compared to WT counterparts (figure 2b). Tumor area in the DMH group
showed no significant difference either phenotypically or between diets. However,
APNKO mice with control diet showed larger tumor area as compared to the APNKO mice
fed Se rich diet. In DSS+DMH group, significant difference was observed between
APNKO and WT mice given the same diet. WT and APNKO mice in DSS+DMH group
fed control diet showed significantly larger tumor area as compared to mice given Se rich
diet (figure 2c).

Colon Selenium Content:

Mice colon Se content (per gram of tissue) was detected by mass spectrometry using the
lyophilized mice colon. The content of the Se was measured in the control and the
DSS+DMH group. A significant increase in the content of Se with Se administration was
found in both APNKO and WT mice. Control group showed more Se content and APNKO
mice showed a decrease in the Se content irrespective of Se rich diet administration (figure
3).
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Oxidative stress in tumor and non-tumor colon tissues:

Nitrotyrosine and 4HNE protein expression studies were conducted to determine the degree
of oxidative stress in the tumor and non-tumor tissue frozen at -80 ºC. No significant
difference was found in the expression of Nitrotyrosine and 4HNE in the colon tumor tissue
section of both WT and APNKO mice in DSS+DMH group given control and Se rich diet.
Significant decrease in the expression of Nitrotyrosine was found in the colon tissue section
of the WT mice given Se rich diet in the DSS+DMH treatment group when compared to
WT mice given control diet (figure 4). No significance was observed in the expression of
4HNE in the colon tissue section of WT mice with Se rich or control diet. Significant
decrease was also observed in the protein expression of both Nitrotyrosine and 4HNE of
colon tissue section of the APNKO mice given Se rich diet when compared to the APNKO
mice given control diet (figure 4).

Selenoproteins Activity and Expression:

Colon tissue that was snapped frozen and stored at -80°C was utilized to determine the total
Gpx activity in all the treatment groups in addition to Gpx 1 and 2 protein expression. Total
Gpx activity was decreased with an increase in severity of the inflammation and cancer.
Control group shows the highest Gpx activity with a significant increase in the activity in
Se rich diet when compared to control diet in both APNKO and WT mice. APNKO mice
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tend to show lower Gpx activity when fed Se rich diet as compared to WT mice given the
same diet. In DSS group, no significant difference was found in the GPX activity between
Se rich diet and the control diet in APNKO and WT mice (figure 5a). DMH group showed
a lower Gpx activity than control and DSS groups. In DMH group, there is a significant
increase in the Gpx activity in animals fed Se rich diet as compared to control diet in both
APNKO and WT mice (figure 5a). DSS+DMH group showed the least Gpx activity with
a significant increase in the Gpx activity with Se rich diet in both APNKO and WT mice
in comparison to control diet. There is a significant decrease in the Gpx activity in APNKO
mice when compared to WT mice fed Se rich diet. No significant difference was found in
the Gpx activity of APNKO and WT mice given control diet (figure 5a). This was followed
by more specific approach of identifying the particular selenoproteins including Gpx-1 and
Gpx-2. A significant increase in Gpx1 expression was observed with Se rich diet for both
APNKO and WT mice, when compared to control diet in control group. No significant
difference in the Gpx-1 expression was found in the Se rich and control diet in APNKO
mice in DSS alone group. However, we found a significant decrease in Gpx-1 expression
with Se rich diet in WT mice as compared to control diet in DSS alone group. In DMH
group, no significance was observed in the Gpx-1 expression between the Se rich and
control diet in WT mice, but APNKO mice showed a significant increase in Gpx-1
expression with Se rich diet. In DSS+DMH group significant increase in the Gpx-1
expression was observed with Se rich diet in both APNKO and WT mice given Se rich diet
when compared to control diet (figure 5b and 5c). Gpx-2 expression was also measured by
using Western blot. We found a significant increase in Gpx-2 expression in the control
group fed Se rich diet when compared to control diet. In DSS group, APNKO mice given
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Se rich diet showed a significant increase in the Gpx-2 expression while WT mice showed
a significant decrease in the Gpx-2 expression as compared to the control diet (figure 5b
and 5d). No significant difference was obtained in DMH alone group (figure 5b and 5c).
DSS+DMH group, with highest severity of chronic inflammation and colon cancer
manifestation, showed a significant increase in the Gpx-2 activity with Se rich diet for both
APNKO and WT mice when compared to control diet. GAPDH was used as a loading
control (figure. 5b and 5c).

Histopathology:

Tissues were stained with Hematoxylin and Eosin (H&E) and analyzed for inflammation,
immune cell infiltration and cancer pathology. Colon tissues in the control group showed
normal appearing histology with well-formed crypts in mucosal layer without any sign of
immune cell infiltration or inflammation (figure 6a). DSS alone group showed infiltration
of the immune cells in the lamina propria of the colon of APNKO mice given control diet
and to a lesser extent in the WT mice. Se administration was shown to reduce the
inflammation and immune cells infiltration in the colon of both the APNKO and WT mice
(figure 6a). DMH alone group given control diet showed inflammation and cell infiltration
in the lamina propria with aberrant crypts. Se diet administration seems to reduce the
severity of the inflammation in both APNKO and WT mice (figure 6a). Finally, mice in
DSS+DMH group showed highest degree of inflammation, infiltration and tumorous
growth as opposed to animals fed Se rich diet. In DSS+DMH group fed control Se diet,
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lamina propria is fully infiltrated with immune cells with a complete changes of the
morphology of the muscularis and submucosa layers. WT mice given Se rich diet in the
DSS alone group showed a significant decrease in the histopathology score as compared to
the WT mice fed control diet in the same group (figure 6b). No significant difference was
observed in the APNKO mice between the two diets in DSS alone group, but the APNKO
mice had a greater score than WT mice. In addition, DMH group had a higher
histopathology score as compared to the DSS group. In DMH alone group, WT mice given
Se rich diet showing significantly lower score as compared to the WT mice administered
control diet. No significance was obtained between the control and Se rich diet in APNKO
mice in DMH alone group, however these mice showed a higher histopathology score than
WT mice (figure 6b). DSS+DMH group showed the highest pathological score as
compared to other groups. Both WT and APNKO mice with Se rich diet showed a
significant reduction in the histopathology score when compared to the same phenotypic
mice with control diet. Interestingly, APNKO mice showed a significantly higher clinical
score when compared to WT mice given the control diet, but no significance was observed
between these groups with Se rich diet (figure 6b).

Cytokine and pshospho-p65 NFĸB expression:

To measure the degree of inflammation, spontaneously secreted pro-inflammatory and
anti-inflammatory cytokines were measured from the colonic tissue samples incubated at
37 ºC and 5% CO2 in RPMI medium. This was followed by the study of phosphor-p65
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NFĸB protein expression. Pro-inflammatory cytokine expression shows no significant
difference in the expression of IL-6, TNF-α and IL-1β in the control, DSS alone and DMH
alone groups between the Se rich and control diet given to APNKO and WT mice.
However, a significant reduction in IL-6, TNF-α and IL-1β levels was observed in APNKO
mice given Se rich diet when compared to control diet. WT mice showed no significant
difference in the level of IL-6, TNF-α and IL-1β. In general DSS+DMH group showed an
increased level of all the pro-inflammatory cytokines including IL-6, TNF-α and IL-1β.
APNKO mice showed a significant increase in the expression of anti-inflammatory
cytokine IL-10 with Se rich diet when compared to control diet in DSS alone, DMH alone
and DSS+DMH group. However no significance was observed in WT mice. A general
trend of an increase of the IL-10 and a decrease in IL-6 and TNF-α levels in mice fed Se
rich diet was observed in both APNKO mice and WT mice in all the treatment groups.

Colon Epithelial and Tumor Cell Apoptosis:

Colonic tissue sections were prepared to perform TUNEL assay for quantification of
apoptosis. No significant difference in colonic epithelial apoptotic cells was observed
between Se rich and control diet in WT and APNKO mice in DSS alone and control groups.
In DMH group, both APNKO and WT mice fed Se rich diet showed a significant decrease
in the TUNEL positive epithelial cells when compared to control diet. APNKO mice
showed a significant decrease in TUNEL positive cells when compared to WT mice given
control diet in DMH alone group. In DSS+DMH group, highest number of apoptotic cells
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was found in all the treatment groups. Significant reduction in the number of apoptotic
cells were observed in Se rich fed diet for both APNKO and WT mice when compared to
control diet. APNKO mice showed significant decrease in the apoptotic cells when
compared to WT mice given both Se rich and control diet. In DSS+DMH group, both
APNKO and WT mice showed a significant increase in the TUNEL positive cell in the
colon tumor tissue section with Se rich diet as compared to control diet.

Cleaved Caspase 9 and phospho-p53 Expression:

TUNEL assay was followed by the mechanistic search for the molecule(s) responsible for
Se mediated apoptosis of the cancer cells. Colon tumor tissue was collected after sacrificing
the mice at the end of the study at day 194. Florescence staining and Western blot analyses
were performed on the sectioned and frozen colon tumor tissue respectively. Significant
increase in cleaved caspase 9 protein expression in the tumor tissue was observed in Se
rich diet in comparison to control diet in DSS+DMH group of both the WT and APNKO
mice by florescence study and Western blot. Both techniques indicated a significant
decrease in the cleaved caspase 9 protein expression in APNKO mice when compared to
WT mice given Se rich diet (figure 7). Phospho p53 expression was also determined in the
tumor tissue by Western blot indicating a significant increase in phospho-p53 with Se rich
diet in both WT and APNKO mice when compared to control diet in the same group (figure
7).
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Goblet Cell Production and Muc 2 Expression:

Alcian blue staining was performed in the colon tissue section of the mice belonging to all
treatment groups and control group. Ratio of goblet to epithelial cell was calculated and a
graph was plotted to determine the effect of Se on goblet cell production. Control group
showed the highest ratio of goblet to epithelial cells with DSS group showing the lowest
ratio. Significant increase in the ratio was found in the WT mice given Se rich diet when
compared to WT mice with control diet belonging to DSS treatment group. No significant
difference in the ratio was observed between APNKO mice Se rich and control diet. In
DMH group, APNKO mice given Se rich diet showed a significant increase in goblet cell
production when compared to APNKO mice given control diet. However, no significance
was observed in the WT mice given Se rich and control diet. In DSS+DMH treatment
group, both APNKO and WT mice showed a significant increase in goblet to epithelial cell
ratio with Se rich diet when compared with control diet belonging to the same genotype
and treatment group. Significant reduction in goblet to epithelial cell ratio was found in the
in all the treatment groups when compared to the control group. This was further followed
by studying the protein expression for Hes-1 and Math-1 in the colon tissue section by
using western blot in DSS+DMH treatment group. No significant difference in the
expression of Hes-1 was found in the both APNKO and WT mice given control and Se rich
diet. However, significant increase in the expression of Math-1 was found in the APNKO
and WT mice given Se rich diet when compared to control diet.
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This was followed by studying the expression of major mucus protein Muc-2. Muc-2
expression was measured in APNKO and WT mice belonging to DSS+DMH treatment
group and significant increase in the protein expression of Muc-2 was found in the APNKO
and WT mice given Se rich diet when compared to mice given control diet.

Serum Adiponectin:

To establish a link between Se and APN, serum APN was determined in the WT mice
belonging to all treatment group. There was a significant decrease in the levels of serum
APN in WT mice belonging to DSS, DMH and DSS+DMH group when compared to
control group. In DSS+DMH group, WT mice given Se rich diet showed a significant
increase in level of serum APN when compared to WT mice given control. No other group
showed any significant increase with Se rich diet administration.

5.5. Discussion:

Colon cancer is one of the major causes of cancer deaths in United States (R. Siegel,
et al., 2014). There are several treatments available for patients with colon cancer, but most
of the treatment methods have mild to severe side effects depending on the stage of colon
cancer and the mode of treatment(Chatterjee et al., 2014; Law, Rogers, & Eng, 2014).
Therefore, it’s imperative to develop alternative treatment methods or provide
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complementary medications that could prevent potential side effects or aid in the treatment
of cancer without severe adverse effects. Our previous study indicated that APNKO mice
showed increased pathology of CICC (Saxena, et al., 2012). APN administration has been
shown to reduce intestinal tumor in APCMin/+ mice model of intestinal cancer (Otani et al.,
2010). Several studies have reported APN as an anti-inflammatory and anti-cancer
adipocytokine (Nagaraju, Aliya, & Alese, 2014; Tae, et al., 2014b). Se has also been used
in the treatment of several diseases including autoimmune disease (Kryczyk & Zagrodzki,
2013; Wimmer, Hartmann, Brustbauer, Minear, & Dam, 2014), different types of cancer
and disorders like diabetes(Rayman, 2012). Although there have been few studies
indicating the protective role of Se in colon cancer, but most of these studies are in-vitro
or lack the mechanism of action of Se in reducing the severity of colon cancer and chronic
inflammation (Barrett et al., 2013; Z. Li, et al., 2013). Other studies have observed an acute
effect of Se administration on colon cancer. In this project, we studied the effect and
different mechanisms of action of Se rich diet on both APNKO and WT mice with chronic
inflammation, cancer and CICC. Se has been used as a prevention in the colon cancer and
not as a potential treatment as the Se rich diet was administered to the mice on the same
day as DSS or DMH or DSS+DMH.

This study has utilized three different treatment groups including DMH alone,
which is a carcinogen and can induce pre-cancerous lesions and colon cancer, DSS alone
group to study chronic inflammation and DSS+DMH, which mimics CICC. In order to
study the physical attributes of the disease progression clinical score including hemoccult,
diarrhea and weight loss was calculated from day 1 till the date of sacrifice (day 194) for
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all the treatment groups and control groups. We found a significant reduction in the clinical
score with Se rich diet in both APNKO and WT mice given DSS alone in all the three DSS
cycle. Decrease in the clinical score was more significant in the second and the third DSS
cycle with mice given Se rich diet showing greater protection from DSS insult when
compared to the control diet. APNKO mice given control diet showed highest clinical score
in the second and third DSS cycle (Clinical Score=8) with an average score of 6. This score
was contributed by diarrhea and fecal hemoccult as the APNKO and WT mice didn’t show
significant weight reduction. APNKO mice tends to have a higher clinical score as APN
has been shown to act as an anti-inflammatory and anti-cancerous molecule which prevents
colon goblet cells apoptosis and aids in the differentiation of epithelial to goblet
cells(Saxena, et al., 2013). This prevents colon from DSS insults leading to lower clinical
score of WT mice as compared to APNKO mice. After the third DSS cycle, both APNKO
and WT mice given control diet continue to show a significantly higher clinical score as
compared to the mice given Se rich diet. This Se mediated protection could be due to the
anti-inflammatory role of Se, which protected colon from DSS insult by negatively
modulating inflammatory cytokines and proteins in DSS alone and DSS+DMH
group(Turanov et al., 2014). DMH alone group showed significance only at the end of the
study as DMH is not a very potent carcinogen to induce the pathology required for a higher
clinical score (Saxena, et al., 2012). However, a significant reduction in the clinical score
was found in the DMH alone group from day 185 till day 194 in APNKO mice given Se
rich diet when compared to the control diet. This could be attributed to the antioxidant
potential of Se which in turns relates to the reduction in the pre-cancerous lesions induced
by DMH (Ghadi, Malhotra, Ghara, & Dhawan, 2013). No significance in the clinical score
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was obtained in the WT mice given DMH treatment as our published data indicate that
APNKO mice are at increased risk of developing colon cancer as compared to WT mice
(Saxena, et al., 2012). Presence of APN provides an additional benefit to WT mice by
preventing precancerous lesions and hence lowering the clinical score when compared to
APNKO mice. DSS+DMH group is an ideal model for studying chronic inflammation
induced colon cancer. Clinical score pattern in this group was very similar to DSS alone
group for the first and the second DSS cycle. However, after the third DSS cycle, clinical
score remained high around 10, till the date of sacrifice (day 194). Significant reduction in
the clinical score was found in both WT and APNKO mice with Se rich diet when
compared to control diet. In this group, Se mediated protection is not only restricted to the
anti-inflammatory and the anti-oxidant potential, but to the ability of Se leading to the
apoptosis of the colon cancer cells causing reduction in tumor size and number and
resulting in decreased fecal hemoccult and diarrhea. Significant reduction in the tumor
number and area was found in the DSS+DMH treatment group with Se rich diet in both
APNKO and WT mice when compared to the control diet. This provided a strong evidence
for the Se mediated protection and an explanation for the lower clinical score with Se rich
diet. These result could also be explained by the published work of Li et al. 2013 that
provided evidence that sodium selenite induces apoptosis of the colorectal cancer cells:
HCT116 and SW620 cells via Bax dependent pathway(Z. Li, et al., 2013). No significance
was found in the tumor number and area of WT and APNKO mice given Se rich and control
diet in DMH alone group except for the tumor number of the APNKO mice. APN has been
considered both as pro-apoptotic and anti-apoptotic molecule depending on the disease
condition. A recent study by Xing et al., 2015 has shown APN to induce apoptosis in
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hepatocellular carcinoma(Xing et al., 2015) while Gao et al, 2014 has published APN to
cause no apoptosis of PC-3; human prostate cell line but inhibits proliferation(Gao &
Zheng, 2014). Another study by Kato et al., 2014 has shown APN to inhibit cellular
proliferation alongwith increased apoptosis with increased caspase-3 and caspase-7
expression(Kato et al., 2014). DMH alone has been known as a mild carcinogen as shown
by our previous publication. Although some APNKO mice with control diet show
increased tumor area, but the variability in the groups lead to no significant difference. This
was followed by an investigation to determine the Se content in the colon tissue supporting
our hypothesis that colon Se content was higher in mice given Se rich diet (figure 3).

After mass spectrometry study, the colon tissue was investigated for the markers of
oxidative stress. Significant reduction in the oxidative stress was found with Se rich diet in
DSS+DMH treatment group as indicated by Nitrotyrosine and 4HNE protein expression
studies (figure 4). These data add support to our hypothesis that Se content in the colon is
inversely related to oxidative stress. Oxidative stress study in AOM/DSS murine model by
Barrett et al. 2013 also indicated that the mice given Se rich diet showed a reduced F 2isoprostanes (marker of lipid peroxidation and oxidative stress) and DNA damage in
response to DSS injury(Barrett, et al., 2013). Se has also been shown to reduce oxidative
stress and lipid peroxidation in DMH treated rats(Ghadi, Malhotra, Ghara, & Dhawan,
2012) and its deficiency is associated with higher levels of iNOS and MDA expression in
chickens(Yu et al., 2014). We went a step further to determine the selenoproteins
responsible for this Se mediated oxidative stress protection by determining the Gpx activity
and protein expression. Gpx activity was found to be significantly higher with Se rich diet
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with an exception of DSS group. Control group showed the highest while the DSS+DMH
has the lowest Gpx activity, but we found a significant increase in the Gpx activity with Se
rich diet when compared to control diet. APNKO mice showed lower Gpx activity, which
could be due to higher oxidative stress as a result of higher degree of inflammation and
cancer pathology. Gpx being a well know antioxidant and major selenoprotein is
considered as an anti-inflammatory marker, which was found to be reduced with greater
inflammation and cancer(Chen, Prabhu, & Mastro, 2013). To further investigate specific
selenoproteins, Gpx-1 and Gpx-2 protein expression were determined as these
selenoproteins have been considered as the major selenoproteins of the gut and has been
widely studied in colon cancer. Our results indicated an increase in both Gpx-1 and Gpx-2
protein expression with Se rich diet with significance in DSS+DMH group indicating the
potential benefit of Se rich diet. Gpx-2 has been shown to be upregulated in colorectal
cancer(Chen, Prabhu, & Mastro, 2013; Florian et al., 2001; Murawaki et al., 2008) and is
considered both protective and detrimental based on stage of cancer(Chen, Prabhu, &
Mastro, 2013). Krehl et al 2011 has shown that Gpx-2 and Se (0.65=4 mg/kg diet) reduced
inflammation and tumor in inflammation associated carcinogenesis, which overlaps with
our model of CICC (Krehl, et al., 2012).

Above results provide an indication of the protective role of Se and APN in CICC,
which lead to further in depth investigation by Hematoxylin and Eosin staining to
determine histopathology scoring of colon tissue section. DSS group showed little
inflammation and infiltration of the immune cells, however increased inflammation,
immune cell infiltration and cancerous lesions along with some visible tumors were found
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in DMH alone group. Significant reduction in the pathology scoring was obtained with Se
rich diet in WT mice given DMH or DSS alone. DSS+DMH group showed the highest
histopathology scoring with severe inflammation and immune cell infiltration along with
severe lesions and abundant tumor regions. Significant reduction in the histopathology
scoring was obtained with Se rich diet and APNKO mice showed increased pathology
when compared to WT mice. APN has been implicated as an anti-cancerous and antiinflammatory adipocytokine leading to APNKO mice at an increased risk of inflammation
and infiltration by immune cells (Saxena, et al., 2012). Lower Se levels has been found in
IBD patients indicating the potential use of Se as an anti-inflammatory and anti-cancerous
compound(Nagy, et al., 2013).

The above results were supported by studying the expression of phospho-NFᴋβ p65
and related cytokine including IL-6, TNF-α, IL-1β and IL-10. phospho-NFᴋβ p65
expression was found to be significantly decreased with Se rich diet in DSS+DMH
treatment group. Se has been shown to downregulate NFᴋβ expression in diabetic rats
(Pillai, et al., 2012). Pro-inflammatory secreted IL-6, TNF-α and IL-1β expression was also
significantly decreased with Se rich diet in APNKO mice with DSS+DMH treatment. Se
deficiency has been shown to increase pro-inflammatory and pro-tumorigenic cytokines
with increase DNA damage in AOM/DSS induced colon tumorigenesis (Barrett, et al.,
2013). No significance was obtained in WT mice and other treatment groups. APN
administration has been shown in APC mice to reduce tumor burden and inflammation
(Otani, et al., 2010). These result were similar to the results of our previous publication
where APNKO mice showed a heightened pro-inflammatory cytokine response than WT
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mice(Saxena, et al., 2012). Full length APN has been shown to reduce the production of
inflammatory markers including TNF-α, IL-8 and IL-6. In addition, it was shown to
suppress NFᴋB p65 activation with decreased intracellular ROS levels in OE19 esophageal
adenocarcinoma cells.

To further investigate the mechanism of action of Se leading to reduce tumor
number and area, TUNEL assay was performed in both the tumor and the non-tumor
regions of the colon tissue sections. The degree of apoptosis was quantified by counting
the TUNEL positive cells to the total epithelial cells. No significance was obtained in the
control and DSS treatment group. Significant reduction in the TUNEL positive cells were
obtained in the normal colon tissue section given Se rich diet when compared to the control
diet in both WT and APNKO mice in DMH and DSS+DMH treatment group. These data
provide an inclination towards the anti-apoptotic role of Se in the non-tumor region of the
colon tissue section indicating towards faster epithelial cell removal or the termination of
the apoptotic pathway which in turn prevents colon from DSS and DMH insult preventing
inflammation, infiltration and cancer pathology. However the data were completely
reversed when the tumor region of the same tissue section was analyzed. There was a
significant increase in the TUNEL positive cell with Se rich diet in the colon tumor tissue
sections of the WT and APNKO mice in the DSS+DMH. Higher apoptosis was also
observed in the WT mice when compared to the APNKO mice. These data provide a proof
to the in –vitro study published by Li et al. 2013 in HCT116 and SW620 colorectal cancer
cells proposing the pro-apoptotic role of sodium selenite on cancer cells (Z. Li, et al., 2013).
It was also found that APNKO mice had lower degree of apoptosis when compared to WT

133

in both tumor and non-tumor region of colon tissue section. APN, as previously mentioned,
has been shown to be both pro and anti-apoptotic depending on the disease condition. To
determine the mode of action of Se and APN as a pro-apoptotic and anti-oxidant,
expression of cleaved caspase-9 and phospho-p53 were determined in the tumor tissue
section. Significant increase in both cleaved caspase-9 and phospho-p53 expression was
found in the tumor tissue section of both WT and KO mice in DSS+DMH treatment groups.
Cleaved caspase-9 expression was also determined by immunofluorescence indicating the
significantly increased expression and localization of cleaved caspase-9 in tumor region of
colon tissue section of both APNKO and WT mice in DSS+DMH group. A recent
publication by Gandhi et al. 2014 has shown that supraphysiologic dosage of selenium lead
to the apoptosis of cancer stem-like cells derived from chronic or acute myelogenous
leukemias by the activation of ATM-p53 dependent apoptotic pathway(Gandhi et al.,
2014). Sodium selenite has also been shown to increase the expression of Bax, Bad, Bim
and activated caspase-9 alongwith the downregulation of Bcl-xL in xenografted human
colorectal carcinoma SW480 cell lines (Y. Yang et al., 2009). We also found a reduction
in the expression of cleaved caspase -9 in APNKO mice but no significant changes in
phospho-p53 expression indicating that APN may lead to the apoptosis of colon cancer cell
by activation of cleaved capase-9. However, in vitro siRNA studies are warranted to
provide conclusive evidence.

After this we also studied the effect of Se rich diet on goblet cell production and
mucus secretion. This was accomplished by using Alcian blue staining and then
determining the ratio of goblet to epithelial cells. This study provide the first evidence of
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the effect of Se rich diet and APN deficiency on goblet cell production in WT and APNKO
mice with CICC. Our study indicated a significant increase in the goblet to epithelial cell
ratio with Se administration in both WT and APNKO mice with CICC. WT mice showed
higher goblet cells than APNKO. This was followed by the molecular investigation to
determine the mechanism for increased goblet cell production. We found a significant
increase in Math-1 protein expression with Se rich diet. Math-1 is a basic helix loop helix
transcription factor involved in the determination of cell fate in multiple tissues including
colon where higher expression of Math-1 is linked with secretory fate of pluripotent colon
stem cells (van Es, de Geest, van de Born, Clevers, & Hassan, 2010). Higher expression of
Math-1 is linked with increase goblet cell phenotype. Muc-2 mucin expression was
determined by using western blot and we found a significant increase in Muc-2 production
with Se rich diet in both APNKO and WT mice with CICC. Muc-2 is one of the major
secretory mucin of the colon and forms the main component of the protective mucus layer.
Suppression of Muc-2 is associated with higher secretion of IL-6 and has been found to aid
in tumor growth (Shan et al., 2014). Muc-2 has also been shown to suppress inflammation
of the intestinal tract and inhibit intestinal tumorigenesis (Van der Sluis, et al., 2006;
Velcich, et al., 2002). Our study provided evidence that the Se rich diet is effective in
increasing goblet cell production and mucin secretion which might be protective in itself
by shielding the colon from toxic insults and gut bacterial infiltration. Further studies could
be required to define the expression of other mucins which forms a part of the colon mucus
to define other mechanism by which Se could enhance colon mucus secretion.
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5.6. Conclusion:
Although there have been several studies indicating the protective role of Se and
APN in colon cancer, but most of these studies are in-vitro, xenograft or lack the
mechanism of action. Our study used a chronic model of inflammation induced colon
cancer and compared it with the just chronic inflammation induced by DSS and precancerous lesion by DMH. CICC by DSS+DMH is one of the most accepted model of
colorectal cancer as it mimics most of the condition associated with human colorectal
cancer. APNKO mice were also used in this study, which indicated a possibility of using
both APN and Se as a complementary treatment for colorectal cancer. Our study has
indicated a dual nature of Se as a pro-apoptotic molecule for cancer cells and at the same
time providing protection to normal colon epithelial cells leading to faster epithelial cell
renewal which lead to further reduction in the inflammation, immune cell infiltration and
colon insult. It also provided evidence for the preventive nature of Se by increasing goblet
cell production and mucus secretion. Absence of APN has also been related with severe
pathology, increased inflammation and reduction of colon cancer cell apoptosis
culminating in to higher degree of CICC. This study although providing several important
conclusions has some limitations. Se was given in the form of food pellets which leads to
unequal intake of Se by mice depending on their food consumption. DSS was administered
through water which again result in differential consumption of DSS by different mice in
the same which could be one of the cause of higher variability in the tumor size in
DSS+DMH treatment group.
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This study provided sufficient evidence to further investigate the role of Se and
APN as an anti-tumor and anti-inflammatory protective non-metal antioxidant and
adipocytokine respectively.

Further studies exploring the role of Se and APN in other

models of colon and intestinal cancer and their effect on goblet cell and mucus production,
changes in gut permeability and the diversity in the gut microbiome may provide further
indication of the mechanism of action of both of these anti-inflammatory and anti-cancer
molecule in inflammation and colorectal cancer.

5.7. Figure Legends:

Figure 5.1. Clinical Score: The 3 graph represents clinical score for 3 different treatment
groups including DSS, DMH and DSS+DMH. Clinical score is a culmination of
hemoccult, diarrhea and weight loss. One way and two way Analysis Of Variance
(ANOVA) was used to calculate significant difference between different groups.
Significant difference was calculated between Se rich and control diet with in the same
phenotype and between APNKO and WT mice either given Se rich or control diet. *p<0.05
and #p<0.01. (n=10).

Figure 5.2. Tumor Quantification: (A) Colon tissue stained with 2% Methylene blue to
represent tumor number and tumor in APNKO and WT mice give Se rich and control diet.
(B) Graph representing the tumor number in APNKO and WT in DSS, DMH and
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DSS+DMH treatment group given Se rich and control diet. (C) Graph representing the
tumor area (mm2) of the APNKO and WT mice in DMH and DSS+DMH treatment group
given Se rich and control diet. Significant difference was calculated using one way
(ANOVA) was used to calculate significant difference between different groups. *p<0.05
between WT and WT+Se in DSS+DMH treatment group and KO and KO +Se in DMH
alone treatment group. #p<0.01 between KO and KO+Se in DSS+DMH treatment group.
**p<0.04 between control and Se rich diet given to WT mice in DSS+DMH treatment
group. €p<0.05 between WT+Se and KO+Se in DSS+DMH treatment group. ¥p<0.05
between WT control diet and KO control diet in DSS+DMH treatment group. ‡p<0.05
between the KO Se rich diet vs WT Se rich diet in DSS+DMH treatment group. (n=10).

Figure 5.3. Mass Spectrometry: Bar graph showing the Se content of the colon tissue in
control and DSS+DMH treatment group administered control and Se rich diet. One way
ANOVA was used to determine the significant difference between the control diet and Se
rich diet belonging to the same treatment and genotype. *p<0.05. (n=5).

Figure 5.4. Oxidative Stress: (A) Western blot and ponceau staining for 4HNE and
Nitrotyrosine expression representing oxidative stress in DSS+DMH colon tissue section.
(B) The graph represents the expression level of 4HNE and Nitrotyrosine in APNKO and
WT mice give control and Se rich diet in DSS+DMH treatment groups. One way ANOVA
was used to determine the significant difference. *p<0.05 represents the significant
difference between the Se rich and control diet within same genotype. (n=5).
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Figure 5.5. Selenoproteins Activity and Expression: (A) Graph representing the Gpx
activity (nmol/min/mg protein) in the colon tissue section of the APNKO and WT mice
given Se rich and control diet in DSS+DMH, DMH, DSS and control group. (B) Western
blot images for Gpx-1 and Gpx-2 protein expression in the colon tissue section of WT and
APNKO mice give Se rich and control diet belonging to Control, DSS, DMH and
DSS+DMH treatment groups. (C) Graph showing the expression of Gpx-1 protein in the
colon tissue section of both APNKO and WT mice given Se rich and control diet in control,
DSS, DMH and DSS+DMH treatment group. (D) Graph showing the expression of Gpx-2
protein in the colon tissue section of both APNKO and WT mice given Se rich and control
diet in control, DSS, DMH and DSS+DMH treatment group. One way ANOVA was used
to determine the significant difference between the Se rich diet and control diet within the
same treatment group with same genotype. *p<0.05 between Se rich and control diet with
same treatment group and genotype. **p<0.03 between Se rich and control diet with same
treatment group and genotype. #p<0.01 between Se rich and control diet with same
treatment group and genotype. #p<0.01 between Gpx activity of KO+Se and WT+Se given
DSS+DMH treatment. (n=5).

Figure 5.6. Histopathology Staining and Scoring: (A) The images represents the
hematoxylin and eosin stained colon tissue section of both APNKO and WT mice
belonging to control, DSS, DMH and DSS+DMH treatment groups. These indicate
pathology including inflammation, infiltration of immune cells and tumor associated with
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the genotype, diet and treatment. (B) Graph representing the histopathology scoring
performed after hematoxylin and eosin staining of the colon tissue section. The scoring
was performed by 2 investigators in the blinded conditions. One way ANOVA was used to
determine the significant difference. *p<0.05 between Se rich and control diet with in the
same genotype and treatment group. #p<0.03 between WT+control diet and KO+control
diet in DSS+DMH treatment group. **p<0.04 between WT+control diet and WT+Se rich
diet in DSS+DMH treatment group. ***p<0.01 KO+control diet and KO+Se rich diet in
DSS+DMH treatment group. (n=5).

Figure 5.7. Markers of Inflammation: (A) The image and the graph represents the
western blot image and the expression levels of phospho-NFĸB p65 and total NFĸB p65 in
both APNKO and WT mice given control and Se rich diet in control, DSS, DMH and
DSS+DMH treatment groups. (n=5) (B) Graph representing the levels of secreted
cytokines from the colon tissue section, incubated in RPMI media at 37ºC overnight. One
way ANOVA was used to determine the significant difference. (n=10) *p<0.05 between
the Se rich and control diet within the same genotype given the same treatment. #p<0.01
between the Se rich and control diet within the same genotype given the same treatment.

Figure 5.8. TUNEL Assay and Apoptosis: (A) Images showing the TUNEL positive
epithelial cells (brown color) in the non-tumor colon tissue section of APNKO and WT
mice with Se rich and control diet in control, DSS, DMH and DSS+DMH treatment group.
The tissue was counterstained with methyl green. (B) Graph representing ratio of the
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number of TUNEL positive cells to the total epithelial cells (degree of apoptosis) in
APNKO and WT colon tissue section given Se rich and control diet in control, DSS, DMH,
DSS+DMH treatment group. (C) Figure depicting TUNEL positive colon tumor cells
(brown color) in the tumor area of colon tissue section of APNKO and WT mice with Se
rich and control diet in DSS+DMH treatment group. (D) Graph showing the ratio of the
number of TUNEL positive colon tumor cells to the total epithelial cells (degree of
apoptosis) in APNKO and WT mice tumor colon tissue section given Se rich and control
diet in DSS+DMH treatment group. The scoring was performed by 2 investigators in the
blinded conditions. One way ANOVA was used to determine the significant difference.
#p<0.04 between the Se rich and control diet within the same genotype and treatment group.

***p<0.01 between WT and WT+Se in DMH treatment group. **p<0.05 between the Se
rich and control diet within the same genotype and treatment group. *p<0.05 between
WT+Se and KO+Se in DSS+DMH treatment group. (n=5).

Figure 5.9. Cleaved caspase-9 and phospho-p53 expression: (A) Figure shows the
fluorescent expression of cleaved caspase-9 (red and pink) in tumor tissue colon section of
the APNKO and WT mice given Se rich and control diet in DSS+DMH treatment group.
DAPI (blue) is used to stain nucleus of the tumor cells. (B) Graph showing the
quantification of the fluorescent expression of cleaved caspase-9 in the tumor colon tissue
section of the APNKO and WT mice given Se rich and control diet in DSS+DMH treatment
group. (C) Western blot images showing the expression of cleaved caspase-9, phospho p53
and GAPDH in tumor colon tissue section of the APNKO and WT mice given Se rich and
control diet in DSS+DMH treatment group. Bar graphs showing cleaved caspase-9 and
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phospho p53 protein expression quantification using Image J software and one way
ANOVA was used to determine the significant difference. *p<0.05 between Se rich and
control diet within the same genotype in DSS+DMH treatment group. **p<0.05 between
KO+Se and WT+Se in DSS+DMH treatment group. #p<0.02 cleaved capase-9 protein
expression in WT+Control Diet and WT+Se diet in DSS+DMH treatment group. (n=5).

Figure 5.10. Goblet Cell production: (A) Figure indicates Alcian blue staining for the
colon tissue section of the both APNKO and WT mice in different treatment groups. Blue
staining indicates goblet cells while the pink stained cells by neutral red are colon epithelia
cells. (B) Graph showing goblet to epithelial cell ratio per view per group. One way
ANOVA was used to determine the significant difference. *p<0.05 between Se rich and
control diet belonging to same phenotype and same treatment group. (n=5).

Figure 5.11. Molecular pathway for goblet cell production and Mucin expression in
DSS+DMH treatment group: (A) Western blot image indicating protein expression of
Muc-2, Math-1, Hes-1 and GAPDH. (B) Graph showing Muc-2 expression normalized by
GAPDH expression in DSS+DMH treatment group. (C) Graph showing Math-1 expression
normalized by GAPDH expression in DSS+DMH treatment group. (D) Graph showing
Hes-1 expression normalized by GAPDH expression in DSS+DMH treatment group. One
way ANOVA was used to determine the significant difference. *p<0.05 between Se rich
and control diet belonging to same phenotype in DSS+DMH treatment group. (n=5).
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Figure 5.12. Serum Adiponectin: Graph showing the level of serum APN in WT mice
belonging to all the treatment group and control group with either Se rich or control diet.
One way ANOVA was used to determine the significant difference. *p<0.05 between Se
rich and control diet belonging to same phenotype in DSS+DMH treatment group. (n=10).
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Figure 5.1. Clinical Score: The 3 graph represents clinical score for 3 different treatment
groups including DSS, DMH and DSS+DMH. Clinical score is a culmination of
hemoccult, diarrhea and weight loss. One way and two way Analysis Of Variance
(ANOVA) was used to calculate significant difference between different groups.
Significant difference was calculated between Se rich and control diet with in the same
phenotype and between APNKO and WT mice either given Se rich or control diet. *p<0.05
and #p<0.01. (n=10).
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Figure 5.2. Tumor Quantification: (A) Colon tissue stained with 2% Methylene blue to
represent tumor number and tumor in APNKO and WT mice give Se rich and control diet.
(B) Graph representing the tumor number in APNKO and WT in DSS, DMH and
DSS+DMH treatment group given Se rich and control diet. (C) Graph representing the
tumor area (mm2) of the APNKO and WT mice in DMH and DSS+DMH treatment group
given Se rich and control diet. Significant difference was calculated using one way
(ANOVA) was used to calculate significant difference between different groups. *p<0.05
between WT and WT+Se in DSS+DMH treatment group and KO and KO +Se in DMH
alone treatment group. #p<0.01 between KO and KO+Se in DSS+DMH treatment group.
**p<0.04 between control and Se rich diet given to WT mice in DSS+DMH treatment
group. €p<0.05 between WT+Se and KO+Se in DSS+DMH treatment group. ¥p<0.05
between WT control diet and KO control diet in DSS+DMH treatment group. ‡p<0.05
between the KO Se rich diet vs WT Se rich diet in DSS+DMH treatment group. (n=10).
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Figure 5.3. Mass Spectrometry: Bar graph showing the Se content of the colon tissue in
control and DSS+DMH treatment group administered control and Se rich diet. One way
ANOVA was used to determine the significant difference between the control diet and Se
rich diet belonging to the same treatment and genotype. *p<0.05. (n=5).
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Figure 5.4. Oxidative Stress: (A) Western blot and ponceau staining for 4HNE and
Nitrotyrosine expression representing oxidative stress in DSS+DMH colon tissue section.
(B) The graph represents the expression level of 4HNE and Nitrotyrosine in APNKO and
WT mice give control and Se rich diet in DSS+DMH treatment groups. One way ANOVA
was used to determine the significant difference. *p<0.05 represents the significant
difference between the Se rich and control diet within same genotype. (n=5).
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Figure 5.5. Selenoproteins Activity and Expression: (A) Graph representing the Gpx
activity (nmol/min/mg protein) in the colon tissue section of the APNKO and WT mice
given Se rich and control diet in DSS+DMH, DMH, DSS and control group. (B) Western
blot images for Gpx-1 and Gpx-2 protein expression in the colon tissue section of WT and
APNKO mice give Se rich and control diet belonging to Control, DSS, DMH and
DSS+DMH treatment groups. (C) Graph showing the expression of Gpx-1 protein in the
colon tissue section of both APNKO and WT mice given Se rich and control diet in control,
DSS, DMH and DSS+DMH treatment group. (D) Graph showing the expression of Gpx-2
protein in the colon tissue section of both APNKO and WT mice given Se rich and control
diet in control, DSS, DMH and DSS+DMH treatment group. One way ANOVA was used
to determine the significant difference between the Se rich diet and control diet within the
same treatment group with same genotype. *p<0.05 between Se rich and control diet with
same treatment group and genotype. **p<0.03 between Se rich and control diet with same
treatment group and genotype. #p<0.01 between Se rich and control diet with same
treatment group and genotype. #p<0.01 between Gpx activity of KO+Se and WT+Se given
DSS+DMH treatment. (n=5).
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Figure 5.6. Histopathology Staining and Scoring: (A) The images represents the
hematoxylin and eosin stained colon tissue section of both APNKO and WT mice
belonging to control, DSS, DMH and DSS+DMH treatment groups. These indicate
pathology including inflammation, infiltration of immune cells and tumor associated with
the genotype, diet and treatment. (B) Graph representing the histopathology scoring
performed after hematoxylin and eosin staining of the colon tissue section. The scoring
was performed by 2 investigators in the blinded conditions. One way ANOVA was used to
determine the significant difference. *p<0.05 between Se rich and control diet with in the
same genotype and treatment group. #p<0.03 between WT+control diet and KO+control
diet in DSS+DMH treatment group. **p<0.04 between WT+control diet and WT+Se rich
diet in DSS+DMH treatment group. ***p<0.01 KO+control diet and KO+Se rich diet in
DSS+DMH treatment group. (n=5).
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Figure 5.7. Markers of Inflammation: (A) The image and the graph represents the
western blot image and the expression levels of phospho-NFĸB p65 and total NFĸB p65 in
both APNKO and WT mice given control and Se rich diet in control, DSS, DMH and
DSS+DMH treatment groups. (n=5). (B) Graph representing the levels of secreted
cytokines from the colon tissue section, incubated in RPMI media at 37ºC overnight. One
way ANOVA was used to determine the significant difference. (n=10).*p<0.05 between
the Se rich and control diet within the same genotype given the same treatment. #p<0.01
between the Se rich and control diet within the same genotype given the same treatment.
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Figure 5.8. TUNEL Assay and Apoptosis: (A) Images showing the TUNEL positive
epithelial cells (brown color) in the non-tumor colon tissue section of APNKO and WT
mice with Se rich and control diet in control, DSS, DMH and DSS+DMH treatment group.
The tissue was counterstained with methyl green. (B) Graph representing ratio of the
number of TUNEL positive cells to the total epithelial cells (degree of apoptosis) in
APNKO and WT colon tissue section given Se rich and control diet in control, DSS, DMH,
DSS+DMH treatment group. (C) Figure depicting TUNEL positive colon tumor cells
(brown color) in the tumor area of colon tissue section of APNKO and WT mice with Se
rich and control diet in DSS+DMH treatment group. (D) Graph showing the ratio of the
number of TUNEL positive colon tumor cells to the total epithelial cells (degree of
apoptosis) in APNKO and WT mice tumor colon tissue section given Se rich and control
diet in DSS+DMH treatment group. The scoring was performed by 2 investigators in the
blinded conditions. One way ANOVA was used to determine the significant difference.
#p<0.04 between the Se rich and control diet within the same genotype and treatment group.
***p<0.01 between WT and WT+Se in DMH treatment group. **p<0.05 between the Se
rich and control diet within the same genotype and treatment group. *p<0.05 between
WT+Se and KO+Se in DSS+DMH treatment group. (n=5).
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Figure 5.9. Cleaved caspase-9 and phospho-p53 expression: (A) Figure shows the
fluorescent expression of cleaved caspase-9 (red and pink) in tumor tissue colon section of
the APNKO and WT mice given Se rich and control diet in DSS+DMH treatment group.
DAPI (blue) is used to stain nucleus of the tumor cells. (B) Graph showing the
quantification of the fluorescent expression of cleaved caspase-9 in the tumor colon tissue
section of the APNKO and WT mice given Se rich and control diet in DSS+DMH treatment
group. (C) Western blot images showing the expression of cleaved caspase-9, phospho p53
and GAPDH in tumor colon tissue section of the APNKO and WT mice given Se rich and
control diet in DSS+DMH treatment group. Bar graphs showing cleaved caspase-9 and
phospho p53 protein expression quantification using Image J software and one way
ANOVA was used to determine the significant difference. *p<0.05 between Se rich and
control diet within the same genotype in DSS+DMH treatment group. **p<0.05 between
KO+Se and WT+Se in DSS+DMH treatment group. #p<0.02 cleaved capase-9 protein
expression in WT+Control Diet and WT+Se diet in DSS+DMH treatment group. (n=5).
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Figure 5.10. Goblet Cell production: (A) Figure indicates Alcian blue staining for the
colon tissue section of the both APNKO and WT mice in different treatment groups. Blue
staining indicates goblet cells while the pink stained cells by neutral red are colon epithelia
cells. (B) Graph showing goblet to epithelial cell ratio per view per group. One way
ANOVA was used to determine the significant difference. *p<0.05 between Se rich and
control diet belonging to same phenotype and same treatment group. (n=5).
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Figure 5.11. Molecular pathway for goblet cell production and Mucin expression in
DSS+DMH treatment group: (A) Western blot image indicating protein expression of
Muc-2, Math-1, Hes-1 and GAPDH. (B) Graph showing Muc-2 expression normalized by
GAPDH expression in DSS+DMH treatment group. (C) Graph showing Math-1 expression
normalized by GAPDH expression in DSS+DMH treatment group. (D) Graph showing
Hes-1 expression normalized by GAPDH expression in DSS+DMH treatment group. One
way ANOVA was used to determine the significant difference. *p<0.05 between Se rich
and control diet belonging to same phenotype in DSS+DMH treatment group. (n=5).
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Figure 5.12. Serum Adiponectin: Graph showing the level of serum APN in WT mice
belonging to all the treatment group and control group with either Se rich or control diet.
One way ANOVA was used to determine the significant difference. *p<0.05 between Se
rich and control diet belonging to same phenotype in DSS+DMH treatment group. (n=10).
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CHAPTER 6

SELENIUM RICH DIET AND ADIPONECTIN ADMINISTRATION ACTS AS A
PROTECTIVE AGENTS IN THE TREATMENT OF INTESTINAL CANCER4

4

Arpit Saxena, Kamaljeet Kaur, Samantha Truman, Matthew Rorro, Bianca Larsen, Emma Fletcher,
Alexander Chumanevich and Raja Fayad. To be submitted.
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6.1 Abstract

Background: Cancer of the digestive tract is the second largest cause of cancer
death in United States. Repeated cycles of inflammation or chronic inflammation has been
considered as an underlying cause of intestinal cancer and patients suffering from IBD is
at an increased risk of developing colon and intestinal cancer. Adiponectin (APN) is an
adipocytokine secreted by the adipocyte and absence of APN has been linked with increase
severity of chronic inflammation induced colon cancer. Selenium (Se) is a non-metal
required by the body as the 21st amino acid selenocysteine and reduces the oxidative stress
by increased production of antioxidant selenoproteins. Purpose: The purpose of this
publication is to study the effect of Se and APN administration on intestinal cancer.
Methods: 4 weeks old APCMin/+ mice were randomly assigned to 4 different treatment
groups including: Min, Min+APN, Min+Se and Min+APN+Se. Mice were fed either Se
rich diet (0.75 ppm) or Se deficient diet (0.02 ppm). Mice were either administered APN
or were given PBS once a week intraperitoneally for a period of 15 weeks. Mice were
monitored for the clinical score throughout the length of this study. Mice were sacrificed
on day 106 and tumor number was counted in both colon and small intestine and tissue was
collected for staining and protein expression studies. Result: Mice administered Se or APN
or both showed a significant decrease in the clinical score, tumor number and tumor area.
Se and APN administration showed a decrease in inflammation but increased cancer cell
apoptosis and goblet cell production. Conclusion: APN and Se rich diet might be used as a
complementary medicine for the treatment of intestinal cancer.
Keywords: Selenium, Adiponectin, APCMin/+, cancer, Goblet cells.
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6.2 Introduction

Cancer of the digestive tract is the second largest cause of cancer death in United
States. These include the cancer of the colon, rectal and small intestine which contributed
to 50,960 deaths in 2015 besides other parts of the digestive tract (R. L. Siegel, Miller, &
Jemal, 2015). Repeated cycles of inflammation or chronic inflammation has been
considered as an underlying cause of intestinal cancer and patients suffering from IBD is
at an increased risk of developing colon and intestinal cancer (E. H. Huang et al., 2006).
High fat diet (HFD) is often linked with increased incidence of intestinal cancer and
inflammation. HFD has been shown to result in two-fold increase in the colonic tumors
when compared with the normal diet (Park, Kim, Seo, & Sung, 2012). Adiponectin (APN)
is an adipocytokine secreted by the adipocyte and absence of APN has been linked with
increase severity of chronic inflammation induced colon cancer (Saxena, et al., 2012).
Serum APN levels is inversely related to obesity and insulin resistance. Epidemiological
study has linked lower levels of APN with increased risk of colon cancer in men (Wei, et
al., 2005). APN administration (1.5 mg/kg weight of mice) has also been shown to decrease
the tumor number in the ApcMin/+ mice model of intestinal cancer (Otani, et al., 2010).

Selenium (Se) is a non-metal required by the body as the 21st amino acid
selenocysteine and reduces the oxidative stress by increased production of antioxidant
selenoproteins. Epidemiological studies had linked lower level of Se with increased risk of
cancer and higher intake of Se resulted in the reduced risk for colon, prostate, lung and
liver cancer (Combs, 2005; Meyer et al., 2005; Whanger, 2004). Se supplementation at the
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supranutritional dosages has been shown to prevent mammary tumor (L'Abbe, Fischer,
Campbell, & Chavez, 1989). Methylseleninic acid (MSeA) supplementation has been
shown to increase the Se content in intestine, muscle and plasma has been shown to reduce
61% tumor growth. Se has been known to produce selenoproteins in the body which acts
as an antioxidant in reducing inflammation and cancer. There are around 30 selenoproteins
associated with the mammalian system. Se supplementation has been shown to increase
blood glutathione peroxidases (Gpx) activity which is further associated with reduced
inflammation and colon cancer (Zeng & Wu, 2015). Gpx2 is the most commonly associated
selenoproteins with the gut and has been shown to reduce colon cancer incidence. Se
supplementation in humans has been reported to significantly increase Gpx-1 and Gpx-2
protein expression. DMH induced carcinogenesis has been shown to significantly reduce
the expression of superoxide dismutase, catalase and Gpx (Ghadi, Ghara, Bhattacharyya,
& Dhawan, 2009). Selenium has also been shown to increase the apoptosis of the cancer
cells. Sodium selenite induces cell cycle arrest (G2) and apoptosis in the SW620 and
HCT116 colon cancer cell line in a dose dependent manner with the increased expression
of Bax and downregulation of Bcl2 (Z. Li, et al., 2013).

Morphology of colon and small intestine changes with inflammation and induction
of cancer. Intestine consist of absorptive epithelial cells and secretory goblet cells. Goblet
cells secrete mucus that forms a protective layer over the epithelial cell layer of the intestine
preventing from harmful toxin and invasion by the gut bacteria which otherwise can lead
to severe inflammation and gut related diseases and disorders. Goblet cells like other cells
of the intestine are derived from the multipotent stem cells. The fate of the stem cells to
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form goblet or epithelial cell lineage depends on the interplay of the genes involved in the
Notch signaling pathways including a transcriptional repressor Hairy and Enhancer of split
type 1 protein (Hes-1) and basic helix-loop-helix transcription factor Math1 (Wong, 2004;
Q. Yang, et al., 2001). Ulcerative colitis is associated with the depletion of goblet cells
induced by the suppression of Math1. Math1 is in turn regulated by Hes- 1 expression and
Notch signaling (Zheng et al., 2011).

Mucus produced by the goblet cells is a viscous polymer formed by glycoproteins
called mucins. There are 15 different mucins genes discovered so far and Muc2 is one of
the major mucin found in the colon mucus. Muc2-/- (knockout) mice has been found to
develop spontaneous colitis leading to the infiltration of the epithelial cell layer by the gut
bacteria (Johansson et al., 2014; Johansson, et al., 2008). Defects in the mucus layer has
also been observed in IL-10 knockout mice, which is an ideal model for the study of
spontaneous colitis (Hasnain et al., 2013).

ApcMin/+ with C57BL/6 background mouse model provides an ideal model of
inflammation induced spontaneous intestinal cancer. ApcMin/+ mice model has been widely
studied for inflammation, cachexia and intestinal cancer. Our earlier publications have
provided conclusive evidences of the protective role of Se rich diet in inflammation and
colon cancer. Besides this our publications indicate that the absence of APN is related with
increased severity of CICC. Colon cancer patients are not only given medication but
complimentary treatment including exercise and dietary intervention. Combination of
exercise, diet and medication is believed to be the most effective treatment for colon cancer
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treatment. On the basis of this idea we hypothesize that the combination of APN
administration and Se rich diet alone and in combination will be effective in reducing the
tumor burden and severity of intestinal cancer. Se and APN has been used as a prevention
for intestinal cancer.

6.3 Material and Methods:

Animal Model: Four week-old APCMin/+ and C57BL/6 mice were obtained from Jackson
Laboratories and bred in the animal facility at the University of South Carolina under the
Institutional Animal Care and Use Committee guidelines. Mice were fed either Se rich diet
(0.75 ppm) or Se deficient diet (0.02 ppm). Mice were either administered APN or were
given PBS once a week intraperitoneally for a period of 15 weeks. 4 weeks old APCMin/+
mice were then randomized into 4 different treatment groups with n=8/group. APN and Se
were administered at Day 1 of the experiment (4 weeks APCMin/+ and C57BL/6 of age).
The

groups

includes:

C57BL/6,

APCMin/+,

APCMin/++APN,

APCMin/++Se

and

APCMin/++APN+Se. Mice were monitored throughout the length of the study for clinical
score that includes weight loss, diarrhea and fecal hemoccult. Mice were sacrificed by
cervical dislocation under anesthesia on day 106. There was no significant difference in
the body weight of APCMin/+ and C57BL/6 mice at the beginning of the study.

Selenium Diet Administration and Food Consumption: Selenium rich diet containing
0.75 ppm of Se per kg were administered to 2 groups on day 1 simultaneously with the
administration of APN or PBS. The diet was administered till the day of sacrifice that is
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day 106. Control diet contains all the components of the Se rich diet except that the Se
content is 0.02 ppm per kg of diet. Food consumption was administered throughout the
length of the study and average food consumption per mice per group was calculated and
a graph was plotted.

Adiponectin Administration: APN was administered intraperitoneally (1.5mg/kg/mice)
once a week for total of 16 weeks to APCMin/++APN and APCMin/++APN+Se groups.

Clinical Score: Clinical score was measured for each mouse in each group from day 1 to
day 106. Mice were sacrificed after the last clinical score measurement. Clinical score is a
combination of diarrhea and hemoccult. Scoring of diarrhea is as follows: 0 = well-formed
pellets, 2 = pasty and semi-formed stools that do not adhere to the anus, 4 = liquid stools
that adhere to the anus. Detection of blood in the stools was determined using hemoccult
kit (BECKMAN COULTER). The higher intensity of blue color indicates greater bleeding.
The followings are the score rates for the fecal hemoccult: 0 = no blood, 2 = positive
hemoccult, 4 = gross bleeding. The total clinical score was the summation of the individual
score of weight loss, diarrhea and fecal hemoccult. The maximum score a mouse could get
is 8. The clinical score was calculated and plotted against days of DSS administration.
Higher clinical score indicates more severity of colon cancer development in animals.
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Colon Tissue and Serum Collection: Blood was collected before sacrifice through retroorbital puncture and was spun down at 10,000 rpm for 18 minutes and serum was obtained
and stored at -20°C to measure APN. Mice colon was excised and flushed clean with PBS.
2mm2 colon tissue section with tumor and non-tumor area was fixed in 10% formalin. 24
hours later, tissues was submerged with with 70% Ethanol followed by paraffin embedding
and sectioning to obtain 5 µm thin section on glass slide. Sections with tumor and nontumor areas were snap frozen on dry ice and stored at -80°C for protein analysis. Another
2mm2 colon tissue section was incubated in RPMI medium containing 5000 IU/mL and
5000 IU/mL penicillin and streptomycin (CELLGRO) respectively at 37°C and 5% CO2
for 24 hours. This was followed by centrifugation at 2500 rpm for 15 minutes. Supernatant
was obtained and stored at -20°C to measure secreted cytokine levels.

Tumor Number and Tumor Area and Histopathology: Mice colon was excised and
flushed with PBS. Tumor number and area were counted under the microscope in all mice
of different groups and significant different was calculated between different groups.
Hematoxylin and Eosin staining was used to determine the morphology of mice
colon. Histopathology was quantified based on the scoring system indicating the severity
of disease and constituting inflammation, immune cell infiltration and degree of tumor.
This was on the scale of 12 where highest score of 4 was given for each parameter, where
0 = no infiltration or no inflammation or no cancer; 2 = moderate infiltration or
inflammation or pre-cancerous lesions; and 4 = severe inflammation with distorted crypts
or infiltration and formation of lymphatic follicles or visible tumors. All the images were

163

taken in 20X magnification with Nikon e600 microscope. The score was measured by two
investigators in blinded fashion.

TUNEL Assay: Degree of apoptosis was measured in the tumor and non-tumor tissue
sections of the colon by TUNEL assay. TUNEL assay (EMD Millipore) was used to
determine the number of TUNEL positive cells and total number of epithelial cells of the
colon in 2mm2 tissue cross-sectional tissue area. 5 sections were randomly selected from
each tissue section and 10 tissue sections were randomly selected from each group. The
ratio of TUNEL positive cell to total epithelial cell were used to determine the ratio of
apoptosis and plotted as a graph for different treatment groups. All the images were taken
in 20X magnification with Nikon e600 microscope.

Alcian blue staining: Standard deparaffinization procedure was followed using xylene
and gradation of ethanol. Alcian blue solution (1 %) of pH 2.5 in 3 % acetic acid and
nuclear fast red in aluminum sulfate was prepared. Tissues were stained with Alcian blue
and counterstained with nuclear fast red solution. Goblet to epithelial cell ratio was counted
per crypt with ten crypts per section and five sections per group.

Protein determination using Western Blot: Colon tissue frozen at -80°C was
homogenized in RIPA buffer added to protease and phosphatase inhibitors (SIGMA). It
was then centrifuged at 10,000 rpm for 15 minutes and supernatant was obtained for protein
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analysis. Protein concentration in the supernatant was determined by using Bradford
protein assay. This was followed by loading equal amounts of protein (50 µg) in each well
for a 10% Sodium Dodecyl Sulphate (SDS) gel electrophoresis. The protein from the gel
was then transferred to a nitrocellulose membrane (Pall Scientific) and blocked with 5%
non-fat dry milk (Biorad) in phosphate buffer saline (PBS) (cellgro) with 0.1% Tween 20.
The membrane was incubated overnight with the primary antibody. The primary antibodies
include Muc-2, Gpx-2 and GAPDH obtained from Genetex. cleaved caspase 9, 4HNE and
Nitrotyrosine were obtained from cell signaling technology. Hes-1 and Math1 were
obtained from abcam. Membrane was washed by PBS containing 0.1% Tween 20 (Biorad).
The membrane was then incubated with secondary antibody (Santa Cruz) followed by
another washing step. The last step includes incubating the membrane in ECL substrate
(Western Bright, Advansta). The film was developed using by using a developer (SRX101A, Konica Minolta Medical & Graphic, INC.) in the dark room. Finally the film was
scanned and the density of the protein bands obtained was analyzed using Image J software.

Enzyme Linked Immunosorbent Assay (ELISA): Spontaneous secreted cytokines were
measured from the tissue incubated in the RPMI medium for 24 hours at 37°C. The media
were collected and centrifuged at 2500 rpm for 16 minutes. Pellet was discarded and the
supernatant was isolated. Cytokines IL-6, TNF-α, IL-1β and IL-10 levels were measured
by using BD OptEIA ELISA kit obtained from BD biosciences and normalized by total
protein content estimated by using standard Bradford assay procedure.

165

Serum Adiponectin: Serum APN was determined in all the treatment groups at the end of
the study. This was achieved by diluting the serum samples to 1:2000 and performing
ELISA using DuoSet mouse/Acrp30 kit (R&D SYSTEMS).

Statistical analysis: Two-way and one-way analysis of variance (ANOVA) was used to
analyze the data with Tukey post hoc-analyses. A p value<0.05 was considered statistically
significant. All the statistical analyses were done by using SigmaStat 3.5 (SPSS).

6.4 Results

Effect of Se and APN on clinical score, body weight and average food consumption:

Clinical score is a combination of diarrhea and hemoccult. Mice were administered
either Se rich diet or control diet (Se deficient diet) on day 1 with simultaneous
administration of either APN or PBS depending on the treatment group. Greater clinical
score is associated with higher degree of severity of intestinal cancer. Clinical score is
compared between 4 different groups including Min, Min+APN, Min+Se and
Min+APN+Se. Min group showed the highest clinical score while Min+APN+Se showed
the lowest score. Min+APN and Min+Se showed similar pattern of clinical score and
showed very less to no significant difference. Min+APN+Se showed zero clinical score till
day 50 and was significantly lower when compared to Min, Min+APN and Min+Se. Min
group showed significantly higher clinical score on day 12, 17, 26, 33,38, 57, 78, 87, 94,
101 and 108 when compared with other treatment groups including Min+APN, Min+Se
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and Min+APN+Se. In addition to clinical score, body weight was also monitored
throughout the length of this study. All the mice in different groups including control has
the same starting body weight. No significant changes in the body weight were observed
till day 52. After day 54, changes in the body weight began to appear between different
treatment groups. Body weight continue to increase till day 50, followed by a decrease in
body weight of Min and Min+APN. However body weight of mice in control, Min+Se and
Min+APN+Se continue to increase till day 108. Body weight of mice in Control, Min+Se
and Min+APN+Se was found to be significantly higher than the Min and Min+APN on
day 78, 87, 94. 96, 101 and 108. No significant difference in the food consumption was
found during the length of the study between different treatment groups.

Colon and small intestine tumor load:

Colon and small intestine polyp count was determined by staining the colon and
small intestine with 2% methylene blue and counting the tumor under a microscope. Min
group has the highest number of tumor in both colon and small intestine with an average
around 5 and 65 for colon and small intestine respectively. Significant reduction in the
number of colon and small intestine tumor was found in Min+APN, Min+Se and
Min+APN+Se when compared with Min (*p<0.05). Significant reduction in tumor number
in both colon and small intestine was also found in the Min+APN+Se group when
compared with Min+APN (#p<0.05).
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Se and APN administration reduces histopathology score:

Hematoxylin and Eosin staining is used to study the mouse small intestine histology
to assess inflammation, immune cell infiltration and degree of cancer. Severity of each is
measured as defined in the method section and histopathology score was assigned to each
group. Control group showed no sign of inflammation, infiltration or any tumor pathology.
Min group showed the highest histopathology score ranging from 8 to 12 while
Min+APN+Se showed the lowest histopathology score with the score ranging from 4 to 6.
This group either showed very less or no tumor and hence the maximum score could not
have exceeded 8. Significant difference was calculated between different treatment groups
in comparison to each other. Both Min+Se and Min+APN+Se showed significant reduction
in the histopathology score (p<0.05) as compared to Min. Min+APN showed no significant
decrease in the histopathology score when compared to Min, however it was significantly
higher in comparison to Min+Se and Min+APN+Se (#p<0.05).

Cytokine Production:

Secreted cytokine production was measured for different treatment groups in the
RPMI medium solution obtained by incubating 2mm2 small intestine tissue at 37°C for 24
hours. Four different secreted cytokines were measured for all treatment groups and
control. IL-6, IL-1β and TNF-α levels were found to be highest in the Min treatment group
and lowest in the Min+APN+Se. Min+Se showed significantly lower IL-6 when compared
to Min, however no significant reduction was found in comparison to Min+APN and
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Min+APN+Se. Min+APN+Se was found to have significantly lower secreted IL-6, IL-1β
and TNF-α in comparison to Min. Significant reduction in secreted TNF-α was also
observed in Min+APN+Se when compared to Min+APN. No significance in any of the
pro-inflammatory or TH1 secreted cytokines was observed between Min+Se and
Min+APN+Se. However reduction in the secreted pro-inflammatory cytokines was
observed in Min+APN+Se when compared with Min+Se. IL-10, being an antiinflammatory cytokine or a TH2 cytokine showed different secretion pattern in different
treatment groups. Highest level of IL-10 was found in Min+APN+Se treatment groups
while the lowest level was found in Min. Significant decrease in secreted IL-10 was found
in the Min and Min+APN when compared to the control group (*p<0.05). Significant
increase in the IL-10 secretion was also detected in the Min+APN+Se when compared with
Min, Min+APN and Min+APN+Se (#p<0.05). No significance was observed in the Min,
Min+APN and Min+Se when compared amongst each other. No significance was also
observed when comparing IL-10 secretion between control and Min+Se.

Serum Adiponectin:

APN was measured in the serum of all the treatment groups. Min and Min+APN
group showed a significant reduction in the serum APN when compared with control group
(**p<0.05). Min+Se and Min+APN+Se showed a significantly higher serum APN when
compared with Min and Min+APN (#p<0.05) treatment groups. Min+Se showed a
significantly higher APN in comparison to control group (*p<0.05). No significant increase
in the serum APN was observed in the Min+APN+Se when compared to control group.
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Goblet Cell Production and Muc 2 expression:

Goblet cell production was measured using Alcian blue staining and counting the
ratio of the goblet to epithelial cell. Goblet to epithelial cell ratio was found to be
significantly reduced in Min group when compared to control group (#p<0.05). The ratio
was found to be significantly higher in Min+APN, Min+Se and Min+APN+Se when
compared with Min (*p<0.05). There was no significant difference in the ratio between
control, Min+APN, Min+Se and Min+APN+Se.
After studying goblet cell production, protein expression of Muc-2, Hes-1 and
Math-1 was determined using western blot. We found a significantly higher Muc-2
expression in Min+APN, Min+Se and Min+APN+Se when compared with Min (*p<0.05),
however no significant increase was observed when compared with control group. Min
showed a significant decrease in expression of Muc-2 when compared with other groups
(#p<0.05). All the treatment groups including control showed no significant change in the
expression of Hes-1 when compared with each other. Math-1 expression followed the same
pattern as Muc-2, where we found a significant increase in expression of Math-1 in
Min+APN, Min+Se and Min+APN+Se when compared to Min.

Cancer Cell Apoptosis:

Cancer cell apoptosis was measured by using TUNEL assay where TUNEL positive
cells and epithelial cells were counted and ratio of the TUNEL positive cells to epithelial
cell was calculated and used to determine the significant difference in cancer cell apoptosis
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in different treatment groups. Control group was included to indicate the pathology of the
colon and to show the degree of apoptosis that is observed in the normal colon tissue section
in comparison to the cancer tissue section. Min showed the lowest degree of cancer cell
apoptosis and Min+Se showed the highest degree of apoptosis. Significant increase in the
cancer cell apoptosis was observed in Min+APN and Min+Se group when compared to
Min (*p<0.05). Significant decrease in the apoptosis was observed in the normal tissue
section of Min+APN+Se in comparison to Min+APN and Min+Se (**p<0.05). No
significance in the apoptosis was observed between Min+APN+Se and Control and Min
treatment groups. This was followed by cleaved Caspase-9 protein expression studies
where we found a significant increase in cleaved Caspase-9 expression in Min+APN+Se
when compared with Min and Min+APN.

Oxidative Stress:

To calculate the degree of oxidative stress, Gpx-2 (anti-oxidant expression),
nitrosylation and lipid peroxidation (4HNE) was measured. No significant changes in the
protein expression of Gpx-2 and 4HNE was observed among the 4 treatment group.
However, a significant reduction in the protein expression of nitrotyrsosine was observed
in Min+Se group (*p<0.05).
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6.5 Discussion

Gastrointestinal cancer remains in the top 3 causes of cancer deaths in United States
and the world. National cancer institute has estimated that the number of new cases to be
142,110 in the United States in the year 2015. There had been a decline in the number of
new cases and cancer deaths in the recent years due to the early screening but still it
continue to cause a significantly higher number of cancer death. The etiology of this cancer
is very wide and range from genetic pre-disposition to toxic exposure and bad lifestyle
(nutrition and exercise). There are several therapies available for the treatment of intestinal
cancer but each therapy is associated with its side effects ranging from mild to severe
including relapse of the tumor and pain. To ameliorate these side effects and to improve
the prognosis and prevent reoccurrence complimentary medicine and therapy need to
utilized in addition to the already know treatment. By the means of this publication, we
hypothesize that APN administration and Se rich diet can act either alone or in conjugation
to reduce the severity of intestinal cancer by acting through several different mechanism
discussed in the publication. Se and APN has been used in this study as a prevention of
intestinal cancer as these were administered at 4 week of age prior to the development of
tumors which is assumed to be at 12 weeks of age.

One the primary outcome of this study is the clinical score and the tumor load which
shows the physical manifestation of intestinal cancer and the efficacy of the treatment. We
found a significant decrease in the clinical score which was a combination of diarrhea and
hemoccult with APN, Se or their combination at several time points during the length of
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the study. Min+APN and Min+Se followed a similar clinical score curve and showed
significant decrease in the clinical score during several points in the study and at the end
of this study. However, mice in Min+APN+Se treatment groups showed a significant
reduction in the clinical score till day 61 starting from day 6 and then significantly lower
clinical score at the end of the study. This pattern could be attributed to the protective role
of both APN and Se in intestinal cancer. Our lab had already provided published evidences
of the increase severity of CICC in APNKO mice when compared to WT mice. Se has been
regarded as anti-inflammatory non-metal with anti-oxidant properties which could have
provided protection form the invasion of immune cell in the colon and delayed the process
of inflammation leading to small intestinal tumors. Combination of both APN and Se might
have provided added protection form inflammation, infiltration and intestinal cancer polyp
formation leading to delayed onset of diarrhea and fecal hemoccult.

After the mice were sacrificed, tumor number in both colon and small intestine was
calculated and significant reduction in the tumor number were found in both with different
treatment. Min+APN+Se was found to have the lowest number of tumors in both colon
and small intestine. Se was found to be more effective in reducing tumor number when
compared with APN alone, however the combination provide the highest decrease in the
tumor number. This decrease in the tumor number could be due to higher degree of cancer
cell apoptosis or could be due to the protection provided by the Se and APN in reducing
inflammation and hence reducing tumor number. Otani et al., 2010 published that APN
administration showed a significant decrease in adenomatous polyp when compared to the
APCMin/+ mice without APN administration (Otani, et al., 2010). Another study by Finley
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JW., 2003 proved that Se obtained from high-Se broccoli decreased ACF incidence rats
with chemically induced colon cancer. Tumor number and volume was also found to be
decreased in APCMin/+ mice with Se administration (Finley, 2003).

This physical measurements were followed by a more in depth investigation by
studying the impact of these treatments on histopathology of the small intestine. This is a
more comprehensive approach to study the manifestation of inflammation, infiltration of
the immune cells and cancer pathology. Histology of the small intestine is rather more
complex than colon in having microvilli at its surface for greater absorption of the nutrition
than waster absorption in colon. APCMin/+ mice without any treatment showed highest
histopathology score with highest level of inflammation, cancer and infiltration of the
immune cells. APN administration alone didn’t have a significant effect on the reduction
of the histopathology score. Se administration either alone or in combination with APN
showed a significant decrease in the histopathology score when compared to the APCMin/+
mice. Min+APN+Se didn’t show greater cancer pathology as it has the lowest tumor
number and hence has the lowest score. APCMin/+ mice with either Se or APN alone showed
lower score due to less inflammation and cancer pathology. This histological data
supported the physical outcomes of the experiment leading to lower tumor load and clinical
score with different treatment.

Another method of measuring inflammation and severity of disease is by studying
the expression of secreted TH1 and TH2 cytokines including IL-6, IL-1β, TNF-α and IL10. We found a significant decrease in the secretion of TH1: pro-inflammatory cytokines
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including IL-6, IL-1β and TNF-α with APN and Se administration and significant increase
in the secretion of TH2 cytokines including IL-10. This indicate a shift in the inflammatory
phenotype to anti-inflammatory phenotype providing another proof of protective effect of
APN and Se administration. This shift could be useful in reducing the severity of intestinal
cancer and related inflammation. Our previous publication indicated that the absence of
APN is linked with an increase in secreted pro-inflammatory cytokines and a decrease in
anti-inflammatory cytokines.

Another important outcome of this study lies in the relationship between APN and
Se rich diet. We found a significant increase in the serum APN with Se rich diet
administration when compared to APCMin/+ mice without any treatment. Min+Se also
showed a significantly higher serum APN when compared with control group. No
significant difference was observed in Min+Se and Min+APN+Se groups indicating that
Se rich diet is sufficient enough to raise serum APN and could maintain higher levels of
serum APN over a period of time. Intraperitoneal injection of APN might prove to be
counterproductive in raising APN levels as they might trigger a negative feed loop in
Min+Se+APN group leading to reduce secretion of indigenous APN. APN administration
in Min+APN group might be effective in raising APN levels significantly higher than Min
group but showed a significant reduction in the serum APN levels when compared with
control group and might not be as effective in raising serum APN level as Se rich diet.
These data provide a proof that Se rich diet might act to increase either APN directly or
reducing inflammation and cancer pathology in APCMin/+ mice leading to higher levels of
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serum APN. Higher levels of serum APN is associated with reduced insulin resistance,
lower degree of inflammation and colon cancer (Obeid & Hebbard, 2012).

To further investigate the mechanism of reduction in tumor count, TUNEL assay
was performed in the small intestine paraffinized tissue sections in all the treatment group
and control group. This was followed by protein expression study of cleaved caspase 9 in
tumor tissue section of all the treatment group and normal intestinal tissue of the control
group. TUNEL assay showed a significant increase in cancer cell apoptosis in the small
intestine tumor region of Min+APN and Min+Se group when compared with Min group.
Se administration showed greater cancer cell apoptosis than APN administration. Since
Min+APN+Se group showed the least number of tumor therefore no tumor tissue section
was obtained in this group and hence the cancer cell apoptosis was not observed in this
group. However we observed normal epithelial cell apoptosis which showed no significant
difference when compared with control group. To further decipher the mechanism leading
to cancer cell apoptosis expression of cleaved capase-9 was studied in tumor tissue section
of all the treatment groups and control group. We found a significant increase in the protein
expression of cleaved caspase 9 in the tumor tissue section of Min+APN+Se group when
compared with Min, Min+APN and control group. We also found an increase in the
expression of cleaved caspase 9 in Min+Se group in comparison to Min, Min+APN and
control group. This data provide evidence that Se leading to the apoptosis of intestinal
cancer cells might be governed by the increased expression of cleaved caspase 9 while
APN mediated apoptosis of the intestinal cancer cell may be governed by an alternative
apoptotic pathway excluding cleaved caspase 9.
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Cancer cell apoptosis was followed by studying goblet cell production and Muc-2
protein expression. Goblet cells are secretory cells of the gut and mainly present in the
colon and small intestine. They secrete mucus which forms a protective layer over the
intestine and protect it from intestinal insult including toxins and gut bacterial invasion.
Reduced mucus production has been linked with increase inflammation and cancer.
Ratio of goblet to epithelial cell was determined using Alcian blue staining and we
found a significant increase in the ratio with both Se and APN administration. Min group
showed a significant decrease in the ratio when compared with control group pointing
towards the protective role of APN and Se in intestinal cancer. However, no significance
in the goblet cell production was found among the different treatments. To study the
molecular mechanism behind this effect expression of Muc-2, Math-1 and Hes-1 was
determined which revealed an increased expression of Math-1 indicating higher conversion
of colon stem cell to secretory phenotype. Muc-2 expression was also significantly higher
with Se and APN administration indicating an increased mucus secretion which forms a
protective layer over the colon and preventing from toxic exposure and gut bacterial
invasion.

This study provided conclusive evidence for the protective role of APN and Se in
intestinal cancer and identify different mechanism by which Se and APN may act to reduce
the severity of intestinal cancer.
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6.6 Figure Legends

Figure 6.1. Clinical Score and Body Weight: (A) The graph represents the differences in
the clinical score between different treatment groups and control. Significant difference
was calculated between the different treatment groups and the control group. *p<0.05
between Min and Min+APN, Min+Se and Min+APN+Se. (B) The line graph represents
the change in the body weight throughout the length of the study. (C) Line graph showing
average food consumption per mice per day. Significant difference was calculated between
different treatment groups. *p<0.05 represents the significant difference between Min vs
Min+APN, Min vs Min+Se and Min vs Min+APN+Se. Student TTEST was used to
determine significant difference between different treatment groups. (n=8).

Figure 6.2. Colon and Small Intestine Tumor Load: (A) The graphs shows difference
in colon tumor number in all the treatment groups. *p<0.05 shows significant difference in
the tumor number between Min vs Min+APN, Min vs Min+Se and Min vs Min+APN+Se.
#

p<0.05 showed significant decrease in the tumor number between Min+APN+Se vs

Min+APN and Min+APN+Se vs Min+Se. (B) The graphs shows difference in small
intestine tumor number in all the treatment groups. *p<0.05 shows significant difference
in the tumor number between Min vs Min+APN, Min vs Min+Se and Min vs
Min+APN+Se. #p<0.05 showed significant decrease in the tumor number between
Min+APN+Se vs Min+APN and Min+APN+Se vs Min+Se. Student TTEST was used to
determine significant difference between different treatment groups. (n=8).
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Figure 6.3. Histopathology: (A) This figure shows the Hematoxylin and Eosin staining
for the small intestine tissue section for the different treatment groups and control. (B) The
graph shows histopathology score out of 12 for the treatment groups and control group.
*p<0.05 Min+Se and Min+APN+Se vs Min. #p<0.05 Min+Se and Min+APN+Se vs
Min+APN. Student TTEST was used to determine significant difference between different
treatment groups. (n=5).

Figure 6.4. Secreted Cytokines: (A) Graph represent the differential expression of
secreted IL-6 in different treatment groups. *p<0.05 significant difference between
Min+Se and Min+APN+Se vs Min. (B) Graph represent the differential expression of
secreted IL-1β in different treatment groups. *p<0.05 significant difference between Min
and Min+APN+Se (C) Graph represent the differential expression of secreted TNF-α in
different treatment groups. *p<0.05 significant difference between Min+APN+Se vs Min.
#

p<0.05 significant difference between Min+APN+Se vs Min+APN (D) Graph represent

the differential expression of secreted IL-10 in different treatment groups. *p<0.05
significant difference between Min and Min+APN vs Control. #p<0.05 significant
difference between Min+APN+Se vs Min, Min+APN and Min+Se. Student TTEST was
used to determine significant difference between different treatment groups. (n=8).

Figure 6.5. Serum Adiponectin: The graph shows the levels of serum APN (mg/ml) in
different treatment groups. *p<0.05 significant difference between Min+Se vs Control.
**p<0.05 significant difference between Min vs Control and Min+Se vs Control. #p<0.05
significant difference between Min+Se and Min+APN+Se vs Min and Min+APN. Student

179

TTEST was used to determine significant difference between different treatment groups.
(n=8).

Figure 6.6. Goblet cell production: (A) This figure shows the Alcian blue staining for the
small intestine tissue section for the different treatment groups and control. (B) The graph
shows the ratio of goblet to epithelial cell for the treatment groups and control group.
*p<0.05 Min+APN Min+Se and Min+APN+Se vs Min. #p<0.05 Min vs control. Student
TTEST was used to determine significant difference between different treatment groups.
(n=5).

Figure 6.7. Change in goblet cell phenotype and Mucin Secretion: (A) Representative
Western blot images showing the protein expression of Muc-2, Hes-1 and Math-1 in the
small intestine. (B) Graph showing the expression of Muc-2 in all the treatment group and
control. *p<0.05 significant difference between Min+APN, Min+Se and Min+APN+Se vs
Min. #p<0.05 significant difference between Min vs control. (C) Graph showing the
expression of Math-1 in all the treatment group and control. *p<0.05 significant difference
between Min+APN, Min+Se and Min+APN+Se vs Min. #p<0.05 significant difference
between Min vs control. (D) Graph showing the expression of Hes-1 in all the treatment
group and control. No significant difference was found between in any treatment groups
and control. Student TTEST was used to determine significant difference between different
treatment groups. (n=5).
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Figure 6.8. Cancer Cell apoptosis: (A) This figure shows the representative 20X images
of TUNEL assay marking cancer cell apoptosis and counterstained with methyl green. The
cells of the tumor undergoing apoptosis range from light to dark brown in color. (B) Graph
representing the quantification of the degree of apoptosis determined by calculating the
ratio of the TUNEL positive cell and total number of epithelial cells in a 20X microscopic
view. 5 views per slide and 8 animals per group were used to calculate significant
difference between different groups. *p<0.05 Min+APN vs Min and Min+Se vs Min.
**p<0.05 Min+APN+Se vs Min+Se Student TTEST was used to determine significant
difference between different treatment groups. (n=5).

Figure 6.9. cleaved Caspase 9 expression: Western blot and bar graph represents the
differential expression of cleaved caspase 9 in different treatment groups. *p<0.05
Min+APN+Se vs Min +APN and #p<0.05 Min+APN+Se vs Min+APN. Student TTEST
was used to determine significant difference between different treatment groups. (n=5).

Figure 6.10. Oxidative Stress: This figure shows the protein expression of 4HNE and
Nitrotyrosine in Min, Min+APN (MA), Min+Se (MS) and Min+APN+Se (MAS) treatment
groups using western blot and the protein expression was normalized by ponceau staining.
*p<0.05 Min+Se vs Min, Min +APN and Min+APN+Se. Student TTEST was used to
determine significant difference between different treatment groups. (n=5).
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Figure 6.1. Clinical Score and Body Weight: (A) The graph represents the differences in
the clinical score between different treatment groups and control. Significant difference
was calculated between the different treatment groups and the control group. *p<0.05
between Min and Min+APN, Min+Se and Min+APN+Se. (B) The line graph represents
the change in the body weight throughout the length of the study. (C) Line graph showing
the average food consumption per mice per day for the length of the study. Significant
difference was calculated between different treatment groups. *p<0.05 represents the
significant difference between Min vs Min+APN, Min vs Min+Se and Min vs
Min+APN+Se. Student TTEST was used to determine significant difference between
different treatment groups. (n=8).
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Figure 6.2. Colon and Small Intestine Tumor Load: (A) The graphs shows difference
in colon tumor number in all the treatment groups. *p<0.05 shows significant difference in
the tumor number between Min vs Min+APN, Min vs Min+Se and Min vs Min+APN+Se.
#
p<0.05 showed significant decrease in the tumor number between Min+APN+Se vs
Min+APN and Min+APN+Se vs Min+Se. (B) The graphs shows difference in small
intestine tumor number in all the treatment groups. *p<0.05 shows significant difference
in the tumor number between Min vs Min+APN, Min vs Min+Se and Min vs
Min+APN+Se. #p<0.05 showed significant decrease in the tumor number between
Min+APN+Se vs Min+APN and Min+APN+Se vs Min+Se. Student TTEST was used to
determine significant difference between different treatment groups. (n=8).

183

Figure 6.3. Histopathology: (A) This figure shows the Hematoxylin and Eosin staining
for the small intestine tissue section for the different treatment groups and control. (B) The
graph shows histopathology score out of 12 for the treatment groups and control group.
*p<0.05 Min+Se and Min+APN+Se vs Min. #p<0.05 Min+Se and Min+APN+Se vs
Min+APN. Student TTEST was used to determine significant difference between different
treatment groups. (n=5).
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Figure 6.4. Secreted Cytokines: (A) Graph represent the differential expression of
secreted IL-6 in different treatment groups. *p<0.05 significant difference between
Min+Se and Min+APN+Se vs Min. (B) Graph represent the differential expression of
secreted IL-1β in different treatment groups. *p<0.05 significant difference between Min
and Min+APN+Se (C) Graph represent the differential expression of secreted TNF-α in
different treatment groups. *p<0.05 significant difference between Min+APN+Se vs Min.
#
p<0.05 significant difference between Min+APN+Se vs Min+APN (D) Graph represent
the differential expression of secreted IL-10 in different treatment groups. *p<0.05
significant difference between Min and Min+APN vs Control. #p<0.05 significant
difference between Min+APN+Se vs Min, Min+APN and Min+Se. Student TTEST was
used to determine significant difference between different treatment groups. (n=8).
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Figure 6.5. Serum Adiponectin: The graph shows the levels of serum APN (mg/ml) in
different treatment groups. *p<0.05 significant difference between Min+Se vs Control.
**p<0.05 significant difference between Min vs Control and Min+Se vs Control. #p<0.05
significant difference between Min+Se and Min+APN+Se vs Min and Min+APN. Student
TTEST was used to determine significant difference between different treatment groups.
(n=8).
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Figure 6.6. Goblet cell production: (A) This figure shows the Alcian blue staining for the
small intestine tissue section for the different treatment groups and control. (B) The graph
shows the ratio of goblet to epithelial cell for the treatment groups and control group.
*p<0.05 Min+APN Min+Se and Min+APN+Se vs Min. #p<0.05 Min vs control. Student
TTEST was used to determine significant difference between different treatment groups.
(n=5).
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Figure 6.7. Change in goblet cell phenotype and Mucin Secretion: (A) Representative
Western blot images showing the protein expression of Muc-2, Hes-1 and Math-1 in the
small intestine. (B) Graph showing the expression of Muc-2 in all the treatment group and
control. *p<0.05 significant difference between Min+APN, Min+Se and Min+APN+Se vs
Min. #p<0.05 significant difference between Min vs control. (C) Graph showing the
expression of Math-1 in all the treatment group and control. *p<0.05 significant difference
between Min+APN, Min+Se and Min+APN+Se vs Min. #p<0.05 significant difference
between Min vs control. (D) Graph showing the expression of Hes-1 in all the treatment
group and control. No significant difference was found between in any treatment groups
and control. Student TTEST was used to determine significant difference between different
treatment groups. (n=5).
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Figure 6.8. Cancer Cell apoptosis: (A) This figure shows the representative 20X images
of TUNEL assay marking cancer cell apoptosis and counterstained with methyl green. The
cells of the tumor undergoing apoptosis range from light to dark brown in color. (B) Graph
representing the quantification of the degree of apoptosis determined by calculating the
ratio of the TUNEL positive cell and total number of epithelial cells in a 20X microscopic
view. 5 views per slide and 8 animals per group were used to calculate significant
difference between different groups. *p<0.05 Min+APN vs Min and Min+Se vs Min.
**p<0.05 Min+APN+Se vs Min+Se Student TTEST was used to determine significant
difference between different treatment groups. (n=5).
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Figure 6.9. cleaved Caspase 9 expression: Western blot and bar graph represents the
differential expression of cleaved caspase 9 in different treatment groups. *p<0.05
Min+APN+Se vs Min +APN and #p<0.05 Min+APN+Se vs Min+APN. Student TTEST
was used to determine significant difference between different treatment groups. (n=5).
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Figure 6.10. Oxidative Stress: This figure shows the protein expression of 4HNE and
Nitrotyrosine in Min, Min+APN (MA), Min+Se (MS) and Min+APN+Se (MAS) treatment
groups using western blot and the protein expression was normalized by ponceau staining.
*p<0.05 Min+Se vs Min, Min +APN and Min+APN+Se. Student TTEST was used to
determine significant difference between different treatment groups. (n=5).
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CHAPTER 7
OVERALL DISCUSSION
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Colorectal Cancer (CRC) is globally the third most commonly diagnosed cancer
and it is the second largest cause of cancer death in United States and ranks fourth in the
estimated new cases every year (R. Siegel, et al., 2014). Cancer of the colon, rectal and
small intestine will contribute to 50,960 deaths in 2015 besides other parts of the digestive
tract (R. L. Siegel, et al., 2015). Repeated cycles of inflammation or chronic inflammation
has been considered as an underlying cause of intestinal cancer and patients suffering from
IBD is at an increased risk of developing colon and intestinal cancer (E. H. Huang, et al.,
2006). The etiology of this cancer is very wide and range from genetic pre-disposition to
toxic exposure and bad lifestyle (nutrition and exercise). There are several therapies
available for the treatment of colon and intestinal cancer but each therapy is associated with
its side effects ranging from mild to severe including relapse of the tumor and pain. To
ameliorate these side effects and to improve the prognosis and prevent reoccurrence
complimentary medicine and new therapy needed to be developed and utilized in addition
to the already know treatment. Therefore the purpose of this dissertation was to study the
effect of APN and Se rich diet on reducing the severity of colon and intestinal cancer and
decipher their mechanism of action. These two could be later used a complimentary
medicine in the treatment of colorectal and intestinal cancer. We hypothesize that APN and
Se could act either alone or complement each other in reducing tumor load and
inflammation by downregulating pro-inflammatory proteins and cytokines and
upregulating anti-inflammatory cytokines and proteins and by increasing cancer cell
apoptosis. In addition to this we hypothesize that APN and Se either alone or in conjugation
could also have an effect on goblet cell production and hence mucus secretion. Mucus can
form a protective layer of the gut providing protection against tumor insult.
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The data published in this dissertation provide conclusive evidence for the use of
APN and Se alone in the treatment of colorectal and intestinal cancer but needed further
experimentation to prove the use of the combination of both in the treatment of intestinal
and colon cancer. Se rich diet has also been shown to increase the production of serum
APN in both the models of spontaneous intestinal cancer and chemically induced colon
cancer. APN administration alone might not be effective in bringing the level of serum
APN comparable to the control group. Administration of APN in addition to Se rich diet
was found to have lower serum APN levels than Se rich diet alone in APCMin/+ model of
intestinal cancer. This could be due to the negative feedback loop activated in response to
excess of APN in the serum or due to the faster removal or breakdown of APN from the
blood (Bauche et al., 2006).

Role of Adiponectin in reducing the severity of colon and intestinal cancer.

Adiponectin is an adipocytokine secreted by the adipose tissue. Adipose tissue is
an active source of several cytokines, hormones and proteins and APN is one of the antiinflammatory compound secreted by it. With Obesity or increased adipose tissue volume,
APN secretion is reduced due to the activation of a negative feedback loop. In addition,
there is an increase necrosis of the adipose tissue leading to invasion by macrophages and
their conversion from M2 to M1 phenotype leading to the vicious cycle of inflammation
(Martinez & Gordon, 2014). During chronic inflammation, there is an increase secretion
of Th1 cytokines including IL-6, IL1 and reduced production of Th2 cytokines including
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IL-10. Besides cytokines there is a complete shift in the inflammatory mediators from
being anti-inflammatory to pro-inflammatory. Repeated cycle of chronic inflammation
leads to pre-cancerous lesion and aberrant crypts in both small and large intestine. This if
untreated can lead to the development of tumors. The 5 year relative survival rate for colon
cancer ranges from 92% at stage I to 11% at stage IV (Brenner, et al., 2014).

APN is an abundant protein with the blood concentration of a healthy individual
ranging from 5-20 µg/mL and accounts for 0.01% of the total blood protein (Fayad, et al.,
2007; J. Y. Kim & Scherer, 2004). It has a complex structure and is structurally
homologous to TNF-α and C1q (complement factor). Its monomer is made of the globular
and collagenous domain and could polymerize in to dimer, trimer and other higher
molecular weight isomer. Greater levels of polymerization leads to low, medium and
higher molecular weight APN. Most of the APN levels in the serum are inversely related
to the body’s visceral fat content. The mechanism of this relationship remains unclear
(Waki, et al., 2003). Lower levels of APN is associated with several disease including
hypertension, type-2 diabetes, dyslipidemia, coronary artery disease, stroke, sleep apnea,
non-alcoholic fatty liver disease, inflammatory bowel disease, colon cancer, breast cancer,
leukemia, prostate and gastric cancer (Kishida, et al., 2014). Our data indicated that the
absence of APN is associated with increased severity of CICC as indicated by higher
clinical score and greater tumor number when compared to WT mice given the same
treatment. Histopathology of the colon tissue section was studied which provided another
support to our data indicating high degree of inflammation, greater infiltration and tumors
associated with APNKO mice in comparison to WT mice. DSS alone group showed
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significantly higher aberrant crypts and several pre-cancerous lesions in APNKO mice.
Our study indicated a link between APN deficiency and greater secretion of proinflammatory cytokines including IL-6, TNF-α, IL-1β and reduced secretion of antiinflammatory cytokine including IL-10. IL-6 has been shown to modulate JAK/STAT3
signaling which in turn is regulated by SOCS (Y. Li, et al., 2010). Our further investigation
indicated a significantly higher expression of Cox-2 and reduced expression of pAMPK in
APNKO mice. APN has been shown to increase the phosphorylation of AMPK and
suppresses the cell growth by inhibiting mTOR (Ouchi, et al., 2004), which could provide
an explanation for higher tumor number in APNKO mice as they showed significantly
reduced activation of AMPK leading to greater tumor cell growth in contrast to WT mice.
Cox-2 was found to be significantly overexpressed in the tumor area, majority of this be
attributed to the overexpression in cancer epithelial cells in addition to the localized
secretion by inflammatory mononuclear cells, fibroblast and vascular endothelial cells. We
also found a significant reduction in serum APN in WT mice with CICC indicating the
colon cancer is linked with reduced secretion of APN. All the above outcome points
towards the deleterious effect of APN deficiency which in the presence of outside stimulus
like carcinogen could instigate the cycle of inflammation which if remain untreated for a
long time could result in tumor formation.

The above stated mechanism directly deals with inflammation and cancer protein
expression, however there might be other alternative pathways leading to protection from
CICC. Goblet cell production and mucus secretion pathways may provide more insight
about the protective role of APN. Goblet cells are the secretory cells of the colon secreting
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mucus which forms a protective layer over the colon and the intestine preventing them
from outside insult and gut bacterial invasion. We found a significant reduction in both
goblet cell number and mucus secretion in APNKO mice with CICC. Direct effect of APN
on mucus secretion was determined by studying mucin production including Muc-1 and
Muc-2; major mucins of the colon using goblet cell lines HT29-CI.16E. APN
administration was found to increase secretion of Muc-2 but not Muc-1 in HT29-CI.16E
goblet cell line. APN administration also reduced the apoptosis of HT29-CI.16E goblet
cells in the presence of Muc-2 through the downregulation of Bax and upregulation of Bcl2.
APN was also found to increase the expression of Math-1 gene through the activation of
its receptor R1 and R2 which is required for increased goblet cell production.

This experiment only provide evidence for the absence of APN and could study the
effect of APN administration on goblet cells through in vitro experimentation. To further
study the direct effect of APN on intestinal cancer APN was administered intraperitoneally
to APCMin/+ mice. Administration of APN resulted in the significant reduction in fecal
hemoccult and diarrhea followed by increased apoptosis of small intestine tumor cells
which culminated in decreased tumor count providing proof for another mechanism by
which APN could reduce the severity intestinal cancer. APN administration also resulted
in greater protein expression of Math-1 which resulted in increased goblet cell production
and higher Muc-2 secretion.

Both the absence of APN and APN administration has shown the protective role of
APN in reducing the severity of both colon and intestinal cancer. To assertion this
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observation, we used 2 different model of colon and intestinal cancer that is both inducible
and genetic. We reached the same conclusion that APN is protective for CICC and
intestinal cancer through reduction of inflammation, increased cancer cell apoptosis and
goblet cell production.

Selenium act as protective antioxidant for colon and intestinal cancer.

Selenium is an essential micronutrient and is widely accepted as an anti-oxidant
non-metal (Maseko, et al., 2014). This micronutrient forms selenocysteine, which is the
twenty-first amino acid and integrates into proteins to form 25 selenoprotein (Metanis &
Hilvert, 2014). It has been shown to play a wide physiological role including immune
function, male fertility and thyroid function. Se can be obtained in the diet through several
sources including Brazil nut, fish, liver, chicken, certain vegetables and meats (Maseko, et
al., 2014). The recommended dietary allowance for Se is 55μg per day for human adults
and the upper safe limit is 400 μg/day. Beneficial effects of Se can be obtained at a dosage
of 200 μg per day. Se has been shown to reduce the severity of cancers including prostate
(Gerstenberger et al., 2015), breast (Arsenyan, et al., 2014) and lung (Okuno, Honda,
Arakawa, Ogino, & Ueno, 2014a) and has acted as a useful supplementation for several
ailments including cystic fibrosis (Ciofu & Lykkesfeldt, 2014), male and female infertility
(Balazs & Racz, 2013), glucose metabolism in type 2 diabetes (Mao & Teng, 2013),
grave’s disease (Kryczyk & Zagrodzki, 2013) and other related inflammatory and
autoimmune diseases. A dosage of 200 μg/day of Se has been shown to decrease the total
incidence of cancer by 25% (Reid, et al., 2008). An inverse association has been established
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between higher Se status and colorectal cancer (Hughes, et al., 2014). The protective effect
of the Se in various diseases and conditions is mostly due to the anti-oxidative property
leading to an increase in the production of selenoproteins like glutathione peroxidases
(Gpx), which neutralize or prevent the formation of reactive oxygen species (ROS)
(Kosaric, et al., 2014). Although there are few studies indicating the protective role of Se
in chronic inflammation and colon cancer, most of these studies used in vitro approach and
lacked the mechanism of action of Se in reducing the severity of CICC and intestinal
cancer. To achieve this we have used two different model of intestinal cancer both
inducible and the genetic model of colon and intestinal cancer and has used Se as a
prevention for both these conditions.

Our study indicated a reduction in the clinical score, tumor number and tumor area
in both the APNKO and WT mice with CICC given Se rich diet. This indicated an
improvement in the physical manifestation of colon cancer and led to further investigation
to study major mechanism of colon cancer prevention. Se rich diet showed an increase in
the production of serum APN in CICC. To check whether dietary Se was able to increase
the total Se content of the colon, mass spectrometry was used which indicated an increase
in the colon Se content in both APNKO and WT mice administered Se rich diet. Gpx
activity was found to be significantly increased with Se rich diet and it lead to an increase
in Gpx-1 and Gpx-2 protein expression. Gpx-2 is more localized in the gut and could be a
major player in reducing oxidative stress in the colon tissue section of both APNKO and
WT mice with Se rich diet. Colon tissue section was analyzed for histopathology which
indicated a reduction in inflammation, infiltration of the immune cells and cancer
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pathology. To decipher the mechanism of action of Se in reducing inflammation, NFᴋB
mediated cytokine expression was studied. A significant decrease in the protein expression
of p-NFᴋB followed by the reduction in the secreted pro-inflammatory cytokines like IL6, TNF-α and Il-1β and increased expression of anti-inflammatory was observed with Se
rich diet in both APNKO and WT mice with CICC.

Cancer cell apoptosis and goblet cell production are two other important
mechanisms by which Se could reduce tumor count and could affect physical manifestation
of colon cancer. Se was found to increase the apoptosis of colon cancer cells and
simultaneously reduce colon epithelial cell apoptosis preventing colon damage and
reducing tumor number and size. This protection rendered by Se leading to reduced
apoptosis of colon epithelial cells could be due to the anti-oxidant nature of Se, lowering
ROS in the epithelial cells and preventing them from oxidative damage. We also found
increased degree of apoptosis in WT mice when compared to APNKO mice indicating that
APN might play an important role in the cancer cell apoptosis. cleaved caspase-9 and
phospho-p53 protein expression was significantly higher in the colon tumor tissue section
of both APNKO and WT mice given Se rich diet indicating a possible mechanism of action
of Se in increasing colon cancer cell apoptosis.

Goblet cells are the secretory cells of the colon which produce mucus and protect
colon from toxic insult. Significantly higher goblet to epithelial cell ration was found in
the colon tissue section of the both APNKO and WT mice with Se rich diet. WT mice had
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higher goblet cell number than APNKO. In addition to this, Math-1 and Muc-2 protein
expression was also found to be significantly higher with Se rich diet in both APNKO and
WT mice with CICC.

All these findings point towards the protective role of Se rich diet in CICC. We
have showed 3 different mechanism of action of Se in reducing the severity of CICC that
includes lower inflammation and inflammatory marker, increase cancer cell apoptosis and
higher goblet cell production. All these 3 pathways works together to reduce the severity
of CICC by lowering clinical score, tumor number and tumor area.

Selenium and APN may work together to reduce the severity of intestinal cancer

To further prove the effectiveness of both APN and Se rich diet in reducing the
severity of colon cancer; APCMin/+ mouse model of spontaneous intestinal cancer was used
in addition to APN and Se rich diet administration either alone or in combination. Both Se
and APN was used as prevention of colon and intestinal cancer. We hypothesize that the
combination of APN and Se rich diet will be more effective in reducing the severity of
intestinal cancer than the individual treatment. Our result confirmed our hypothesis
partially as we found a reduction in clinical score, tumor number and tumor area with
combination of Se and APN administration but the difference was not significant in
comparison to Se rich diet alone. However we found a significant difference in comparison
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to APN administration alone. We also found a significant reduction in the histopathology
score and pro-inflammatory cytokines production in small intestine tissue section obtained
from mice belonging to Min+APN+Se groups when compared with Min groups but we
failed to find a significance difference between Min+APN, Min+Se and Min+APN+Se.
They tend to produce similar effect Min+Se almost mimicking Min+APN+Se group.

Intestinal cancer cell apoptosis was also significantly increased with APN and Se
administration alone but we fail to obtain the tumor tissue section in the Min+APN+Se
group and hence only epithelial cell apoptosis was observed which was found to be similar
to control group. However, cleaved caspse-9 protein expression was determined in the
intestinal cancer tissue sections and we found a significant increase in the expression with
the combination of Se and APN. This provide an indirect measure that the combination is
effective in increasing of intestinal cancer cell apoptosis. Goblet cell production was also
found to be significantly higher in with APN, Se or APN+Se administration. However,
again we failed obtain any added advantage of the combination treatment for Math-1 and
Muc-2 protein expression and goblet cell production. Contrarily the combination showed
a decreased in the serum APN levels when compared with Se rich diet alone. This could
be explained by the negative feedback loop for APN which might have been active and
could have reduced serum APN levels.

Our study didn’t indicate any significant advantage of Se and APN combination
treatment but proved that Se rich diet was the most effective in reducing the severity of
intestinal cancer.
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Summary

In summary, by the means of this dissertation, we have demonstrated the protective
role of APN, Se and their combination in the treatment of CICC and intestinal cancer. Se
or APN or both were effective in reducing clinical score, tumor number and tumor area in
both CICC and intestinal cancer. They might act by reducing inflammation and infiltration
of the immune cells which will prevent the transition from pre-cancerous lesions to tumor
formation and might even prevent the formation of aberrant crypts. Another mechanism of
their action is by the increasing cancer cell apoptosis which resulted in reduced tumor
number and tumor size. They might also improve the production of goblet cells by
activation of Math-1 and increase mucus secretion by increased production of gut specific
mucin Muc-2. Se in addition to all these protective effect is a well-known anti-oxidant and
was effective in reducing oxidative stress by the upregulation of selenoprotein antioxidants
like Gpx-1 and Gpx-2 and hence might be protective to the colon epithelial cells. We also
found a relationship between APN and Se and showed that Se rich diet was effective in
increasing serum APN.

Future Direction

This study provided some novel insight about the role of Se and APN and their
combination in reducing the severity of colon and intestinal cancer and established a
relationship between the two. However, there might still be some gaps in understanding
the complete action of Se and APN in cancer cell apoptosis and goblet cell production. It
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would be interesting to study other mechanism of action of Se and APN in increasing
cancer cell apoptosis especially by modulation of protein expression of Bax and Bcl 2.
Selenoprotein expression was only studied in the normal colon tissue, it will interesting to
study the expression of Gpx-1 and Gpx-2 in colon tumor tissue. Besides Gpx, no other
selenoproteins were studied and there are total 25 selenoproteins known which might put
light on the dual nature of Se where Se is protective for normal colon epithelial cells and
pro-apoptotic to colon tumor cells. Also the protective effect of Se and APN on reducing
colon epithelial cell apoptosis remained unclear and need more mechanistic investigation
in addition to proliferation assay. Although the combination of Se and APN was most
effective in reducing tumor but none of the mechanism shown in the dissertation provided
a complete justification of the outcome, pointing towards the need to study other
mechanism of action. The inflammatory cytokine study were restricted to secreted
cytokines but studying serum cytokine may provide a better outcome and might reveal
novel pathways. APCMin/+ mice model of intestinal cancer is a result of a mutation in the
APC gene leading to uncontrolled expression of β Catenin. Higher expression of β Catenin
is associated with greater inflammation and higher tumor load. Therefore one of the future
direction will be to study the effect of APN and Se rich diet administration on the
expression of β Catenin which could provide evidence for the reduction in the tumor load
and clinical score. Most of the molecular study for the last aim was done with small
intestine and might be a reason for non-significance in APN+Se treatment. Colon tissue
study might result in a better outcome for this aim.
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Both of the studies implicating the role of Se in the treatment of colon and intestinal
cancer studied Se as the prevention by administering Se before the development of the
tumor. One of the future direction for this dissertation could be to study the effect of Se as
a treatment by administering Se after 12 weeks of age in APCMin/+ mice model of intestinal
cancer. Tumor have already been formed by 12 weeks of age and Se could be used as a
treatment for intestinal cancer. Also, Se could also be administered in the DSS+DMH
inducible model of colon cancer after the second DSS administration as tumor might have
been developed by that time and Se could be used as a treatment. Using a treatment
approach might provide a better insight about the mechanism of action on Se in the
treatment of colon and intestinal cancer.

Any treatment given for colon or intestinal cancer have an effect on gut bacteria
which might provide another avenue for future research. Exercise has been shown to be
effective in reducing the incidence of several cardiovascular diseases and cancer. Medium
intensity exercise might provide complimentary benefits in reducing the severity of
symptoms associated with colorectal cancer and could be studied in conjugation with Se
rich diet. Since we have already shown that Se is effective in reducing the severity of CICC
and intestinal cancer, it will be intuitive to study the effect of individual selenoproteins on
colorectal cancer. Using non-conventional therapies and complementary medicine might
provide a reduction in the symptoms and reoccurrence associated with colorectal cancer
and might lead to the development of novel pharmacological interventions for colon cancer
treatment.
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DETAILED PROTOCOL
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DAKO/ProHisto IHC Protocol

1. Put slides in a glass slide holder and place in the following solutions serially
(rocking at room temperature):
a.
xylene: 5 min., swishing every 2 min. (UNDER THE
HOOD)
b.
xylene: 5min., swishing every 2 min. (UNDER THE
HOOD)
c.
100% EtOH: 2 min., swishing every 30 sec.
d.
95% EtOH: 2 min.,rocking.
e.
80% EtOH: 2 min., rocking.
f.
f.70% EtOH: 2min., rocking.
g.
50% EtOH: 2 min., rocking.
h.
dd H2O: 2x3min., rocking.
i.
2. Put slides with fixed cells in a glass slide holder and place in the following solutions
serially (rocking at room temperature):
 1xTBST (pH 7.6) 5 min
 2x3min. in 1xTBST
3. Transfer slide holder into plastic container and put in 1xCitrate Antigen Retrieval
Buffer (stored at 4°C). To prepare 1xCAR Buffer: add 30ml of 10xCAR Buffer
(ProHisto) to 270ml of dH2O.
Take off metal handle.
4. Autoclave for min 20 min (max 30 min). In 5th floor small autoclave, choose
“liquid-slow exhaust” and set time for 25 min. Sign name in log book. Sample done
in 1 hour total. If using ProHisto box, add 15 ml Antigen Retrieval Buffer per well.
Autoclave 8 min on slow exhaust. Done in 25 - 30 min.
5. Retrieve sample from autoclave using gloves and tray. Let sit 20 min at RT in
Citrate Buffer.
6. Wash in 1xTBST for 5 min.
7. Wipe off back and sides of slide with Kimwipe tissues; lay flat on benchtop and
cover tissue with 1-3 drops of Peroxidase Block (DAKO), stored at 4°C in the
fridge. Incubate 30 min at RT, checking every 5-10 min. to make sure samples don’t
dry out. Add more Peroxidase Block if slides starting to dry.
8. Put slides back into slide carrier and wash 3x3min in 1xTBST.
9. Dilute primary antibody in ProHisto Antibody Dilution Buffer, stored at 4°C in the
fridge. Minimum of 3 ml needed per slide for ProHisto box.
10. Incubate 12 to 72h, rocking at 4° C.
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11. Put slides back into glass slide carrier and wash 2x10 min. in 1xTBST.
12. Wipe off back and sides of slides with a Kimwipe, place flat on benchtop, and add
1-3 drops of Labeled Polymer Yellow (DAKO) straight from the bottle, just enough
to cover tissue. Make sure to use proper DAKO kit, e.g. DAKO #K400611 for
monoclonal primary antibodies (host species is mouse), or DAKO # K400911 for
polyclonal primary antibodies (host species is rabbit). Incubate 30 min at RT,
adding more polymer if slides start to dry out.
13. As soon as slides are incubating, mix up a DAB solution. The ratio of the solution
is 1ml solution 3a (Buffered Substrate): 1 drop 3b (liquid DAB and chromagen).
Mix well. Make enough so there is 200 ul per slide. Let the mixed solution sit RT
30-60 min. before using.
14. Put slides in glass slide carrier and wash 2X 5 min. in 1X TBST.
15. Wash slides in dH2O 1X 3 min.
16. Wipe slides with Kimwipe, keeping tissue moist, and add DAB solution. Check the
staining of one slide first by testing a positive: Incubate with 100-200 ul of DAB
solution, starting at 30 seconds. Check using the microscope at 40X. Keep note of
DAB times. Wash slides as soon as staining is optimal with dH2O.
17. Wash slides in dH2O 1 X 3 min.
18. Counterstain using 0.5% Methyl Green. Add 200 ml of methyl green onto tissue
and incubate at RT for 2 min. Rinse in containers of dd H2O until slides are clean
and let dry, with slides standing vertically on their ends.
19. Add one drop of permount, put on coverslip, and smooth out bubbles using big end
of pipettor tip. Label slides with: date, antibody, dilution, and timing. After 4-5
hours, clean off extra permount with xylene. (xylene is optional-only if covering
tissue).

ImmunoHistoChemistry Protocol
(for paraffin-embedded tissues)

1. Set the water bath at 95-100oC.
2. For formalin-fixed, paraffin-embedded tissues, deparaffinize sections by 3x5
min xylene washes.
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3. Prepare 90 ml of 1X solution of the Epitope Unmasking Solution from its 10X
stock [ProHisto]. This is also called the Citrate Antigen Retrieval Buffer or just
Citrate Buffer. It is stored at 4oC. Pour the solution in a heat-resistant coplin jar,
and put the jar into the water bath. Put a thermometer into the coplin jar and wait
for the temperature to rise to 95-100oC.
4. Wash 2x5 min in 100% ETOH.
5. Wash 1x3 min in 95% ETOH and 1x3 min in 70% ETOH.
6. Wash 2x3 min in dH2O.
7. Wash 1x5 min (1X) Amplifying IHC wash buffer [ProHisto] – kept at R.T., (1X
TBST or 1X PBST can also be used). Wash again 2x3 min with the wash buffer.
8. Once the temperature of the epitope unmasking solution/citrate buffer reaches
~95oC, place the slides into it. Place the lid onto the coplin jar loosely. Incubate the
slides in the citrate buffer for 30 minutes.
9. Turn off the water bath and remove the coplin jar from it and close it tightly. Keep
the jar containing the slides at R.T. for 20-30 minutes, allowing the temperature to
slowly come down to R.T.
10. Wash 1x5 min with 1X wash buffer.
11. Wipe off extra liquid from the slides and cover the tissue with Peroxidase Block
(Dako) – kept at 4oC, and incubate the slides for 30 minutes at R.T., checking every
5-10 minutes so that the slides don’t dry out. Add more peroxidase block if slides
start to dry out.
12. Wash 3x3 min with 1X wash buffer.
13. Dilute the primary antibody in (ProHisto) Amplifying Antibody Dilution Buffer
stored at 4oC. [3.5 ml solution is enough to cover a single slide kept in a slide
compartment box.
14. Incubate for 12-72 hours at 4oC, rocking.
15. Wash 2x10 min in 1X wash buffer.
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16. Wipe off excess liquid from the slides and cover the tissues with Labelled PolymerHRP-anti-Rabbit (Dako), kept at 4oC, and incubate the slides for 30 min at R.T.,
adding more polymer if slides start to dry out – [secondary antibody]. As soon as
the slide incubation starts prepare DAB solution = 1 ml DAB+ Substrate Buffer
(Dako) + 1 drop of DAB chromogen (BrdU In-situ Staining Kit), and leave it at
R.T. till the slide incubation gets over.
17. Wash 2x5 min with wash buffer.
18. Wash 1x3 min in dH2O.
19. Wipe off the excess liquid from the slides keeping the tissue moist. Cover the
tissues with the prepared DAB solution, and incubate 30 sec to a maximum of 8
minutes (till the desired colour intensity is developed), checking it under the
microscope.
20. Wash 1x3 min in dH2O.
21. Counterstain with 0.5% Methyl Green, for 30 seconds.
22. Follow the following steps OR keep the counterstained slides, and then rinse
thoroughly in water until the stain no longer fades. Keep the slides for drying O/N,
OR follow the following steps for dehydration :23. Wash 1x2 min with 95% EtOH.
Wash 2x3 min with 100% EtOH.
Wash 2x5 min with xylene.
20-30 minutes air dry.
24. Mount the slides with permount, and view under the microscope.
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RIPA Homogenization Buffer
(for homogenization of colon samples for Western Blot)

To RIPA buffer (commercially available from SIGMA: R0278-50ML; 091M6007), add
the following:
Sodium pyrophosphate – 2.5 mM; [Stock prepared – 100mM]
Sodium Flouride – 5 mM; [Stock – 500 mM]
β-glycerophosphate – 1 mM; [Stock – 100 mM]
Sodium orthovandate – 1mM; [Stock – 1M]
Protease inhibitor – 1:100
Use 200 μl of the above freshly prepared buffer for homogenization of the tissue (colon)
samples weighed beforehand (usually 20-30 mg sample is used).
Once the tissue is homogenized completely, add 200 μl more of the buffer (total 400 μl) to
the homogenized tissue sample.
Centrifuge the above contents at 12000 rpm at 4OC for 15 minutes.
Perform Bradford protein estimation assay on the samples using 10X dilution.
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Protein estimation Protocol

1). Label eppendorfs A through J and keep them on ice. Keep the protein samples also on
ice.
2). Label the wells of the template to be used in the microplate reader.
3). Prepare BSA standard concentrations as follows:Eppendor

Protein amount

f

(µg)

A

0

B

1

C

2

D

3

E

4

F

5

G

6

H

7

4). Loading of samples: add 10 µl of each protein sample (as per duplicates or triplicates)
and the standards (should be loaded after the test samples) to each of the wells.
5). Prepare the Bradford dye solution by adding 4 ml of dye (Biorad) to 16 ml of ddH2O.
Add 200 µl of the prepared dye to each of the wells.
6). Incubate in dark at R.T. for 12 minutes, and read the plate using the plate reader:* new experiment – template – file – instrument set up – read mode “endpoint” – read
speed “step” – measurement filter “595 nm” – mix time “3 sec” – mix speed “low” –
instrument control “close door” – read.
7). Collect data and standard curve for analysis.

ApopTagTM TUNEL Assay (Kit)
[DO NOT touch dry tissue with film]
1. Purchase Apop-Tag kit from Millipore (Product #S7100).
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2. For formalin-fixed, paraffin-embedded tissues, deparaffinize sections by 3x5
min xylene washes.
3. Wash 2x5 min in 100% ETOH.
4. Wash 1x3 min in 95% ETOH and 1x3 min in 70% ETOH.
5. Wash 1x5 min in PBS.
6. Dilute proteinase K (Millipore product # 21627 Stock = 200µg/ mL) to 20 ug/ml
in PBS, 40 µl is enough to cover a medium-sized tissue. Incubate with slides for
15 min at RT (cover the tissue only)
7. Wash slides 2x2 min in dH2O.
8. Peroxidase quench / blocking in 3% H2O2 in PBS for 5 min at RT (cover the
tissue only).
9. Rinse slides 2x5 min in PBS or dH2O.
10. Blot off extra liquid.
11. Add equilibration buffer for at least 10 seconds at RT (cover the tissue only)
12. Blot off extra liquid.
13. Add TdT enzyme as a working solution: 77uL of reaction buffer + 33uL of TdT
enzyme - are sufficient for 2 sections), (use ~15 µl for each tissue).
14. Incubate at 37oC for 1 hour in a humidified chamber (2 to 2.5 hrs).
15. Add working strength stop solution (1mL stop solution and 34 ml dH2O). Agitate
for 15 sec and incubate for 10 min at RT.
16. Remove an aliquot of anti-digoxigenin conjugate. Warm to RT.
17. Wash slides 3x1 min in PBS.
18. Blot off excess liquid.
19. Add anti-digoxigenin conjugate to each slide.
20. Incubate in humidified chamber for 30 min at RT.
21. Wash slides 4x2 min in PBS.
22. Prepare working strength DAB peroxidase substrate: 1ml DAB buffer + 1-2 drops
of DAB chromogen.
23. Incubate slides with DAB for 3-6 min (8 min) – keep viewing under the
microscope until the desired colour intensity is development.
24. Wash the slides 3x1 min in dH2O.
25. Wash slides for 1x5 min in dH2O.
26. Counterstain with hematoxylin (filter before with whatman filter paper) – 1-2
min.
27. Counterstain with methyl green (if not using hematoxylin) – 30 sec.
28. Wash the slides with dH2O until the counterstain no longer fades.
29. Dehydrate with 1 x 2 min wash with 95% EtOH.
30. 100% EtOH 2 x 3 min.
31. Xylene 2 x 5 min
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32. Air-dry for ~30 minutes (if xylene was used, or O/N if dehydration steps were
avoided).
33. Mount with xylene based permount solution.
34. Air-dry for 20 minutes, and view under the microscope.

Western Blot protocol

1. Protein homogenization: Ref. RIPA buffer protocol.
2. Protein normalization: calculated as the amount of protein that will be loaded on
the gel (prepare a proper loading pattern for the gel that is needed to be run); ref.
any normalization file on computer.
3. Gel preparation:
Resolving gel – 10% polyacrylamide
for 2 gels
dH2O –
gel buffer –
40% acrylamide –
10% SDS –
10% APS –
TEMED -

4.9 ml
2.5 ml
2.475 ml
200 μl
50 μl as 10% soln
or a pinch in powder form
5 μl

Stacking gel – 5% polyacrylamide
for 2 gels
dH2O –
3.062 ml
gel buffer –
1.25 ml
40% acrylamide –
0.638 ml
10% SDS –
50 μl
10% APS –
25 μl as 10% soln
or a pinch in powder form
TEMED 5 μl
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for 1 gel
2.45 ml
1.25 ml
1.238 ml
100 μl
50 μl as 10% soln
4 μl

4. Load the Resolving gel on the gel preparation apparatus and add 70% ethanol on
top of it immediately using a syringe. Let the gel solidify for 30 minutes.
5. After removing the 70% ethanol from the apparatus (by inverting the apparatus),
blot the inside of the gel using a tissue paper.
Now load the stacking gel on top and put on the gel comb. Let the gel fluid leak
out during the comb insertion and do not try to wipe it out immediately. Let the
gel solidify for another 30 minutes.
Prepare the running buffer during this time.
6. Prepare 1X running buffer:
Tris – 3 g
Glycine – 14.4 g
SDS – 1 g
in dH2O, and make up the volume to 1 liter

7. Pour running buffer into the gel running tub and place the gel cassette with the gel
held into it, inside the tub (use a dummy plate for the gel cassette in case only 1
gel is to be run). Remove the gel comb once the gel is completely submerged in
the gel running buffer.

8. Prepare Laemmli/loading buffer:
To make 20 ml of 4X stock:
0.5 M Tris-HCl (pH 6.8) – 8 ml
SDS – 1.6 g
100% glycerol – 8 ml
14.7 M β-mercaptoethanol – 8 ml
0.5 M EDTA – 2 ml
Bromophenol Blue – 16 mg
dH2O – 1.2 ml
9. Denaturation of protein samples and loading: Add the normalized volumes of
the protein samples to 4X Laemmli buffer in the ratio 2:1::protein:buffer and
vortex. Keep the eppendorfs in water bath/heating block for boiling for 12
minutes. During this time prerun the gel at 100 V for 10 – 15 minutes.
Spin the eppendorfs for 2-3 seconds, vortex the contents and again give them a
short spin.
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10. Load the samples on the gel using the prepared loading pattern, and run the gel at
80 V for first 10 minutes and then at 110 – 120 V for the rest of the time.
*Prepare transfer buffer at this time.
Stop the gel immediately once the dye starts coming out of the gel in case the
protein is low molecular weight and let it run more for around 5 minutes after the
dye comes out in case the protein of interest is of a high molecular weight.

11. * Preparation of 1X transfer buffer:
Tris – 3 g
Glycine – 14.4 g
Methanol – 200 ml
in dH2O, and make up the volume to 1 liter
 Prepare 1.5 liters of transfer buffer for the transfer step.
12. Tranfer: Pour the transfer buffer in a glass tray and soak the fiber, filter paper
and the nitrocellulose membrane that will be used in the process [use forceps to
handle the nitrocellulose membrane].
Remove the gel from gel plate by hydrating them enough by pouring transfer
buffer towards the side of the gel containing wells. Gently remove one of the
plates and cut out parts of the gel containing stacking gel and the bottom end that
usually contains ripples which may interfere with the transfer process.
13. Arrange the contents as below:
Black side of transfer cassette
Fiber
Filter paper
Gel
Nitrocellulose membrane
Filter paper
Fiber
Transparent side of transfer cassette
Close the cassette and put it into the transfer apparatus (black side of transfer
cassette facing black side of apparatus).
14. Fill the whole of the transfer apparatus tub with transfer buffer and put at 4oC, 220
mA for 3 hours, on a stirrer plate. Put a magnetic stirrer inside the transfer
apparatus tub and set rotation to 200 rpm.
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15. Discard transfer buffer, gel and filter paper; and wash the nitrocellulose
membrane with 1X PBS for 10 minutes.
16. Cut out extra membrane based on the size of the protein.
17. Block the membrane using 1X PBS with 0.1% tween 20 and 5% milk for 1 hour.
18. Add primary antibody to the membrane prepared in a suitable ratio in 1X PBS
with 0.1% tween 20 and 5% milk, and incubate for the desired time (16
hours/overnight/24 hours/48 hours/72 hours) at 4oC, shaking.
19. Wash membrane 5x10 minutes with 1X PBS containing 0.1% tween 20.
20. Add secondary antibody to the membrane prepared at a ratio of 1:2000 – 1:3000
in 1X PBS containing 0.1% tween 20 and 5% milk and incubate for 1 hour at R.T.
21. Repeat the wash as in step 19, using 6 washes. At the start of 4th wash, switch on
the chemiluminescent film developer machine. At the start of 5th wash, put the
ECL bottles at R.T. from 4oC.
22. Add equal quantities of both the solutions – Detection Reagent 1 (Peroxide
solution) and Detection Reagent 2 (Luminol Enhancer solution) from either the
ThermoECL or AdvanstaECL kit – to the membrane [1 ml of both solutions (total
2ml) is needed for a single membrane]. Incubate in dark for 10 minutes.
Meanwhile, prepare the cellotape, cling wrap and gel developer cassette for
developing the membrane.
23. Remove the nitrocellulose membrane from the ECL solution and wrap safely
using a transparent wrapping film. Fix the film in the cassette using tape and
immediately close the cassette.
24. Switch off all lights in the dark room keeping only the red light. Cut the
chemiluminescence film into half or use it full size according to the number of
membranes being exposed, and keep it on top of the membrane to be developed.
Close the cassette and keep in a dark place (closed drawer) for an appropriate time
of exposure; you can switch on the lights at this time.
Note: some proteins need less time while others may need more time to be
obtained on the chemiluminesence film, based on their levels of expression in any
sample.
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25. Switch off the lights and remove the exposed film from the membrane in the
cassette and put it in the developer machine. DO NOT turn on the lights again
until a “ready” light appears on the machine and it beeps. Obtain the developed
film from the developer machine and analyse.
Keep another film for exposure on to the gel-blotted membrane for lesser or more
time than the previous attempt to get the right amount of exposure level on it; ie,
repeat steps 24 and 25 if and when necessary.

Alcian Blue Staining Protocol
Solutions and Reagents:
3% Acetic Acid Solution:
Glacial acetic acid ----------------- 3 ml
Distilled water --------------------- 97 ml
Alcian Blue Solution (pH 2.5):
Alcian blue, 8GX -------------------- 1 g
Acetic acid, 3% solution ----------- 100 ml
Mix well and adjust pH to 2.5 using acetic acid.
0.1% Nuclear Fast Red Solution:
Nuclear fast red ------------------- 0.1 g
Aluminum sulfate------------------ 5 g
Distilled water ---------------------100 ml
Dissolve aluminum sulfate in water. Add nuclear fast red and slowly heat to boil and
cool. Filter and add a grain of thymol as a preservative.
Procedure:
1.
2.
3.
4.
5.
6.
7.
8.
9.

Deparaffinize slides and hydrate to distilled water.
Stain in alcian blue solution for 30 minutes.
Wash in running tap water for 2 minutes.
Rinse in distilled water.
Counterstain in nuclear fast red solution for 5 minutes.
Wash in running tap water for 1 minute.
Dehydrate and through 95% alcohol, 2 changes of absolute alcohol, 3 minutes
each.
Clear in xylene or xylene substitute.
Mount with resinous mounting medium.
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Hematoxylin and Eosin Staining Protocol
1. Deparaffinize in Xylene I and II and III (3 minutes)
2. Rehydrate
a. EtOH 100% (3 minutes)
b. EtOH 100% (3 minutes)
c. EtOH 95% (3 minutes)
d. EtOH 95% (3 minutes)
e. EtOH 70% (3 minutes)
3. Rinse in distilled water (5 minutes)
4. Stain in hematoxylin (6 minutes) Filter before each use to remove oxidized particles
5. Rinse in running tap water (15 minutes)
6. Decolorize in acid alcohol (1 second)
7. Rinse well in tap water (5 minutes)
8. Immerse in ammonia water (3 Seconds)
9. Rinse in tap water (5 minutes)
10. Counterstain in Eosin (15 seconds)
11. Dehydrate
a. EtOH 95 % (3 minutes) Discard after each use
b. EtOH 95% (3 minutes)
c. EtOH 100 % (3 minutes)
d. EtOH 100 % (3 minutes)
12. Clear in Xylene I and II (5 minutes)
13. Mount with Cytoseal in fume hood.

Adiponectin ELISA protocol
1. Prepare reagents, standard dilutions, control, and samples as directed in the kit. Make
1:200 dilution of the serum samples.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch
containing the desiccant pack, and reseal.
3. Add 50 μL of Assay Diluent RD1W to each well.
4. Add 50 μL of Standard, control, or sample* per well. Tap plate gently for one minute.
Cover with the adhesive strip provided. Incubate for 3 hours at room temperature.
5. Aspirate each well and wash, repeating the process four times for a total of five washes.
Wash by filling each well with Wash Buffer (400 μL) using a squirt bottle, manifold
dispenser, or autowasher. Complete removal of liquid at each step is essential to good
performance. After the last wash, remove any remaining Wash Buffer by aspirating or
decanting. Invert the plate and blot it against clean paper towels.
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6. Add 100 μL of Mouse Adiponectin Conjugate to each well. Cover with a new adhesive
strip. Incubate for 1 hour at room temperature.
7. Repeat the aspiration/wash as in step 5. 8. Add 100 μL of Substrate Solution to each
well. Incubate for 30 minutes at room temperature. Protect from light. 9. Add 100 μL of
Stop Solution to each well. Gently tap the plate to ensure thorough mixing. 10. Determine
the optical density of each well within 30 minutes, using a microplate reader set to 450 nm.
If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is
not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This
subtraction will correct for optical imperfections in the plate. Readings made directly at
450 nm without correction may be higher and less accurate.

IL-6 ELISA protocol
1. Bring all reagents and samples to room temperature (18 - 25°C) prior to use. It is
recommended that all standards and samples be run in duplicate. A standard curve is
required in each assay run.
2. Remove required quantity of test strips/wells, place in well holder. Note: Wells are
provided in breakable 8-well strips. Strips may be “broken” into individual wells, replaced
in well holder, and assayed. Return any unused wells to sealed pouch for 2 - 8°C storage.
3. Pipette 50 μL of ELISA Diluent into each well.
4. Pipette 50 μL of each standard (see Reagent Preparation, step 2) and sample into
appropriate wells. Gently shake/tap the plate for 5 seconds to mix. Cover wells with Plate
Sealer and incubate for 2 hours at room temperature.
5. Prepare Working Detector. Within 15 minutes prior to use, pipette required volume of
Detection Antibody into a clean tube or flask. Add in required quantity of Enzyme
Concentrate (250×), vortex or mix well. For a full 96-well plate, add 48 μL of Enzyme
Concentrate into 12 mL of Detection Antibody.
6. Decant or aspirate contents of wells. Wash wells by filling with at least 300 μL/well
prepared Wash Buffer (see Reagent Preparation, step 4), followed by decanting/aspirating.
Repeat wash 4 times for a total of 5 washes. After the last wash, blot plate on absorbent
paper to remove any residual buffer. Complete removal of liquid is required for proper
performance.
7. Add 100 μL of prepared Working Detector (see step 5 above) to each well. Cover wells
with Plate Sealer and incubate for 1 hour at room temperature.
8. Wash wells as in Step 6, but a total of 7 times. Note: In this final wash step, soak wells
in wash buffer for 30 seconds to 1 minute for each wash. Thorough washing at this step is
very important.
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9. Add 100 μL of TMB One-Step Substrate Reagent to each well. Incubate plate (without
Plate Sealer) for 30 minutes at room temperature in the dark.
10. Add 50 μL of Stop Solution to each well. 11. Read absorbance at 450 nm within 30
minutes of stopping reaction. If wavelength correction is available, subtract the optical
density readings at 570 nm from readings at 450 nm.
IL-10 ELISA protocol

1. Coat microwells with 100 µL per well of Capture Antibody diluted in Coating Buffer
(1;250 dilution) . Seal plate and incubate overnight at 4° C.
2. Aspirate wells and wash 3 times with ≥ 300 µL/well Wash Buffer. After last wash, invert
plate and blot on absorbent paper to remove any residual buffer.
3. Block plates with ≥ 200 µL/well Assay Diluent. Incubate at RT for 1 hour.
4. Aspirate/wash as in step 2.
5. Prepare standard and sample dilutions in Assay Diluent. Standard: 2000 pg/mL will be
the highest standard and prepare other standard by serial dilution.
6. Pipette 100 µL of each standard, sample, and control into appropriate wells. Seal plate
and incubate for 2 hours at RT.
7. Aspirate/ wash as in step 2, but with 5 total washes.
8. Add 100 µL of Working Detector (Detection Antibody + SAv-HRP reagent 1:250
dilution for detection and HRP dilution is on the bottle) to each well. Seal plate and
incubate for 1 hour at RT.
9. Aspirate/ wash as in step 2, but with 7 total washes.
10. Add 100 µL of Substrate Solution to each well. Incubate plate (without plate sealer) for
30 minutes at room temperature in the dark.
11. Add 50 µL of Stop Solution or 1N HCL to each well.
12. Read absorbance at 450 nm within 30 minutes of stopping reaction. If wavelength
correction is available, subtract absorbance at 570 nm from absorbance 450 nm.
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IL-1β ELISA protocol

1. Coat microwells with 100 µL per well of Capture Antibody diluted in Coating Buffer
(1;250 dilution). Seal plate and incubate overnight at 4° C.
2. Aspirate wells and wash 3 times with ≥ 300 µL/well Wash Buffer. After last wash, invert
plate and blot on absorbent paper to remove any residual buffer.
3. Block plates with ≥ 200 µL/well Assay Diluent. Incubate at RT for 1 hour.
4. Aspirate/wash as in step 2.
5. Prepare standard and sample dilutions in Assay Diluent. Standard: 1000 pg/mL will be
the highest standard and prepare other standard by serial dilution.
6. Pipette 100 µL of each standard, sample, and control into appropriate wells. Seal plate
and incubate for 2 hours at RT.
7. Aspirate/ wash as in step 2, but with 5 total washes.
8. Add 100 µL of Detection Antibody diluted in Assay Diluent to each well. Dilution 1:250.
Seal plate and incubate for 1 hour at RT.
9. Aspirate/ wash as in step 2, but with 5 total washes.
10. Add 100 µL of Enzyme Reagent diluted in Assay Diluent (dilution on the bottle) to
each well. Seal plate and incubate for 30 min at RT.
11. Aspirate/ wash as in step 2, but with 7 total washes.
12. Add 100 µL of Substrate Solution to each well. Incubate plate (without plate sealer) for
30 minutes at room temperature in the dark.
13. Add 50 µL of Stop Solution to each well.
14. Read absorbance at 450 nm within 30 minutes of stopping reaction. If wavelength
correction is available, subtract absorbance at 570 nm from absorbance 450 nm.

TNF-α ELISA protocol

1. Bring all reagents and samples to room temperature (18 - 25°C) prior to use. It is
recommended that all standards and samples be run in duplicate.
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2. Remove the required quantity of test strips/wells and place in well holder.
Note: Wells are provided in breakable 8-well strips. Strips may be “broken” into individual
wells, replaced in a well holder, and assayed. Return any unused wells to sealed pouch for
2 - 8°C storage.
3. Pipette 50 μL of ELISA Diluent into each well.
4. Pipette 50 μL of each standard (see Reagent Preparation, step 2) and sample into
appropriate wells. Cover wells with Plate Sealer and incubate for 2 hours at room
temperature.
5. Decant or aspirate contents of wells. Wash wells by filling with at least300 μL/well
prepared Wash Buffer (see Reagent Preparation, step 3)followed by decanting/aspirating.
Repeat the wash 4 times for a totalof 5 washes. After the last wash, blot the plate on
absorbent paper toremove any residual buffer. Complete removal of liquid is required
forproper performance.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
10 www.bdbiosciences.com
6. Add 100 μL of Detection Antibody to each well. Cover wells with Plate Sealer and
incubate for 1 hour at room temperature.
7. a. Prepare Enzyme Working Reagent.
b. Pipette the required volume of Enzyme Diluent into a clean tube or flask. Add in the
required quantity of Enzyme Concentrate (250×) and vortex or mix well. For a full 96-well
plate, add 48 μL of Enzyme Concentrate into 12 mL of Enzyme Diluent.
8. Wash wells as in Step 5.
9. Add 100 μL of Enzyme Working Reagent (see step 7 above) to each well. Cover wells
with Plate Sealer and incubate for 30 minutes at room temperature.
10. Wash wells as in Step 5, but a total of 7 times.
Note: In this final wash step, soak wells in wash buffer for 30 seconds to 1 minute for each
wash. Thorough washing at this step is very important.
11. Add 100 μL of TMB One-Step Substrate Reagent to each well. Incubate plate (without
Plate Sealer) for 30 minutes at room temperature in the dark.
12. Add 50 μL of Stop Solution to each well.
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13. Read absorbance at 450 nm within 30 minutes of stopping the reaction. If wavelength
correction is available, subtract the optical density readings at 570 nm from readings at 450
nm. A standard curve is required in each assay run.
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APPENDIX B
DOCTORAL DISSERTATION PROTOCOL

Adiponectin and Selenium rich diet can act as a complimentary medicine in
the treatment of intestinal and chronic inflammation induced colon cancer.

By

Arpit Saxena

March 20, 2015
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Summary
Background and Significance: Colon cancer is the second largest cause of cancer death
in United States. Chronic inflammation and obesity predispose patients to colon cancer.
Adipose tissue is a source of bioactive substances called adipokines. Adiponectin (APN),
an adipokine has anti-inflammatory property and found at lower levels in obese patients.
Our preliminary data has shown that APN knockout (KO) mice had severe clinical
manifestation associated with chemically induced colon cancer. Selenium (Se), a trace
mineral and a dietary supplement, is inversely associated with cancer risk and possess antiinflammatory and anti-carcinogenic properties. Furthermore, Se deficiency is associated
with immune dysfunction, impaired resistance to microbial and viral infections, inadequate
phagocytosis and antibody production. Colon insults by toxins and gut permeability also
induce chronic inflammation caused by gut flora that activates the body’s immune system,
leading to the vicious cycle of chronic inflammation, which culminates into colorectal
cancer. The overall purpose of this dissertation is to determine if chronic inflammation
leading to colon and intestinal cancer are regulated by APN or Se rich diet or both. The
working hypothesis is that APN deficiency will decrease goblet cell mucous production in
colon leading to greater chronic inflammation and exacerbate the clinical symptoms and
tumor load related to colon cancer. Se rich diet alone or in combination with APN
administration will increase goblet cell production and apoptosis of cancer cells leading to
reduced clinical symptoms, tumor load and inflammation. To test this hypothesis following
specific aims will be used:
Specific Aim 1: To determine if chronic inflammation induced colon cancer (CICC)
is regulated by APN.

245

Specific Aim 2: To determine if Se rich diet can interact with APN to regulate CICC.
Specific Aim 3: To determine if APN administration and Se rich diet can act in
conjugation to regulate intestinal inflammation and cancer in APCMin/+ mice model.
The primary objectives of this study are to: 1) determine whether CICC is effected by APN
deficiency and to identify its effect on clinical manifestation, tumor load and inflammation,
2) elucidate how APN deficiency have an effect on goblet cell production and hence mucus
secretion, 3) determine how Se rich diet could interact with APN to modulate clinical score,
tumor load, inflammation and selenoproteins expression, 4) study how Se rich diet and
APN deficiency could have an effect on cancer cell apoptosis and goblet cell production,
5) determine how APN administration and Se rich diet could have an effect on intestinal
cancer modulating clinical score, tumor load, goblet cell production and cancer cell
apoptosis and 6) study how APN and Se rich diet could impact oxidative stress and
inflammation. The rationale for this proposal comes from several published manuscripts
and our preliminary data. Our preliminary data indicated that the APNKO mice
administered dimethylhydrazine (DMH) to induce colon cancer showed significantly
higher clinical score and tumor number when compared to wild type (WT) mice given the
same treatment. Se rich diet (0.75 ppm) was found to be effective in reducing clinical score
and tumor number in both WT and APNKO mice administered DMH with a greater
significance in APNKO mice. Our preliminary results are also supported by the published
data of Mutoh et al., 2011 who had shown that APN-/- in APCMin/+ mice increased the
tumor load by 3.2-fold, by the age of 9 weeks and 3.4-fold by the age of 12 weeks when
compared with APN+/+ APCMin/+ mice. AOM induced colon tumor formation was found to
be significantly higher in APN-/- when compared to the APN+/+ mice. The novelty of this

246

dissertation lies in studying the effect and the different mechanism of action of APN and
Se rich diet on chronic inflammation induced by dextran sodium sulfate (DSS), colon
cancer (by DMH) and CICC by DSS and DMH. In addition, we will also be studying the
role of APN administration either alone or in conjugation with Se rich diet on APC Min/+
mice model of intestinal cancer.

Limitations and Pitfalls
1. DSS induced colitis and DSS+DMH induced CICC are 2 different models and vary
from DMH induced cancer (preliminary data), in pathology and the stage of cancer.
In these new model it is possible that the APNKO and WT mice show similar
pathology, clinical score and tumor load.
2. Loss of adiponectin may not have an effect on goblet cell production and hence
mucus secretion.
3. APN administration on the goblet cell lines may cause greater apoptosis of the
goblet cells rather than being anti-apoptotic and hence leading to lower mucin
production.
4. Se administration as shown by previous publications might cause colon tumor cell
apoptosis, but may not be effective in epithelial cell recovery or proliferation of
epithelial cell to recover from colon insult.
5. There is no published data indicating the role of Se in goblet cell production
therefore it might be possible that Se might not increase goblet cell production and
hence no increased mucus secretion.
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6. Se rich diet might not be effective in reducing the severity of intestinal cancer in
the APCMin/+ mouse model of intestinal cancer, as it is a completely different model
system from the DMH model of colon cancer
7. APN administration might not be effective in reducing the severity of intestinal
cancer in the APCMin/+ mouse model of intestinal cancer.
8. Combination of Se and APN might not produce additive effects and might not be
effective in significantly reducing the pathology, clinical score and tumor number
when compared with individual treatments.
9. APN dosage may not be effective in reducing the severity of intestinal cancer.
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Working Model

Central idea of this dissertation is to study the protective effect of APN and Se
rich diet on intestinal cancer and CICC and delineate the mechanism for this protection. To
achieve this, we will be using the inducible (DSS+DMH) model for studying CICC and
APCMin/+ mice model for studying intestinal cancer. DMH+DMH and APCMin/+ mice
models are very widely used model for studying colon and intestinal cancer respectively
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(Tong, et al., 2011). Colon cancer in most of the cases is preceded by cycles of chronic
inflammation and exposure to carcinogen sparking the formation of colon polyp. Colon
and intestinal cancer at the clinical level is marked by blood in stools, diarrhea, weight loss,
nausea, vomiting, constipation and constant fatigue. At the molecular level, colon and
intestinal cancer is marked by increase in pro-inflammatory marker and proteins and
suppression of anti-inflammatory response. Earlier stage pathology of the colon and
intestine indicates pre-cancerous lesion and inflammation, which later on develops into
colon tumors of varying size and shape. Our model of CICC is very near to mimic human
stage II and III of colon cancer progression. Additionally, APCMin/+ mutation accounts for
majority of the intestinal and colon cancer cases along with a large similarity in the
symptoms with human condition. There have been published study indicating the role of
Se rich diet and APN administration in colorectal or intestinal cancer but these studies are
limited in explaining the mechanism of action and most of the studies are in vitro. Also the
combination of the above intervention has never been used in colon or intestinal cancer
related studies.

This thesis is divided in to 3 different aims, where the 1st aim is based on our
preliminary experiment, which indicate that APNKO mice showed a significantly higher
clinical score when compared to WT mice treated with DMH to induce colon cancer. We
also found a significant increase in the tumor number in APNKO mice when compared to
WT mice given DMH to induce colon cancer. On the basis of our preliminary data, we are
trying to study whether CICC is regulated by APN deficiency. APN has been considered
as an anti-inflammatory, antidiabetic and anti-cancer molecule secreted by the adipose
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tissue. However, in obese individuals, a reduction in serum APN has been reported (Nigro,
et al., 2014). APN has been shown to decrease inflammation by the activation of AMPK
(A. Y. Kim, et al., 2010). Our first aim will study the effect of APN deficiency on chronic
inflammation induced colon cancer. In this aim, we will determine the effect of APN on
clinical score, tumor load and inflammatory markers associated with chronic inflammation
and CICC. Aim 1.2 will study the effect of APN through AMPK and STAT3 activation
and Cyclooxygenase (Cox) -2 mediated chronic inflammation and cancer. In addition to
this we will study the effect of APN on hairy and enhancer of split (Hes)-1 and mouse
atonal homolog (Math)-1 mediated goblet cell production and mucus secretion. The last
part of this aim will study the how APN administration on goblet cell lines could affect
goblet cell production and mucin secretion.

Our second aim is also based on our preliminary data where we found that Se rich
diet (0.75ppm) was effective in reducing the clinical score and tumor number of mice with
colon cancer. Se has been widely studied for it benefits in reducing inflammation, oxidative
stress and to some extent leads to the reduction in cancer pathology. Se has been found to
cause apoptosis of the colon cancer cells in vitro (Luo, et al., 2013). In this aim, we will
study the role of Se and APN in reducing the severity of chronic inflammation and colon
cancer by administering Se rich diet to APNKO and WT mice model with chronic
inflammation, colon cancer and CICC. Aim 2.1 will study the reduction in tumor and
clinical score through the mechanism leading to colon cancer cell apoptosis in the response
to Se rich diet and serum APN. Since Se is a well-known antioxidant and anti-inflammatory
non-metal, it could be easily derived that Se rich diet might be increasing the production
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of antioxidant selenoproteins like Glutathione peroxidase (Gpx) I and II which could
reduce overall oxidative stress in the state of CICC and hence reducing inflammation
leading to reduce pathology of CICC (Aim 2.2). It could be possible that Se might play an
important role in increasing the goblet cell production and the secretion of mucus from
goblet cells providing protection form the DSS and DMH induced colon insult, which will
be studied under aim 1.3.

There have been very limited studies indicating the protective role of APN
administration on colon or intestinal cancer (Luo, et al., 2013). In aim 3 of this proposal
will study the protective effect of both APN administration and Se rich diet on intestinal
cancer. This will provide a reinforcement of our previous aims by studying a genetic model
of intestinal and colon cancer (APCMin/+) along-with exploring the effect of APN
administration alone and in conjugation with Se rich diet on colon cancer. Aim 3.1 will
study the clinical score, colon and intestinal tumor number and area, histopathology and
inflammation and infiltration of immune cells; mainly concerning the physical attributes
of intestinal and colon cancer in both colon and iliac part of small intestine. Sodium selenite
has been shown to cause apoptosis of colon cancer cell in vitro by the activation of Bax
dependent mitochondrial pathway (Z. Li, et al., 2013). APN treatment has also been shown
to increase the apoptosis of the implanted colon cancer cells (Moon, et al., 2013). Aim 3.2
will determine the effect of both co-administration and individual effect of Se rich diet and
APN administration on caspase 9 and 3 mediated apoptosis of the cancer cells in addition
to goblet cell production. This aim will also study the pathways leading to the change in
the phenotype from epithelial to goblet cells (Hes1 and MATH1 expression) and mucin
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production (Muc2 and Muc4). Aim 3.3 will further study the in-depth mechanism
providing an explanation for the protective effect of the Se rich diet and APN on reducing
oxidative stress (Nitrosylation and Lipid Peroxidation) by increasing Gpx1 and Gpx2
expression. This aim will further focus on the downregulation of TGF-β and β – Catenin
leading to increase expression of gut barrier proteins and reducing cellular proliferation
and gut barrier dysfunction. By the means of this proposal will test the role Se rich diet and
APN in murine model of intestinal and colon cancer.
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PRELIMINARY DATA

Preliminary data for Experiment 1:
Clinical Score:
Colon cancer was induced in DMH treatment group in both the APNKO (n=5) and WT
(n=5) mice by administrating DMH intraperitoneally once a week for 12 weeks at a
concentration of 20mg/kg body weight of mice. Clinical score which is a summation of
weight loss, diarrhea and fecal hemoccult was determined during the length of the study
thrice a week till the date of sacrifice (day 194). We found a significant increase in the
clinical score of the APNKO mice on day 76, 105 and 128 as compared to WT mice given
the same treatment (figure1). Clinical score of the APNKO mice remain significantly
higher than the WT mice from day 128 till day 153 (day of sacrifice).
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Figure 1: Clinical Score- DMH treatment: The graph compares the clinical score of the
APNKO and WT mice given the same DMH treatment starting from day 4 till day 128.
Significant difference was determined using TTEST. **p<0.05, #p<0.01.

Mice were sacrificed on day 153 and the colon was excised and flushed with PBS. Colon
was cut open longitudinally and stained with 2% methylene blue to count the tumor number
and tumor area. Significant increase in the tumor number and area was found in the
APNKO mice as compared to the WT mice given the same treatment (figure 2).

Figure 2: Tumor number and area- DMH treatment: The graph compares the tumor
number and area of the APNKO and WT mice given the same DMH treatment. Significant
difference was determined using TTEST. *p<0.03.
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Preliminary data for Experiment 2:
Clinical Score:
Colon cancer was induced in DMH treatment group in both the APNKO (n=5) and WT
(n=5) mice given either control (0.02 ppm Se) or Se rich diet (0.75 ppm Se) by
administrating DMH intraperitoneally once a week for 12 weeks at a concentration of
20mg/kg body weight of mice. Clinical score which is a summation of weight loss, diarrhea
and fecal hemoccult was determined during the length of the study thrice a week till the
date of sacrifice (day 194). We found a significant decrease in the clinical score of both the
APNKO and WT mice given Se rich diet as compared to APNKO and WT mice
respectively given the control diet (figure 3).

Figure 3: Clinical Score- DMH treatment: The graph compares the clinical score of the
APNKO and WT mice given Se rich diet with the same genotype given control diet from
day 25 till day 194. Significant difference was determined using TTEST. *p<0.05,
#p<0.01.
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Mice were sacrificed on day 194 and the colon was excised and flushed with PBS. Colon
was cut open longitudinally and stained with 2% methylene blue to count the tumor number
and tumor area. Significant decrease in the tumor number was found in both APNKO and
WT mice given Se rich diet when compared to the same genotypic mice given control diet
(figure 2). However, no significance was found in the tumor area of the APNKO and WT
mice given Se rich and control diet. APNKO mice showed a higher tumor area when
compared to the WT mice.

Figure 4: Tumor number and area- DMH treatment: The graph compares the tumor
number and area of the APNKO and WT mice given Se rich diet the same genotypic mice
given control diet. Significant difference was determined using TTEST. *p<0.05.
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RESEARCH DESIGN AND METHODS

Overall research Design: The overall purpose of this study is to determine the effect of
Se rich diet, and APN on colon and intestinal cancer. There have been few studies
indicating the role of Se rich diet and APN on colon cancer but most of these study lack
the mechanism of action of these interventions and there is no study which indicate the
combination of these intervention. Since colon cancer is a complex set of condition
originating from chronic inflammation, obesity and toxic exposure so it is necessary to use
a combination of these intervention to alleviate the symptoms associated with chronic
inflammation and colon cancer.
This research proposal has been divided into 3 different aims, where our 1st aim
deals with studying effect of APN deficiency on DSS+DMH model of CICC. This aim is
based on our preliminary data where we found a significant increase in clinical score and
tumor number in APNKO mice when compared to WT mice with DMH induced colon
cancer. In the first aim we will study the mechanism of action of APN in reducing the
severity of chronic inflammation and CICC. The preliminary data for the 2nd aim indicate
that Se rich diet (0.75 ppm) reduces the clinical score and tumor load of both APNKO and
WT mice given Se rich diet when compared to the control diet (0.02 ppm). This aim will
study the effect of Se rich diet and APN deficiency on chronic inflammation and CICC.
Mechanism dealing with the protective effect of Se and APN in reducing the severity of
colon cancer will be studied under this aim including colon cancer cell apoptosis, goblet
cell production and oxidative stress. In the last aim we will try to replicate the use of Se
rich diet in APCMin/+ mouse model of intestinal cancer; providing another proof for the use
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of Se rich diet in colon and intestinal cancer. Along with this intervention, this aim will
also delineate the role of APN administration and the combination of Se rich diet and APN
administration on APCMin/+ model of intestinal cancer. This aim will provide the first proof
of use of combinatorial approach for reducing the severity of intestinal cancer and related
inflammation. This aim will also study different signaling pathways related to the effect of
Se and APN administration in reducing the severity of intestinal cancer.

AIM 1: To determine if CICC is regulated by APN.

Rationale: Our preliminary data indicated that APN deficiency increase the severity of
DMH induced colon cancer as indicated by significantly higher clinical score and tumor
number in APNKO mice when compared to the WT mice given the same treatment. APN
is an adipocytokine secreted by the adipose tissue which has been identified as an antiinflammatory and anti-cancer molecule (Byeon, et al., 2010). Studies have linked obesity
with increased risk of colon cancer (Calle & Kaaks, 2004; Le Marchand, Wilkens, Kolonel,
Hankin, & Lyu, 1997). Lower expression of APN has been found in obese patients when
compared to non-obese individuals (Barresi, Tuccari, & Barresi, 2009; Meilleur et al.,
2010) reflecting that lower serum of APN is linked with increased risk of human colorectal
cancer (Wei, et al., 2005). APN has been shown to stimulate AMPK phosphorylation and
mediate its anti-inflammatory and anti-cancer function through the activation of AdipoR1
and AdipoR2 receptors in HT29 and LoVo colon cancer cell lines (A. Y. Kim, et al., 2010).
APN has been shown to alleviate stromal cell Cox-2 expression (Awazawa et al., 2011).
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Adipocytokines including APN has an effect on carcinogenesis with a little information
about its role in chronic inflammation and progression and development of colon cancer.
There are several evidences available indicating the protective role of APN in inflammation
and cancer but there are very few studies published in colon cancer. Most of the studies
conducted in the field are in vitro and lacks the mechanistic explanation for APN medicated
protection. Very few to none of the studies have identified the role of APN on goblet cell
production and mucus secretion which is one of the major pathway leading to colon
protection against toxin and gut bacterial invasion. In order to answer the above questions,
this aim has been designed to study the effect of APN deficiency on clinical score, tumor
load and inflammation in chronic inflammation, colon cancer and CICC. The effect of APN
on goblet cell production and mucus secretion along with the effect of APN administration
on goblet cell line leading to goblet cell production will be studied in this aim.
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AIM 1.1 To study the effect of APN deficiency on clinical score, tumor load and
inflammation in CICC.
AIM 1.2 To determine the effect of APN deficiency on AMPK mediated
inflammation and mucus secretion.
AIM 1.3 To study how APN administration could affect goblet cell production and
epithelial to goblet cell transition with mucin production in goblet cell lines.

Experimental Design Specific AIM 1: Aim 1 will study the effect of APN deficiency on
chronic inflammation, colon cancer and CICC. In this aim, 6-8 weeks old, male and female
APNKO and C57BL/6 mice will be randomly divided into 4 different treatment groups
including control, DSS alone, DMH alone and DSS+DMH. DSS alone group will receive
3 cycle of 2% DSS in the drinking water. DMH alone group will receive intraperitoneally
injections of 20mg/kg of DMH, once a week for 12 weeks to induce colon cancer and
DSS+DMH groups will receive one intraperitoneal injection of DMH (20mg/kg) on day 4
and 3 cycles of DSS to induce CICC. Mice will be monitored for the clinical score
throughout the length of the study and will be sacrificed on day 153. Mice colon will be
collected for protein expression studies, secreted cytokines and histochemical analysis.
Remaining part of the colon will be stained with 2% methylene blue for counting the tumor
number and tumor area. HT29-Cl.16E and Ls174T goblet cell lines cells will be seeded
and cultured in the Dulbecco's modified Eagle's medium (DMEM). These cells will be
incubated with the different dosages of APN to determine its effect of mucin secretion and
goblet cell apoptosis. Aim 1 is subdivided in to 3 different sub-aims exploring the
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mechanism of action of APN in reducing the severity of chronic inflammation, colon
cancer and CICC. Aim 1.1 will study the effect of APN deficiency clinical score, tumor
load and inflammation. Aim 1.2 will study the effect of APN deficiency on AMPK
mediated STAT3 phosphorylation, Cox-2 expression and goblet to epithelial cell ratio and
mucus secretion. Aim 1.3 will study the effect of differential concentration of APN
administration on goblet cell apoptosis and mucin secretion. Unpaired TTEST and One
Way ANOVA will be used for statistical analysis with a p≤0.05 as significant.

Experiment 1: This experiment will identify whether APN play a role in modulating the
severity of chronic inflammation, colon cancer and CICC through goblet cell production
and mucus secretion.

Animal Model and Handling: Six to eight week old male APNKO and C57BL/6 (WT)
were obtained from Jackson Laboratories and bred in the animal facility at the University
of South Carolina. They will be housed in conventional animal room and treated in the
animal facility at the University of South Carolina. All APNKO mice were homozygous
for APN deficiency

(−/−)

. The mice were on a 12:12 h light–dark cycle in a low stress

environment (22 °C, 50% humidity and low noise) and had access to food (Purina Chow)
and water ad libitum. All animal care followed institutional guidelines under a protocol
approved by the Institutional Animal Care and Use Committee at the University of South
Carolina. APNKO and WT mice were randomly assigned to 8 different treatment groups
(n=10 mice per group): 1) APNKO+DMH+DSS; 2) WT+DMH+DSS; 3) APNKO+DMH;
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4) WT+DMH; 5) APNKO+DSS; 6) WT+ DSS 7) APNKO+Control 8) WT+ Control. The
body weight of both APNKO and WT mice showed no significant difference at the
beginning of the study. Mice will be monitored throughout the length of the study for
clinical score including weight loss, diarrhea and fecal hemmoccult. Mice will be sacrificed
by cervical dislocation on day 153. Blood will be collected before sacrifice through retroorbital puncture, spin down at 10,000 rpm for 18 minutes and serum will be isolated and
stored at -20°C for measuring serum APN. Mice colon will be excised and flushed clean
with PBS. 2 mm2 colon tissue section with tumor and non-tumor area will be fixed in 10%
formalin and after 24 hours will be replaced with 70% ethanol followed by paraffin
embedding and sectioning to obtain 5-6 mm thin section on glass slide. 2 mm2 colon tissue
section with tumor and non-tumor area will be snap frozen on dry ice and stored at -80°C
for protein expression studies and another 2 mm2 colon tissue section will be incubated in
RPMI medium at 37°C for 24 hours followed by centrifugation at 2500 rpm for 15 minutes.
Supernatant will be obtained and stored at -20°C for secreted cytokine expression.

Figure 1: It shows different treatment groups with the number of mice used in each group
(n=10) for Aim 1
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Material and Methods
Chronic Inflammation and Colon Cancer
Depending on the treatment group, mice will be either administered DSS or DMH or both.
DSS will be administered alone to induce chronic inflammation. DMH will be injected to
induce cancer while the combination of both will be given to induce CICC. DSS will be
administered in 3 cycles where one cycle constitutes 2% DSS (MP Biochemicals, MW:
36,000-50,000) in drinking water for 5 days followed by 5 days of normal drinking water.
DSS will be administered on day 4, 27 and 50 to induce chronic inflammation. DMH
(Sigma Aldrich) will be injected intraperitoneally at a concentration of 20mg/kg either once
for DSS+DMH treatment group on day 4 or once a week for 12 weeks for DMH alone
group. These concentration and model have been well established to study chronic
inflammation and colon cancer.

Clinical Score
Clinical score will be measured for each mouse in each group from day 25 to day 194.
Mice will be sacrificed after the last clinical score measurement. Score for the weight loss
is based on the following published scale where 0 = 0–5% weight loss; 1 = 6–10% weight
loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. Scoring
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of diarrhea is as follows: 0 = well-formed pellets, 2 = pasty and semi-formed stools that do
not adhere to the anus, 4 = liquid stools that adhere to the anus. Detection of blood in the
stools will be determined using hemoccult kit (BECKMAN COULTER). The higher
intensity of blue color indicates greater bleeding. The followings are the score rates for the
fecal hemoccult: 0 = no blood, 2 = positive hemoccult, 4 = gross bleeding. The total clinical
score will be the summation of the individual score of weight loss, diarrhea and fecal
hemoccult. The maximum score a mouse could get is 12. The clinical score will be
calculated and plotted against days of DSS administration or duration of the experiment.
Higher clinical score indicates more severity of colon cancer development in animals.

Colon Tissue and Serum Collection:
Blood will be collected before sacrifice through retro-orbital puncture and spun down at
10,000 rpm for 18 minutes and serum will be obtained and stored at -20°C to measure
APN. Mice colon will be excised and flushed clean with PBS. 2mm2 colon tissue section
with tumor and non-tumor area will be fixed in 10% formalin. 24 hours later, tissues will
be submerged in 70% ethanol followed by paraffin embedding and sectioning to obtain 5
µm thin section on glass slide. Sections with tumor and non-tumor areas will then be snap
frozen on dry ice and stored at -80°C for protein analysis. Another 2mm2 colon tissue
section will be incubated in RPMI medium containing 5000 IU/mL and 5000 IU/mL
penicillin and streptomycin (CELLGRO) respectively at 37°C and 5% CO2 for 24 hours.
This will be followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be
obtained and stored at -20°C to measure secreted cytokine levels.
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Tumor Number and Tumor Area and Histopathology:
Mice colon will be excised and flushed with PBS. Tumor number and area will be counted
under the microscope for all mice of different groups and significant difference will be
calculated between different groups given different treatment and genotype.

Hematoxylin and Eosin staining will be used to determine the morphology of mice
colon. Histopathology will be quantified based on the scoring system indicating the
severity of disease and constituting inflammation and immune cell infiltration.
Quantification of severity of disease including inflammation and immune cell infiltration
was done on the scale of 4 for both the parameters, where 0 = no infiltration or no
inflammation; 2 = moderate infiltration or inflammation; and 4 = severe inflammation with
distorted crypts or infiltration and formation of lymphatic follicles. All the images were
taken in 20× magnification with Nikon e600 microscope. The scale bar represents 120 µm.
The score will be measured by two investigators in blinded fashion.

Cell culture
HT29-Cl.16E and Ls174T cells (ATCC) will be seeded on porous nitrocellulose filters
(MILLIPORE filters HAHY, porosity 0.45 µm; 2×106 cells per filter) to provide improved
access to basolateral membrane of cells. The cells will be cultured in Dulbecco's modified
Eagle's medium (DMEM) (GIBCO) supplemented with 10 % (v/v) heat-inactivated fetal
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calf serum (FCS) (GIBCO). HT29-Cl.16E and Ls174T cells form at confluence
homogeneous monolayer of differentiated goblet cells, secreting a mucus gel in the culture
medium. HT29-Cl.16E and Ls174T cells (106/well) will be incubated at 37 °C and 5 %
CO2 in the presence of different dosages of recombinant APN (0, 0.25, 0.5, 1.0, 1.5, 2.0
µg/mL) in one experiment and with APN (2 µg/mL), TNF-α (10 ng/mL), and APN+TNFα (PROSPEC) for 24 h in other experiment.

Protein determination using Western Blot:
Colon tissue frozen at -80°C will be homogenized in RIPA buffer added to protease and
phosphatase inhibitors (SIGMA). It will be then centrifuged at 10,000 rpm for 15 minutes
and supernatant will be collected for protein analysis. Protein concentration in the
supernatant will be determined by using Bradford protein assay. This will be followed by
loading equal amounts of protein (50 µg) in each well for a 10% Sodium Dodecyl Sulphate
(SDS) gel electrophoresis. The protein from the gel will then be transferred to a
nitrocellulose membrane (Pall Scientific) and blocked with 5% non-fat dry milk (Biorad)
in phosphate buffer saline (PBS) (cellgro) with 0.1% Tween 20. The membrane will be
incubated overnight with the primary antibody. The primary antibodies include AMPK,
pAMPK, Cox-2, STAT-3 and pSTAT3 obtained from Cell Signaling Technology.
Membrane will be washed by PBS containing 0.1% Tween 20 (Biorad). The membrane
will then be incubated with secondary antibody (Santa Cruz) followed by another washing
step. The last step includes incubating the membrane in ECL substrate (Western Bright,
Advansta). The film will be then developed by using a developer (SRX-101A, Konica
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Minolta Medical & Graphic, INC.) in the dark room. Finally the film will be scanned and
the density of the protein bands obtained will be analyzed using Image J software.

Mucus Thickness
Mucus thickness will be measured with micropipettes connected to a micromanipulator
(LEITZ) with a digimatic indicator (IDC SERIES 543, Mitutoyo). The degraded luminal
mucus layer was removed. Glass tubing (borosilicate tubing with 1.2 mm OD and 0.6 mm
ID; Frederick Haer) will be pulled with a pipette puller (pp-83; NARISHIGE
SCIENTIFIC) to a tip diameter of 1–3 µm and to prevent mucus adhering to glass, the
pipettes were siliconized by dipping the tip of the micropipette into a silicone solution
followed by drying at 100 °C for 30 min. The luminal surface of the mucus gel will be
visualized by placing graphite particles (activated charcoal, extra pure, Merck) on the gel,
and the colonic epithelial cell surface was visible through the microscope. The micropipette
will be inserted into the mucus gel at an angle of ~30° (θ) to the surface. The distances
traveled by the micropipette from the luminal surface of the mucus gel to the epithelial cell
surface will be measured with a digimatic indicator connected to the micromanipulator,
and a mean value (A) was calculated. The mucus thickness (T) will be calculated using the
formula T=A (sin θ). Mean of four to five different measurements will be taken as one
thickness value.
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Alcian Blue Staining
Standard deparaffinization procedure will be followed using xylene and gradation of
ethanol. Alcian blue solution (1 %) of pH 2.5 in 3 % acetic acid and nuclear fast red in
aluminum sulfate will be prepared. Tissues will be stained with Alcian blue and
counterstained with nuclear fast red solution. Goblet to epithelial cell ratio will be counted
per crypt with ten crypts per section and five sections per group.

Enzyme Linked Immunosorbent Assay (ELISA):
Spontaneous secreted cytokines will be measured from the tissue incubated in the RPMI
medium for 24 hours at 37°C. The media will be collected and centrifuged at 2500 rpm for
16 minutes. Pellet will be discarded and the supernatant is isolated. Cytokines IL-6, TNFα, IL-1β and IL-10 levels will be measured by using BD OptEIA ELISA kit obtained from
BD biosciences and normalized by total protein content estimated by using standard
Bradford assay procedure. Muc1 and Muc2 production was measured both in colonic
epithelial cells and in HT29-Cl.16E and Ls174T cell supernatant by ELISA (USCN LIFE
SCIENCE) using standard protocol.

Genes knockdown using siRNA
Small interfering RNA (siRNA) (40 nM) targeting MUC2, Bax, APN R1 and R2
(QIAGEN), and Math-1 was transfected in HT29-Cl.16E and Ls174T cells (106) using
lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions.
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Controls were transfected with unrelated siRNA (CsiRNA) (SANTA CRUZ, QIAGEN,
and INVITROGEN). Reductions of cell-surface proteins were analyzed with flow
cytometry. The efficacy of knockdowns was assessed by conventional semi-quantitative
RT-PCR. Assays were performed 2 days after transfection.

TUNEL Assay
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick-end labeling
(TUNEL) technique was used as per manufacturer instructions (R&D systems) to detect
DNA strand breaks in situ. After treating cells with APN (2 µg/mL), TNF-α (10 ng/mL),
and APN+TNF-α pelleted cells were rinsed with PBS and TUNEL staining procedure was
performed. Cells were then counterstained with methyl green. Negative controls were
performed by substituting PBS for TdT enzyme, which exhibited no immunostaining.
Enumeration of apoptotic nuclei was made on ten slides per treatment, using a Zeiss light
microscope with a 40× objective and a 10× eyepiece. All nuclei counted showing a brown
labeling. The incidence of apoptotic nuclei was given as the percentage relative to total
nuclei (apoptotic ratio). The data are representative of three repeated experiments, all
displaying similar results.

Reverse transcription-polymerase chain reaction
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to
determine the efficacy of siRNA transfection and relative gene expression in HT29-Cl.16E
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and Ls174T cells and colonic epithelial cells. Total cellular RNA was isolated using TRIzol
reagent (Invitrogen) according to the manufacturer's instructions. A total of 2.5 mg
extracted RNA was used as the template for complementary DNA (cDNA) synthesis using
the Thermoscript reverse transcription-polymerase chain reaction system (Invitrogen).
Semi-quantitative PCR was performed for Muc2, Bax, APN R1 and R2, Hes-1, and Math1 using the following primer pairs: MUC2 forward primer (FP) (5-GACATTTGTCAT
GTACTCGGC-3) and reverse primer (RP) (5-GCAAGGACTGAACAA AGACTC-3),
Bcl-2 (FP-59-GACTTCGCCGAGATGTCCAG-39 and RP-5-TCACTTG TGGCT
CAGATAGG-3), Bax (FP-59-GGTTTCATCCAGGATCGAGACGG-3 and RP-5ACAAAGATG

GTCACGGTCTGCC-3),

GAPDH

(HT29-Cl.16E

cells)

(FP-5-

GCAGGGGGGAGCCAAAAGGG-3 and RP- 5-TGCCAGCCCCAGCGTCAAAG-3),
Hes1 (FP-CAGCCAGTGTCAACACG ACAC and RPTCGTTCATGCACTCGCTGAG),
Math1 (FP-AGTGACGGAGAGTTTTCCCC and RP-CTGCAGCCGTCCGAAGTCAA),
and GAPDH (colonic epithelial cells) (FP- GTCATCA TCTCCGCCCCTTCTGC and RPGATGCCTGCTTCACCACC TTCTTG). The synthesized cDNA was amplified by RTPCR assay; the PCR cycle consisted of 94 °C for 1 min, 56 °C for 2 min, and 72 °C for 1
min, with final extension at 72 °C for 10 min. Relative mRNA abundance of Math-1, hes1, and ratio of Bax/Bcl-2 was calculated using semi-quantitative RT-PCR and Image J
software (NCBI) for densitometry. GAPDH was used as a loading control and the gels
were run thrice using different samples from the same group to calculate significant
difference.
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Statistical analysis

Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and Oneway ANOVA will be used to analyze the data with Tukey post hoc-analyses. A p<0.05 will
be considered statistically significant. All the statistical analyses will be done using
SigmaStat 3.5 (SPSS, Chicago, IL).

Primary Outcomes:

Clinical Score: Clinical score was measured for each mouse in each group from day 4 to
day 153. Mice were sacrificed after the last clinical score measurement. Clinical score is a
summation of 3 different score including weight loss, diarrhea and fecal hemoccult. The
scoring system is as follows:

Table 1: It shows clinical
score

measurement

criteria.

The maximum score a mouse could get is 12. Fecal hemoccult scoring was obtained using
a kit from Beckman Coulter, which turns the fecal blood into blue color. The higher

272

intensity of blue color indicates greater bleeding. The clinical score was calculated and
plotted against days of DSS administration. Higher clinical score indicated more severity
of colon cancer.

Tumor Number and Tumor Area: Mice colon was excised and flushed with PBS. At this
point the tumor number and area were counted for that part of the colon, which was excised
for paraffin embedding, freezing and RPMI medium. The rest of the colon was fixed in
10% formalin for 24 hours and then stored in 70% ethanol. The colon was stained with 2%
methylene blue. Tumor number and area was counted under the microscope for all the mice
in different groups and significant different was calculated between different groups and a
graph was plotted.

Chronic Inflammation: Chronic inflammation will be measured in the colon of all the
mice in different group by measuring secreted cytokines. Secreted cytokines will be
measured from the tissue incubated in the RPMI medium for 24 hours at 37°C. Cytokines
like IL-6, TNF-α, IL-1β and IL-10 will be measured. This will be followed by Hematoxylin
and Eosin staining of the colon tissue section fixed in formalin and embedded in paraffin
wax to study chronic inflammation and immune cell infiltration. STAT3 is an indicator of
inflammation and has been shown to overexpress in many cancers. Phosphorylation of
STAT3 will indicate the degree of inflammation and its protein expression will be
measured using western blot. Increased expression of pro-inflammatory cytokines and
proteins and decrease production of anti-inflammatory cytokines indicates greater
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inflammation. Greater degree of inflammation indicated by abnormal crypts and
infiltration of the immune cells indicates higher severity of colon cancer.

Goblet Cell Production, Mucus Secretion and Apoptosis: Increase in the goblet cells and
hence increase mucus production is one of the protective mechanisms that could play an
essential role in the colon cancer prevention. Alcian blue staining will be used to determine
the ratio of goblet to epithelial cells in the colon tissue section for all the treatment groups.
Higher ratio will be an indication of increase number of goblet cell and hence increase
mucus secretion. Hes-1 and Math-1 gene expression will be determined in the colon tissue
of the APNKO and WT mice belonging to all treatment groups as they will provide indirect
measure for epithelial to goblet transition and goblet cell production. Mucus thickness will
also be determined to get a direct measure of mucus secretion and hence mucus mediated
protection in the control, DSS, DMH and DSS+DMH treatment groups. Whether mucin
secretion is APN dependent will be studied by giving different concentration of APN to
the HT29-CI.16E cells and measuring the secretion of Muc1 and Muc2 in the culture media
by ELISA. Goblet cell apoptosis will measured under different treatment conditions
including APN administration (2 μg/mL), TNF-α mediated apoptosis (10 ng/mL) and coadministration of TNF-α and APN to determine if APN is directly involved in the apoptosis
of the goblet cells. Mechanism of goblet cell apoptosis will be further investigated by
studying the gene expression of Bax and Bcl2 in goblet cell under different treatment
conditions.
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APMK and Cox-2 Expression: AMPK has been known for its ant-inflammatory and anticancer properties and is activated during cellular stress. APN increase the rate of
phosphorylation of AMPK and has been known to suppress cell growth by downregulating
mTOR (Ouchi, et al., 2004). AMPK has been known to inhibit the activity of Cox-2; an
enzyme that is overexpressed during inflammation and cancer. This aim will study the
protein expression of phospho-AMPK and AMPK by western blot and localization
expression of Cox-2 in the colon tissue section by immunohistochemistry.

Serum Adiponectin: Higher levels of serum APN has been reported in trained individuals.
Obesity and cancer is linked with lower APN levels making it a prospective candidate in
the treatment for colon cancer. Serum APN will be determined in the WT mice in all the
treatment groups using ELISA.

AIM 2: To determine if Se rich diet can interact with APN to alleviate CICC.

Rationale: Our preliminary data indicate that Se rich diet (0.75 ppm) was effective in
reducing clinical score and tumor number DMH induced colon cancer. APNKO showed
greater clinical score and tumor load when compared to WT mice. A recent study by Li et
al., 2013 have shown that Se induces G1/M cell cycle arrest and apoptosis of the HCT116
and SW620 colorectal cancer cells (Z. Li, et al., 2013). They also found that Se treatment
leads to the upregulation and translocation of Bax from cytosol to mitochondria, increased
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expression of caspase 3 and downregulation of Bcl-2 and increased loss of MMP in a dose
dependent manner in HCT116 and SW620 colorectal cancer cell lines. Another recent
study by Maseko et al., 2014 discovered that Se rich Agaricus bisporus supplementation
increased Gpx-1 and Gpx-2 expression level in rat colon (Maseko, et al., 2014). Se
deficient diet (0.01mg Se as sodium selenite per kg) has been found to exacerbate colonic
tissue injury inflicted by DSS treatment and induced oxidative stress as indicated by DNA
damage further culminating in increased inflammation and carcinogenesis (Barrett, et al.,
2013). Although there have been few publications indicating the protective role of Se in
colorectal cancer but they lack the in depth mechanism of action of Se in reducing the
severity of colon cancer. Most of the studies are in-vitro and hence lack in-vivo approach.
In addition, there is no published literature indicating an interaction between Se rich diet
and APN and their combined effect on inflammation and colorectal cancer. Therefore to
provide more mechanistic explanation and to study whether Se and APN can act
synergistically, aim 2 is designed to define the role of Se rich diet and APN on CICC and
study the different possible explanations for their protective role on colorectal cancer.
These include determining the role of Se and APN on tumor load and clinical score,
changes in the different inflammatory markers, modulation of the anti-oxidant potential of
the colon through variation in the expression of selenoproteins like Gpx-1 and Gpx-2.
Studying the effect of Se rich diet and APN in increasing cancer cell apoptosis by increased
expression of cleaved caspase 9 and lastly by determining their role on goblet cell
production.
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AIM 2.1 To study the effect of selenium rich diet on clinical score and tumor load in
CICC.
AIM 2.2 To study the effect of Se rich diet on pro-inflammatory and anti-inflammatory
cytokines production and selenoproteins expression.
AIM 2.3 To study the effect of Se rich diet on colon cancer cell apoptosis and goblet
cell production.

Experimental Design Specific AIM 2: Aim 2 will study the effect of Se rich diet (0.75)
on DSS induced chronic inflammation, DMH mediated colon cancer and CICC. In addition
to this we will study the mechanism of action of Se in reducing the severity of colon cancer.
Four weeks old male and female C57BL/6 mice (WT) and APNKO mice with C57BL/6
background will be randomized in to 4 different treatment groups including Control, DSS,
DMH and DSS+DMH and each group will be fed 2 different types of diet including Se rich
(0.75 ppm) and Se deficient (0.02 ppm) diets. This will result in total 16 groups (n=9).
Based on the respective group, mice will be administered 2% DSS in the drinking water
for 3 different cycles either alone or with a single injection of DMH (20mg/kg mouse
weight). In DMH alone group mice will be administered DMH injection intraperitoneally
(20mg/kg mouse weight) once a week for 12 weeks. This will result in the formation 3
different treatment groups translating into DSS indicating chronic colitis, DMH indicating
mild colon cancer and DSS+DMH reflecting CICC and a control group. Mice will be
monitored for clinical score, 3 times a week and will be sacrificed on day 194. Mice colon
will be collected for protein expression studies, histochemical analysis, fluorescent staining
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and mass spectrometry. Remaining part of the colon will be stained with 2% methylene
blue for counting the number of tumors and tumor area. Aim 2 is subdivided in to 3
different sub-aims studying the effect of Se rich diet on chronic inflammation and colon
cancer in addition to its mechanism of action in both WT and APNKO mice. Aim 1.1 will
study the effect of Se rich diet on chronic inflammation, colon cancer and CICC in WT and
APNKO mice. Aim 1.2 will study the effect of Se rich diet on the oxidative potential of
the colon and its consecutive effect on oxidative stress and inflammation. Aim 1.3 will
study the effect of Se rich diet on colon cancer cell apoptosis with respect to caspase
expression and increasing goblet cell production and hence providing protection form the
colorectal cancer by increase mucus secretion. Unpaired TTEST and One Way ANOVA
will be used for statistical analysis with a p≤0.05 as significant.
Experiment 2: This experiment will identify the effect of Se rich diet and APN on
increasing anti-oxidant potential, apoptosis of cancer cells, goblet cell production and
decreasing inflammation and pathology of chronic inflammation and colon cancer.
Animal Model and Handling: Four weeks old C57BL/6 (WT) mice will be obtained from
Jackson Laboratories and will be bred in the animal facility at the University of South
Carolina under the IACUC
guidelines. The mice will be
fed regular chow and ad
libitum. Four weeks old
mice

will

randomized

be
in

then
to

16

different treatment groups
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with n=10. The mice will then be acclimatized to the animal facility for 24 days in a low
stress environment (22°C, 50% humidity and low noise) with 12:12 hours of light-dark
cycle and the first DSS or DMH administration will be done on day 25. The groups include:
WT+Normal

Diet,

WT+Se

Diet,

APNKO+Normal

WT+DSS+Normal

Diet,

WT+DSS+Se

Diet,

APNKO+DSS+Se

Diet,

WT+DMH+Normal

Diet,

APNKO+Se

APNKO+DSS+Normal
Diet,

WT+DMH+Se

Diet,
Diet,
Diet,

APNKO+DMH+Normal Diet, APNKO+DMH+Se Diet, WT+DSS+DMH+Normal Diet,
WT+DSS+DMH+Se

Diet,

APNKO+DSS+DMH+Normal

Diet

and

APNKO+DSS+DMH+Se Diet. Mice will be fed Se rich diet and control diet on day 25.
They will be monitored throughout the length of the study for clinical score including
weight loss, diarrhea and fecal hemmoccult. Mice will be sacrificed by cervical dislocation
on day 194. Blood will be collected before sacrifice through retro-orbital puncture, spin
down at 10,000 rpm for 18 minutes and serum was isolated and stored at -20°C for
measuring serum APN. Mice colon will be excised and flushed clean with PBS. 2 mm2
colon tissue section with tumor and non-tumor area will be fixed in 10% formalin and after
24 hours will be replaced with 70% ethanol followed by paraffin embedding and sectioning
to obtain 5-6 mm thin section on glass slide. 2 mm2 colon tissue section with tumor and
non-tumor area will be snap frozen on dry ice and stored at -80°C for protein expression
studies and another 2 mm2 colon tissue section will be incubated in RPMI medium at 37°C
for 24 hours followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be
obtained and stored at -20°C for secreted cytokine expression studies.
Figure 2: It shows different treatment groups with the number of mice used in each group
(n=10) for Aim 2.

279

Material and Methods

Chronic Inflammation and Colon Cancer
Depending on the treatment group, mice will be either administered DSS or DMH
or both. DSS will be administered alone to induce chronic inflammation. DMH will be
injected to induce cancer while the combination of both will be given to induce CICC. DSS
will be administered in 3 cycles where one cycle constitutes 2% DSS (MP Biochemicals,
MW: 36,000-50,000) in drinking water for 5 days followed by 5 days of normal drinking
water. DSS will be administered on day 25, 50 and 75 to induce chronic inflammation.
DMH (Sigma Aldrich) will be injected intraperitoneally at a concentration of 20mg/kg
either once for DSS+DMH treatment group on day 25 or once a week for 12 weeks for
DMH alone group. These concentration and model have been well established to study
chronic inflammation and colon cancer.

Selenium Diet Administration
Selenium rich diet containing 0.75 ppm of Se per kg will be administered to 8
groups on day 25 simultaneously with the administration of DSS, DMH, or both or to the
Control group. The diet will be administered till the day of sacrifice that is day 194. Control
diet
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contains all the components of the Se rich diet except that the Se content is 0.02 ppm per
kg of diet.

Clinical Score
Clinical score will be measured for each mouse in each group from day 25 to day
194. Mice will be sacrificed after the last clinical score measurement that is on day 194.
Score for the weight loss is based on the following published scale where 0 = 0–5% weight
loss; 1 = 6–10% weight loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 =
>20% weight loss. Scoring of diarrhea is as follows: 0 = well-formed pellets, 2 = pasty and
semi-formed stools that do not adhere to the anus, 4 = liquid stools that adhere to the anus.
Detection of blood in the stools will be determined using hemoccult kit (BECKMAN
COULTER). The higher intensity of blue color indicates greater bleeding. The followings
are the score rates for the fecal hemoccult: 0 = no blood, 2 = positive hemoccult, 4 = gross
bleeding. The total clinical score will be the summation of the individual score of weight
loss, diarrhea and fecal hemoccult. The maximum score a mouse could get is 12. The
clinical score will be calculated and plotted against days of DSS administration. Higher
clinical score indicates more severity of colon cancer development in animals.

Colon Tissue and Serum Collection:
Blood will be collected before sacrifice through retro-orbital puncture and spun
down at 10,000 rpm for 18 minutes and serum will be obtained and stored at -20°C to
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measure APN. Mice colon will be excised and flushed clean with PBS. 2mm2 colon tissue
section with tumor and non-tumor area will be fixed in 10% formalin. 24 hours later, tissues
will be submerged in 70% ethanol followed by paraffin embedding and sectioning to obtain
5 µm thin section on glass slide. Sections with tumor and non-tumor areas will then be snap
frozen on dry ice and stored at -80°C for protein analysis. Another 2mm2 colon tissue
section will be incubated in RPMI medium containing 5000 IU/mL and 5000 IU/mL
penicillin and streptomycin (CELLGRO) respectively at 37°C and 5% CO2 for 24 hours.
This will be followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be
obtained and stored at -20°C to measure secreted cytokine levels.
Tumor Number and Tumor Area and Histopathology:
Mice colon will be excised and flushed with PBS. Tumor number and area will be
counted under the microscope in all mice of different groups and significant different will
be calculated between different groups.
Hematoxylin and Eosin staining will be used to determine the morphology of mice
colon. Histopathology will be quantified based on the scoring system indicating the
severity of disease and constituting inflammation, immune cell infiltration and degree of
tumor. This will be calculated on the scale of 12 where highest score of 4 was given for
each parameter, where 0 = no infiltration or no inflammation or no cancer; 2 = moderate
infiltration or inflammation or pre-cancerous lesions; and 4 = severe inflammation with
distorted crypts or infiltration and formation of lymphatic follicles or visible tumors. All
the images will be taken in 20X magnification with Nikon e600 microscope. The score will
be measured by two investigators in blinded fashion.
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TUNEL Assay:
Degree of apoptosis will be measured in the tumor and non-tumor tissue sections
of the colon by TUNEL assay. TUNEL assay (EMD Millipore) will be used to determine
the number of TUNEL positive cells and total number of epithelial cells of the colon in
2mm2 tissue cross-sectional tissue area. 5 sections will then be randomly selected from
each tissue section and 10 tissue sections will be randomly selected from each group. The
ratio of TUNEL positive cell to total epithelial cell will be used to determine the ratio of
apoptosis and plotted as a graph for different treatment groups. All the images will be taken
in 20X magnification with Nikon e600 microscope.
Protein determination using Western Blot:
Colon tissue frozen at -80°C will be homogenized in RIPA buffer added to protease
and phosphatase inhibitors (SIGMA). It will be then centrifuged at 10,000 rpm for 15
minutes and supernatant will be collected for protein analysis. Protein concentration in the
supernatant will be determined by using Bradford protein assay. This will be followed by
loading equal amounts of protein (50 µg) in each well for a 10% Sodium Dodecyl Sulphate
(SDS) gel electrophoresis. The protein from the gel will then be transferred to a
nitrocellulose membrane (Pall Scientific) and blocked with 5% non-fat dry milk (Biorad)
in phosphate buffer saline (PBS) (cellgro) with 0.1% Tween 20. The membrane will be
incubated overnight with the primary antibody. The primary antibodies include Gpx-1,
Gpx-2 and GAPDH obtained from Genetex. phospho-NFκB p65, NFκB p65, phospho-p65,
cleaved caspase 9, MDA, 4HNE and Nitrotyrosine will be obtained from cell signaling
technology. Membrane will be washed by PBS containing 0.1% Tween 20 (Biorad). The
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membrane will then be incubated with secondary antibody (Santa Cruz) followed by
another washing step. The last step includes incubating the membrane in ECL substrate
(Western Bright, Advansta). The film will be then developed by using a developer (SRX101A, Konica Minolta Medical & Graphic, INC.) in the dark room. Finally the film will
be scanned and the density of the protein bands obtained will be analyzed using Image J
software.
Enzyme Linked Immunosorbent Assay (ELISA):
Spontaneous secreted cytokines will be measured from the tissue incubated in the
RPMI medium for 24 hours at 37°C. The media will be collected and centrifuged at 2500
rpm for 16 minutes. Pellet will be discarded and the supernatant is isolated. Cytokines IL6, TNF-α, IL-1β and IL-10 levels will be measured by using BD OptEIA ELISA kit
obtained from BD biosciences and normalized by total protein content estimated by using
standard Bradford assay procedure.
Immunofluorescence:
Colon tumor tissue sections will be deparaffinzed by xylene and dehydrated by
different concentrations of ethanol. The sections will then undergo heat mediated antigen
retrieval step with 10nM citrate buffer (Prohisto), 0.05% Tween 20, pH 6.0 in an autoclave
at 121°C, 15 psi for 20 minutes. The tissues will be then blocked with 10% goat anti-rabbit
serum with PBS. Tissues will be incubated in a primary antibody that is cleaved caspase 9
(Cell Signaling Technology) for overnight incubation. This will be followed by 5 washing
steps and 2 hour- incubation with anti-rabbit secondary antibody (Aexa Flour 488) (Cell
Signaling Technology). Finally the tissue section will be mounted with a DAPI based
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mounting media (Genetex) and covered with a coverslip. 10 random 20X magnification,
2x2 images of the 8 slides per group belonging to different mice will be taken and
quantified by using Image J software.
Mass Spectrometry:
Colon tissues will be freeze-dried using lyophilizer and weight prior to be used for
mass spectrometry. The tissue will then be digested using aqua regia (1 mL of optima grade
nitric acid plus 3 mL of optima grade hydrochloric acid) at 140°C and the final volume will
then be brought to 10 ml. The samples will be analyzed for Selenium using the Finnigan
ELEMENT2 double focusing magnetic sector field inductively coupled plasma-mass
spectrometer (ICP-MS). Iridium will be used as the internal standard. The instrument will
be calibrated for element 82Se. The samples will be analyzed immediately after the initial
calibration. The samples will then be diluted (5X) and the instrument blank will be set at
0.31 ppb of Se.

Statistical analysis
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and Oneway ANOVA will be used to analyze the data with Tukey post hoc-analyses. A p
value<0.05 will be considered statistically significant. All the statistical analyses will be
done using SigmaStat 3.5 (SPSS, Chicago, IL).
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Primary Outcomes:

Clinical Score: Clinical score will be measured for each mouse in each group from day 25
to day 194. Mice were sacrificed after the last clinical score measurement. Clinical score
is a summation of 3 different score including weight loss, diarrhea and fecal hemoccult.
The scoring system is as follows:

Table 1: It shows clinical
score

measurement

criteria.

The maximum score a mouse could get is 12. Fecal hemoccult scoring was obtained using
a kit from Beckman Coulter, which turns the fecal blood into blue color. The higher
intensity of blue color indicates greater bleeding. The clinical score was calculated and
plotted against days of DSS administration. Higher clinical score indicated more severity
of colon cancer.
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Tumor Number and Tumor Area: Mice colon will be excised and flushed with PBS. At
this point the tumor number and area will be counted for that part of the colon, which was
excised for paraffin embedding, freezing and RPMI medium. The rest of the colon was
fixed in 10% formalin for 24 hours and then stored in 70% ethanol. The colon will then be
stained with 2% methylene blue. Tumor number and area will be counted under the
microscope for all the mice in different groups and significant difference will be calculated
between different groups and a graph was plotted.

Selenium Content: Se content in the colon of each mice belonging to different groups will
be measured by mass spectrometry which would provide a direct measure of colon Se
content. Se content will measured as nmol/gm of the colon tissue and significant difference
between different groups will be calculated and represented on a graph.

Chronic Inflammation: Chronic inflammation will be measured in the colon of all the
mice in different group by measuring secreted cytokines. Secreted cytokines will be
measured from the tissue incubated in the RPMI medium for 24 hours at 37°C. Cytokines
like IL-6, TNF-α, IL-1β and IL-10 will be measured followed by pNFκB protein
expression. This will be followed by Hematoxylin and Eosin staining of the colon tissue
section fixed in formalin and embedded in paraffin wax to study chronic inflammation and
immune cell infiltration. Increased expression of pro-inflammatory cytokines and proteins
and decrease production of anti-inflammatory cytokines indicates greater inflammation.
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Greater degree of inflammation indicated by abnormal crypts and infiltration of the
immune cells indicates higher severity of colon cancer.

Oxidative Stress: Oxidative stress will be measured in the colon tissue sample which were
snap frozen at -80°C by performing western blot for 4HNE, a marker for lipid peroxidation,
nitrotyrosine, a marker of nitrosylation and iNOS (inducible nitric oxide synthase) a wellknown marker for increased oxidative stress. Higher oxidative stress measured by
increased nitrosylation, lipid peroxidation and NO production is indicative of greater
severity of chronic inflammation and colon cancer.

Apoptosis: Apoptosis will be measured in the tumor tissue and the normal tissue section of
the colon by TUNEL assay. TUNEL positive cells and total number of epithelial cells will
be counted and the ratio of TUNEL positive cell to total epithelial cell will determine the
degree of apoptosis. Degree of apoptosis will also be measured by determining the protein
expression for caspase 9 and caspase 3 in both tumor and non-tumor colon tissue section
of all the treatment groups. Greater degree of epithelial cell apoptosis in the non-tumor area
of the colon tissue section is indicative of increase pathology and severity of colon cancer.
However, increased colon cancer cell apoptosis is indicative of an effective treatment and
better prognosis.
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Goblet Cell: Increase in the goblet cells and hence increase mucus production is one of the
protective mechanisms that could play an essential role in the colon cancer prevention.
Alcian blue staining will be used to determine the ratio of goblet to epithelial cells in both
the tumor and non-tumor colon tissue section for all the treatment groups. Higher ratio will
be an indication of increase number of goblet cell and hence increase mucus secretion. This
will be further confirmed by studying the expression of Hes-1 and Math-1, which are
involved in the differentiation of epithelial cell to goblet cells. Along with this protein
expression study for mucins, indicator of mucus production including Muc 1 and Muc 2
will be studied. Higher number of goblet cells, mucin production and increased expression
of Math-1 is indicative of reduced severity and pathology of chronic inflammation and
colon cancer.

AIM 3: To study the effect of Adiponectin and Selenium administration on intestinal
cancer.

Rationale: Aim 3 will study the role and the mechanism of action of both Se and APN
administration on intestinal cancer. Our preliminary data indicated that APN deficiency
leads to greater severity of CICC with greater tumor number and area. Higher pathology
scoring was observed with APN deficiency with CICC when compared to WT mice.
APNKO mice showed greater incidence of aberrant crypts as compared to WT mice. This
data was further supported by increase pro-inflammatory cytokine and protein production
in APNKO mice when compared to WT mice. Recent study by Tae et al., 2014 has shown
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that the patients with advanced adenoma and colorectal cancer (CRC) has lower serum
APN concentration when compared to the control group (Tae et al., 2014a). APN Receptor
showed higher expression in normal epithelium when compared to epithelium tissue of
CRC patients (Tae, et al., 2014a). APN has always been considered to have dual opposite
functions with globular variant of APN as a pro-inflammatory marker and full-length
protein to be anti-inflammatory. Globular APN mRNA showed increased expression in the
colorectal tumors as compared to the adjacent mucosa indicating a pro-inflammatory and
pro-cancerous role of globular APN in CRC carcinogenesis (Vetvik et al., 2014).
Intraperitoneal administration of full length APN (1.5 mg/kg/week) has been shown to
significantly reduced polyps, especially polyps larger than 2mm diameter in small intestine
in APCMin/+ mice model of intestinal cancer (Otani, et al., 2010). Another recent study has
shown that administration of APN alone or in combination with an anti-diabetic drug
metformin reduces the IL-1β regulated malignancy in human (LoVo) and mouse (MCA38)
cell lines in a STAT3 and AMPK/LKB1 dependent manner (Moon & Mantzoros, 2013).
One the basis of the published literature, our preliminary data of AIM 1 and our published
manuscript, we hypothesize that the administration of full length APN alone and/or in
addition to Se rich diet will reduce the severity of intestinal inflammation and cancer in the
APCMin/+ mouse model of intestinal cancer.
AIM 3.1 To study the effect of APN administration and Se rich diet on clinical score
and tumor load in APCMin/+ mice model of intestinal cancer.
AIM 3.2 To study the effect of APN administration and Se rich diet on goblet cell
production and cancer cell apoptosis.
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AIM 3.3 To determine the effect of APN administration and Se rich diet on oxidative
stress, TGF- β, β catenin and ZO-1 mediated gut barrier alterations cellular proliferation
and tumor invasion.

Experimental Design Specific AIM 3: Aim 3 will study the study the effect of Se rich
diet (0.75 ppm) and APN administration (1.5mg/kg/week) on the APCMin/+ mouse model
of intestinal cancer. This aim is further divided in to three separate aims where the first aim
deals with the role of APN administration and Se rich diet either in combination or alone
on clinical score which includes diarrhea, fecal hemoccult and weight loss and intestinal
tumor number and area. Four weeks old male and female APCMin/+ mice with C57BL/6
background will been randomized in to 3 different treatment groups including APC Min/+
mice with control diet (Se = 0.02 ppm) and APN administration, APCMin/+ mice with Se
rich diet (Se=0.75ppm) and APCMin/+ mice with Se rich diet and APN administration.
C57BL/6 will be used as a control group. 4 weeks old APCMin/+ mice will be administered
APN (1.5mg/kg/week) for 20 weeks. Depending on the group, the mice population will
either be administered Se rich diet or control diet at 4 weeks of age till 20 weeks of age.
APCMin/+ mice have been known to develop larger polyps at 16 weeks of age with a peek
at 19-20 weeks. Mice will be sacrificed at the end of the study at day 140 and serum, small
intestine, colon and spleen will be collected for further proteomic and genomic studies.
Aim 3.2 will study the mechanism of action of APN and Se rich diet on reducing the
severity of intestinal cancer. This aim will study the how APN and Se rich diet could play
a role in prevention of intestinal cancer by increasing mucus production through increase
differentiation of epithelial cells to goblet cells. Another mechanism that will be studied
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includes studying their role in the cancer cell apoptosis through the activation of caspases.
The third sub aim (3.3) will further study the role of both APN and Se rich diet on oxidative
stress which has been considered as one of the major mechanism leading to chronic
inflammation and hence intestinal cancer. It will also study their effect on β- catenin, TGFβ and junctional proteins like ZO1 and occludin which are responsible for severe
inflammation, cellular proliferation and EMT. Unpaired TTEST and One Way ANOVA
will be used for statistical analysis with a p≤0.05 as significant.

Experiment 3: This experiment will study the effect of Se rich diet and APN
administration on increasing anti-oxidant potential, apoptosis of cancer cells, goblet cell
production and decreasing inflammation and pathology of intestinal cancer.

Animal Model and Handling: Six to Eight weeks old APCMin/+ mice were obtained from
Jackson Laboratories and bred in the animal facility at the University of South Carolina
under the IACUC guidelines. The mice were fed regular chow and ad libitum. Four weeks
old APCMin/+ mice were then randomized in to 6 different treatment. Se rich diet and control
diet will be administered to mice on day 28. The groups include: APC Min/++Control Diet
(n=10), APCMin/++Se Diet (n=10), APCMin/++APN (n=6), APCMin/++Se+APN (n=6) and
Control group (C57BL/6, n=10). Mice were monitored throughout the length of the study
for clinical score including weight loss, diarrhea and fecal hemmoccult. Food and water
consumption of the mice will be monitored. Mice will be sacrificed by cervical dislocation
on day 113. Blood will be collected before sacrifice through retro-orbital puncture, spin
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down at 10,000 rpm for 18 minutes and serum will be isolated and stored at -20°C for
measuring serum APN. Mice colon will be excised and flushed clean with PBS. 2 mm2
colon tissue section with tumor and non-tumor area will be fixed in 10% formalin and after
24 hours will be replaced with 70% ethanol followed by paraffin embedding and sectioning
to obtain 5-6 mm thin section on glass slide. 2 mm2 colon tissue section with tumor and
non-tumor area will be snap frozen on dry ice and stored at -80°C for protein expression
studies and another 2 mm2 colon tissue section will be incubated in RPMI medium at 37°C
for 24 hours followed by centrifugation at 2500 rpm for 15 minutes. Supernatant w
obtained and stored at -20°C for secreted cytokine expression.

Figure 3: It shows different treatment groups with the number of mice used in each group
(n=10) for Aim 2.
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Material and Methods
Selenium Diet Administration
Selenium rich diet containing 0.75 ppm of Se per kg will be administered to 2 groups on
day 1 of the study. The diet will be administered till the day of sacrifice that is day 114.
Control diet contains all the components of the Se rich diet except that the Se content is
0.02 ppm per kg of diet.
Adiponectin Administration
APN

(Creative

Biochemicals,

NY)

will

be

administered

intraperitoneally

(1.5mg/kg/mouse) once a week for 16 weeks starting day 1 in four weeks old APCMin/+
mice belonging to group APCMin/+ mice+APN and APCMin/+ mice+Se+APN.
Clinical Score
Clinical score will be measured for each mouse in each group from day 1 to day 113. Mice
will be sacrificed after the last clinical score measurement. Score for the weight loss is
based on the following published scale where 0 = 0–5% weight loss; 1 = 6–10% weight
loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. Scoring
of diarrhea is as follows: 0 = well-formed pellets, 2 = pasty and semi-formed stools that do
not adhere to the anus, 4 = liquid stools that adhere to the anus. Detection of blood in the
stools will be determined using hemoccult kit (BECKMAN COULTER). The higher
intensity of blue color indicates greater bleeding. The followings are the score rates for the
fecal hemoccult: 0 = no blood, 2 = positive hemoccult, 4 = gross bleeding. The total clinical
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score will be the summation of the individual score of weight loss, diarrhea and fecal
hemoccult. The maximum score a mouse could get is 12. The clinical score will be
calculated and plotted against length of the study. Higher clinical score indicates more
severity of colon cancer development in animals.
Colon Tissue and Serum Collection:
Blood will be collected before sacrifice through retro-orbital puncture and spun down at
10,000 rpm for 18 minutes and serum will be obtained and stored at -20°C to measure
APN. Mice colon and SI will be excised and flushed clean with PBS. 2mm 2 SI and colon
tissue section with tumor and non-tumor area will be fixed in 10% formalin. 24 hours later,
these tissues will be submerged in 70% ethanol followed by paraffin embedding and
sectioning to obtain 5 µm thin section on glass slide. Sections with tumor and non-tumor
areas will then be snap frozen on dry ice and stored at -80°C for protein analysis. Another
2mm2 colon tissue section will be incubated in RPMI medium containing 5000 IU/mL and
5000 IU/mL penicillin and streptomycin (CELLGRO) respectively at 37°C and 5% CO2
for 24 hours. This will be followed by centrifugation at 2500 rpm for 15 minutes.
Supernatant will be obtained and stored at -20°C to measure secreted cytokine levels.
Tumor Number and Tumor Area and Histopathology:
Mice colon and SI will be excised and flushed with PBS. This will be followed by fixing
the tissue in 10% formalin followed by 70% ethanol. Colon and SI will be stained with 2%
methylene blue. Tumor number and area will be counted under the microscope in all mice
belonging to different treatment groups and significant difference will be calculated.
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Hematoxylin and Eosin staining will be used to determine the morphology of mice colon.
Histopathology will be quantified based on the scoring system indicating the severity of
disease and constituting inflammation, immune cell infiltration and degree of tumor. This
will be calculated on the scale of 12 where highest score of 4 was given for each parameter,
where 0 = no infiltration or no inflammation or no cancer; 2 = moderate infiltration or
inflammation or pre-cancerous lesions; and 4 = severe inflammation with distorted crypts
or infiltration and formation of lymphatic follicles or visible tumors. All the images will be
taken in 20X magnification with Nikon e600 microscope. The score will be measured by
two investigators in blinded fashion.
TUNEL Assay:
Degree of apoptosis will be measured in the tumor and non-tumor tissue sections of the SI
and colon by TUNEL assay. TUNEL assay (EMD Millipore) will be used to determine the
number of TUNEL positive cells and total number of epithelial cells of the colon in 2mm2
tissue cross-sectional tissue area. 5 sections will then be randomly selected from each tissue
section and 10 tissue sections will be randomly selected from each group. The ratio of
TUNEL positive cell to total epithelial cell will be used to determine the ratio of apoptosis
and plotted as a graph for different treatment groups. All the images will be taken in 20X
magnification with Nikon e600 microscope.
Protein determination using Western Blot:
Colon tissue frozen at -80°C will be homogenized in RIPA buffer added to protease and
phosphatase inhibitors (SIGMA). It will be then centrifuged at 10,000 rpm for 15 minutes
and supernatant will be collected for protein analysis. Protein concentration in the
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supernatant will be determined by using Bradford protein assay. This will be followed by
loading equal amounts of protein (50 µg) in each well for a 10% Sodium Dodecyl Sulphate
(SDS) gel electrophoresis. The protein from the gel will then be transferred to a
nitrocellulose membrane (Pall Scientific) and blocked with 5% non-fat dry milk (Biorad)
in phosphate buffer saline (PBS) (cellgro) with 0.1% Tween 20. The membrane will be
incubated overnight with the primary antibody. The primary antibodies include Gpx-1,
Gpx-2 and GAPDH obtained from Genetex. phospho-NFκB p65, NFκB p65, phospho-p65,
cleaved caspase 9, MDA, 4HNE and Nitrotyrosine will be obtained from cell signaling
technology. Membrane will be washed by PBS containing 0.1% Tween 20 (Biorad). The
membrane will then be incubated with secondary antibody (Santa Cruz) followed by
another washing step. The last step includes incubating the membrane in ECL substrate
(Western Bright, Advansta). The film will be then developed by using a developer (SRX101A, Konica Minolta Medical & Graphic, INC.) in the dark room. Finally the film will
be scanned and the density of the protein bands obtained will be analyzed using Image J
software.
Enzyme Linked Immunosorbent Assay (ELISA):
Spontaneous secreted cytokines will be measured from the tissue incubated in the RPMI
medium for 24 hours at 37°C. The media will be collected and centrifuged at 2500 rpm for
16 minutes. Pellet will be discarded and the supernatant is isolated. Cytokines IL-6, TNFα, IL-1β and IL-10 levels will be measured by using BD OptEIA ELISA kit obtained from
BD biosciences and normalized by total protein content estimated by using standard
Bradford assay procedure.
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Immunofluorescence:
Colon tumor tissue sections will be deparaffinzed by xylene and dehydrated by different
concentrations of ethanol. The sections will then undergo heat mediated antigen retrieval
step with 10nM citrate buffer (Prohisto), 0.05% Tween 20, pH 6.0 in an autoclave at 121°C,
15 psi for 20 minutes. The tissues will be then blocked with 10% goat anti-rabbit serum
with PBS. Tissues will be incubated in a primary antibody that is ZO-1 () for overnight
incubation. This will be followed by 5 washing steps and 2 hour- incubation with antirabbit secondary antibody (Aexa Flour 488) (Cell Signaling Technology). Finally the tissue
section will be mounted with a DAPI based mounting media (Genetex) and covered with
a coverslip. 10 random 20X magnification, 2x2 images of the 8 slides per group belonging
to different mice will be taken and quantified by using Image J software.
Statistical analysis
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and Oneway ANOVA will be used to analyze the data with Tukey post hoc-analyses. A p
value<0.05 will be considered statistically significant. All the statistical analyses will be
done using SigmaStat 3.5 (SPSS, Chicago, IL).
Primary Outcomes:
Clinical Score: Clinical score will be measured for each mouse in each group from day 1
to day 112. Mice will be sacrificed after the last clinical score measurement. Clinical score
is a summation of 3 different score including weight loss, diarrhea and fecal hemoccult.
The scoring system is as follows:
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Table 1: It shows clinical
score

measurement

criteria.

The maximum score a mouse could get is 12. Fecal hemoccult scoring will be obtained
using a kit from Beckman Coulter, which turns the fecal blood into blue color. The higher
intensity of blue color indicates greater bleeding. The clinical score will be calculated and
plotted against duration of study. Higher clinical score indicated more severity of colon
cancer.
Tumor Number and Tumor Area: Mice colon and small intestine (SI) will be excised and
flushed with PBS. At this point the tumor number and area will be counted for that part of
the colon and SI, which was excised for paraffin embedding, freezing and RPMI medium.
The rest of the colon and SI will be fixed in 10% formalin for 24 hours and then stored in
70% ethanol. The fixed SI and colon will be stained with 2% methylene blue. Tumor
number and area will be counted under the microscope for all the mice in different groups
and significant difference will be calculated between different groups and a graph will be
plotted.
Chronic Inflammation: Chronic inflammation will be measured in the colon and SI of all
the mice in different group by measuring secreted cytokines. Secreted cytokines will be
measured from the tissue incubated in the RPMI medium for 24 hours at 37°C. Cytokines
like IL-6, TNF-α, IL-1β and IL-10 will be measured followed by pNFκB protein
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expression. This will be followed by Hematoxylin and Eosin staining of the colon tissue
section fixed in formalin and embedded in paraffin wax to study chronic inflammation and
immune cell infiltration. Increased expression of pro-inflammatory cytokines and proteins
and decrease production of anti-inflammatory cytokines indicates greater inflammation.
Greater degree of inflammation indicated by abnormal crypts and infiltration of the
immune cells indicates higher severity of intestinal cancer.
Oxidative Stress: Oxidative stress will be measured in the SI and the colon tissue sample
which were snap frozen at -80°C by performing western blot for 4HNE, a marker for lipid
peroxidation, nitrotyrosine, a marker of nitrosylation and iNOS (inducible nitric oxide) a
well-known marker for increased oxidative stress. Higher oxidative stress measured by
increased nitrosylation, lipid peroxidation and NO production is indicative of chronic
inflammation and intestinal cancer.
Apoptosis: Apoptosis will be measured in the tumor tissue and the normal tissue section of
the colon and SI by TUNEL assay. TUNEL positive cells and total number of epithelial
cells will be counted and the ratio of TUNEL positive cell to total epithelial cell will
determine the degree of apoptosis. Degree of apoptosis will also be measured by
determining the protein expression for caspase 9 and caspase 3 in both tumor and nontumor colon and SI tissue section of all the treatment groups. Greater degree of epithelial
cell apoptosis in the non-tumor area of the colon and the SI tissue section is indicative of
increase pathology and severity of colon cancer. However, increased cancer cell apoptosis
is indicative of an effective treatment and better prognosis.
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Goblet Cell: Increase in the goblet cells and hence increase mucus production is one of the
protective mechanisms that could play an essential role in the colon cancer prevention.
Alcian blue staining will be used to determine the ratio of goblet to epithelial cells in both
the tumor and non-tumor intestine tissue section for all the treatment groups. Higher ratio
will be an indication of increase number of goblet cell and hence increase mucus secretion.
This will be further confirmed by studying the expression of Hes-1 and Math-1, which are
involved in the differentiation of epithelial cell to goblet cells. Along with this protein
expression study for mucins, indicator of mucus production including Muc 1 and Muc 2
will be studied. Higher number of goblet cells, mucin production and increased expression
of Math-1 is indicative of reduced severity and pathology of colon cancer.
TGF-β and Cellular Proliferation: TGF-β is a 25 kDa cytokines that plays a critical role
in carcinogenesis, homeostasis, cell proliferation, migration, apoptosis, fibrosis,
differentiation of cell and wound healing. TGF-β signaling pathway is one of the most
common altered signaling. It can play a dual role as a tumor suppressor and as a cancer
promotor. Higher TGF-β protein levels is associated with an increased incidence of tumor
reoccurrence (Friedman, et al., 1995). TGF-β alongwith β catenin has been shown to
enhance EMT and angiogenesis leading to greater severity of colon cancer (Lampropoulos,
et al., 2012). We will study the protein expression of TGF-β through western blot. Lower
TGF-β expression will provide an indication of reduced severity of colon cancer.
Canonical Wnt Pathway and β Catenin: Wnt pathway is well known pathway leading to
cellular proliferation. In APCMin/+ mice model of intestinal cancer there is mutation of APC
gene leading to intestinal cancer. APC protein is a negative regulator of β catenin and
prevents cellular proliferation and epithelial to mesenchymal transition (EMT). β catenin
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and junctional protein expression of ZO-1 and occludin by Western blot will be studied to
show the effect of APN or Se or both on cellular proliferation and EMT. β catenin
alongwith TGF- β has been shown to induce morphogenetic changes in epithelial cells
leading to greater proliferation, inflammation and intestinal cancer.
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